{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### To know the current working directory\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'/home/sobha/Orion-CustomNER'"
      ]
     },
     "execution_count": 1,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pwd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[nltk_data] Downloading package punkt to /home/sobha/nltk_data...\n",
      "[nltk_data]   Package punkt is already up-to-date!\n"
     ]
    }
   ],
   "source": [
    "import nltk\n",
    "nltk.download('punkt')\n",
    "from nltk import word_tokenize,sent_tokenize"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import pandas as pd\n",
    "from nltk import sent_tokenize"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "from glob import glob # glob (short for global) is used to return all file paths that match a specific pattern. ."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Step 1: Collect inclusive and exclusive criterion data separately "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### - Download chia dataset and list the directory contents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['DataCollection_Preparation-Copy1.ipynb',\n",
       " 'base_config.cfg',\n",
       " 'middle.ann',\n",
       " '.ipynb_checkpoints',\n",
       " 'train.spacy',\n",
       " 'DataCollection_Preparation.ipynb',\n",
       " 'spacyannotation.json',\n",
       " 'preprocess.ipynb',\n",
       " 'command prompt-spacy',\n",
       " 'dev.spacy',\n",
       " 'config.cfg',\n",
       " 'DataCollection_Preprocessing.ipynb',\n",
       " 'chia_with_scope.zip',\n",
       " 'middle.txt',\n",
       " 'screenshot.png',\n",
       " 'inclusion_data.txt',\n",
       " 'inclusion_sentence.txt',\n",
       " 'exclusion_data.txt',\n",
       " 'chia_with_scope',\n",
       " 'output']"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "os.listdir(\".\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Since we need customized annotations we need to collect all the txt files and annotate based on our use case requirements\n",
    "- separate the txt files according to inclusion and exclusion criteria\n",
    "- get the recursive filepaths using glob"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "inc_file_paths = glob(\"chia_with_scope/*_inc.txt\")\n",
    "exc_file_paths = glob(\"chia_with_scope/*_exc.txt\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "#print(inc_file_paths)\n",
    "#print(exc_file_paths)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Create a dataset by adding the contents of all the text files\n",
    " - Create 2 datasets : one for inclusion criteria and the other for exclusion criteria"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "inc_data = [] # inclusion criteria data\n",
    "exc_data = [] # exclusion criteria data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### loop through the files and append data to the main dataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "for inc_file in inc_file_paths:\n",
    "    with open(inc_file, \"r\", encoding=\"unicode_escape\") as f:\n",
    "        data = sent_tokenize(f.read())\n",
    "        inc_data.extend(data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Type 2 Diabetes\\nHypertension\\nEstimated glomerular filtration rate (eGFR) > 30 ml/min\\nUse of Ace Inh and ARB for control of blood pressure who are willing to be placed on alternate drug(s) in the washout period for blood pressure control',\n",
       " 'Clinical and radiologic diagnosis of primary knee osteoarthritis (Kellgren & Lawrence I, II or III); \\nCapability to understand the Informed Consent Form; \\nChronic pain for at least 3 months prior to inclusion, measured by VAS.',\n",
       " '(VAS 4 or above); \\nAbsence of skin injures, infections or tumor in the target knee; \\nAvailability to comply with the visits.',\n",
       " 'All patients presenting for elective shoulder arthroscopic procedures will be eligible for enrollment.',\n",
       " \"Age: 18 to75 years old;\\nPathologically diagnosed with advanced gastric cancer (including adenocarcinoma of the gastroesophageal junction) with measurable metastases outside the stomach (measuring = 10mm on spiral CT scan, satisfying the criteria in RECIST 1.1);\\nFailure of prior therapy (during or after treatment) in patients who have received at least two prior chemotherapy regimens;\\nECOG PS of 0-2;\\nHB = 90g / L\\nANC = 1.5 Ã\\x97 109 / L\\nPLT = 80 Ã\\x97 109 / L\\nBilirubin <1.25 times the upper limit of normal (ULN)\\nALT and AST <2.5 Ã\\x97 ULN; liver metastases, if any, the ALT and AST<5 Ã\\x97 ULN\\nSerum Cr = 1 Ã\\x97 ULN endogenous creatinine clearance>50ml/min (Cockcroft-Gault formula)\\nAn expected survival of = 3 months;\\nPatient received apatinib treatment regimen at investigators' discretion;\\nPatient has to voluntarily join the study and sign the Informed Consent Form for the study;\\nPregnancy test (serum or urine) has to be performed for woman of childbearing age within 7 days before enrolment and the test result must be negative.\",\n",
       " 'They shall take appropriate methods for contraception during the study until the 8th week post the last administration of study drug.',\n",
       " 'For men, (previous surgical sterilization accepted), shall agree to take appropriate methods of contraception during the study until the 8th week post the last administration of study drug.',\n",
       " 'Acutely ill hospitalised children\\nNeed for intravenous fluid therapy',\n",
       " 'Provision of informed consent prior to any study specific procedures;\\nMen and women 18 years and older;\\nGroup I PAH, defined as a mPAP=25mmHg, PCWP<15mmHg and PVR[The PVR =(mPAP-PCWP)/CO]>3.0 Woods unit.',\n",
       " 'Diagnosis of schizophrenia or schizoaffective disorder \\nIf entering the study as an inpatient, hospitalization was recent \\nCurrently receiving treatment with an atypical antipsychotic and continuation on the medication has been recommended \\nAssumes primary responsibility for taking medication \\nCurrently living in a stable environment',\n",
       " 'Able to give informed consent\\nRight-handed\\nAge between 18-50 years old,\\nPhysically and neurologically healthy [confirmed by a comprehensive medical history]\\nCurrent PTSD diagnosis',\n",
       " 'Female at birth and identifies as female gender\\nAge 18 years or older\\nAble to understand and provide consent in English or Spanish\\nHIV negative by 4th generation test (Ag/Ab test) or combination of enzymeimmunoassay (EIA) and HIV RNA\\nCreatinine clearance = 60 ml/min (via Cockcroft-Gault formula)\\nCondomless sex in the last 3 months with one or more male partners of unknown HIV status known to be at substantial risk of HIV infection (IDU, bisexual, sex for goods, recently incarcerated, from a country with HIV prevalence >1%, interpersonal Partner Violence);\\nSTI (rectal or vaginal gonorrhea or syphilis) diagnosis during the last 6 months.',\n",
       " 'Previous post-exposure prophylaxis (PEP) use during the last 12 months.',\n",
       " 'Has at least one HIV-infected sexual partner for =4 weeks.',\n",
       " 'Sex for exchange of money, goods or services',\n",
       " 'Male or female term baby with gestational >37 weeks and postnatal age < or= 28 days\\nBirthweight >2500g\\nWritten informed consent of parent or guardian',\n",
       " 'ASA physical status 1 or 2\\nWritten informed consent\\nCardiovascular disease\\nPulmonary disease\\nLiver disease\\nCNS disease\\nAlcohol or drug abuse\\nChronic intake of CNS active drugs\\nBody mass index > 35\\nDiabetes mellitus\\nHypersensitivity or allergy to one of the study drugs',\n",
       " 'Patient diagnosed by HRCT Core Lab with eligible heterogeneous disease distribution and at least one complete oblique fissure.',\n",
       " 'Age from 40 to 75 years \\nBMI < 32 kg/m2 \\nFEV1 < 40% of predicted value, FEV1/FVC < 70% \\nTLC > 120% predicted, RV > 150% predicted.',\n",
       " 'Stable with < 20 mg prednisone (or equivalent) qd \\nPaCO2 < 50mm Hg \\nPaO2 > 45 mm Hg on room air \\n6-min walk of > 50m (without rehabilitation) or > 100m (with rehabilitation) \\nNonsmoking for 4 months prior to initial interview and throughout screening \\nThe patient agrees to all protocol required follow-up intervals.',\n",
       " 'The patient has no child bearing potential \\nThe patient is willing and able to complete protocol required baseline assessments and procedures',\n",
       " 'Infants in the newborn intensive care unit\\nTPN cholestasis of at least 2.5 mg/dl\\nAnticipated TPN treatment for at least one month\\nsigned informed consent',\n",
       " 'Phase I: Patients must have histologically confirmed R/R NHL or HL (defined by WHO criteria).',\n",
       " 'Patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are eligible.',\n",
       " 'In addition, patients with NHL other than diffuse large B cell lymphomas (DLBCL) must have received at least 2 prior therapies.',\n",
       " 'Patients with DLBCL and HL will be eligible if there is no available standard therapy.',\n",
       " 'Phase II: Patients must have histologically confirmed R/R NHL (as defined by WHO criteria).',\n",
       " 'Patients with NHL other than diffuse large B cell lymphomas (DLBCL) must have received at least 2 prior therapies.',\n",
       " 'Patients with DLBCL will be eligible if there is no available standard therapy.',\n",
       " 'Must have received front line chemotherapy.',\n",
       " 'No upper limit for the number of prior therapies \\nEvaluable Disease in the Phase I, and measurable disease in the Phase II \\nAge > 18 years \\nECOG performance status < 2 \\nPatients must have adequate organ and marrow function \\nAdequate Contraception \\nAbility to understand and the willingness to sign a written informed consent document',\n",
       " 'Moderate to severe rheumatoid arthritis\\nTaking methotrexate without adequate control of symptoms\\nHave at least one cardiovascular risk factor (eg, current smoker, high blood pressure, high cholesterol levels, diabetes mellitus, history of heart attack, family history of coronary heart disease, extra-articular RA disease)',\n",
       " 'Premenopausal women\\n18-35 years old\\nFSH levels < 10 mIU/ml\\nAFC> 10\\nRegular cycles\\nBMI < 28\\nSigned informed consent',\n",
       " \"valid driver's license\\nenglish-speaking and literate\",\n",
       " \"- Patient with IVF cycle and therefore having frozen-thawed embryos\\nRegular menstruation cycle\\nPatient's willingness to participate in the study\",\n",
       " 'The subject must be willingly and able to provide written informed consent\\nAge 19 years of age or older (The age of consent in Nebraska)\\nHCV treatment-naÃ¯ve, as defined as no prior exposure to any Interferon (IFN), RBV, or other FDA approved or experimental HCV-specific direct-acting antiviral agent\\nHCV RNA level at most 6 months prior to the Baseline/Day 1 visit.',\n",
       " 'HCV genotyping 1a, 1b, or mixed 1a/ab.',\n",
       " 'Any non-definitive results will exclude the subject from study participation.',\n",
       " 'Alcohol misuse as defined by the Alcohol Use Disorders Identification Test (AUDIT) score subjects must score > 8 (associated with harmful or hazardous drinking)\\nHistory of a liver biopsy showing cirrhosis (e.g.',\n",
       " 'Metavir score = 4 or Ishak score > 5)\\nFibroscan showing cirrhosis or results > 12.5 kPa\\nFIBRO Spect II index consistent with F3 or F4 AND an AST : platelet ration index (APRI) of > 2 during Screening\\nLiver biopsy within 2 years of Screening showing absence of cirrhosis\\nFibroscan within 6 months of Baseline/Day1 with a result of = 12.5 kPa\\nFIBRO Spect II Index consistent with F0- F2 AND APRI of = 1 during Screening\\nLiver imaging within 6 months of Baseline/Day 1 to exclude hepatocellular carcinoma HCC) is required\\nALT < 10 x the upper limit of normal (ULN)\\nAST < 10 x ULN\\nDirect bilirubin < 2.0 x ULN\\nPlatelets > 50,000\\nHbA1c < 8.5%\\nCreatinine clearance (CLcr) = 60 mL /min, as calculated by the Cockcroft-Gault equation\\nHemoglobin = 11 g/dL for female subjects; = 12 g/dL for male subjects.',\n",
       " 'Albumin = 2.5 g/dL\\nINR = 1.5 x ULN unless subject has known hemophilia or is stable on an anticoagulant regimen affecting INR.',\n",
       " 'Subject has not been treated with any investigational drug or device within 30 days of the screening visit.',\n",
       " 'ADHD',\n",
       " 'Patients undergoing surgeries in the upper limb (arm, forearm or hand)',\n",
       " 'Patient is currently participating in a Novartis Oncology sponsored study receiving pasireotide (LAR and/or s.c.) and has fulfilled all required assessments in the parent study (unless the study is being terminated) and patients that are benefiting from the study drug have no other alternatives\\nPatient is currently benefiting from the treatment with pasireotide, as determined by the investigator\\nPatient has demonstrated compliance, as assessed by the investigator, with the parent study requirements\\nWillingness and ability to comply with scheduled visits, treatment plans and any other study procedures\\nWritten informed consent obtained prior to enrolling in roll-over study and receiving study medication â\\x80¢ If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness',\n",
       " 'Signed informed consent form\\nMacula edema secondary to BRVO\\nBCVA of 77 to 20 letters assessed with the use of ETDRS charts\\nCRT <U+2267>250Âµm',\n",
       " 'Good general health\\nOlder than the age of legal consent (i.e.',\n",
       " '18 years old)\\nSonographic diagnosis of ovarian endometrioma with diameter at least 4cm on 2 separate scans at least 6 weeks apart\\nNo contraindication to use of progesterone or combined oral contraceptive pills\\nNot attempting to conceive either at the time of study entry or for at least 2 years after surgery\\nWilling and able to participate after the study has been explained',\n",
       " \"Patients on chronic statin treatment (>30 days) scheduled for isolated CABG, including on- or off-pump or repeat (redo's) revascularisation procedures\\nStable or unstable angina, including non ST-segment-elevation acute coronary syndrome (NSTE-ACS)\\nAge = 18 years\\nWritten informed consent\",\n",
       " 'Patients underwent percutaneous coronary intervention with drug-eluting stent;',\n",
       " 'Ulcerative colitis patients with moderate to severe activity who achieved a clinical remission by the first course of corticosteroids\\nNewly diagnosed or without steroid use during last 1 year\\nEndoscopic Mayo subscore >0',\n",
       " 'Newly diagnosed glioblastoma (GBM), WHO grade IV.',\n",
       " 'Diagnosis of diabetes mellitus\\nBest corrected visual acuity 20/32 - 20/320\\nDiabetic macular edema involving the center of the macula\\nOptical coherence tomography central subfield thickness of at least 250 microns',\n",
       " 'patients with renal cancer coming to the laparoscopic radical nephrectomy',\n",
       " '37 weeks gestation or greater\\nLiving, singleton fetus\\nNo major fetal malformations\\nCephalic presentation\\nNo prior uterine scar\\nIntact fetal membranes\\nQualifies for prostaglandin administration according to current Parkland protocol\\nHave a cervical dilation of 2 centimeters or less, measured at the level of the internal os\\nHave an indication for induction or attempted induction of labor according to Parkland protocol',\n",
       " 'HIV-1 infected males or females \\nover 18 years of age \\nsigned informed consent \\ncurrently receiving a stable antiretroviral regimen comprising of: \\ntwo or more licensed NRTIs \\none licensed NNRTI or boosted protease inhibitor \\nno previous protease inhibitor resistance documented on HIV-1 genotypic resistance testing \\nfailure of current antiretroviral regimen due to: \\ntoxicity, intolerance or virological failure if receiving an NNRTI containing regimen at screening \\ntoxicity or intolerance if receiving a boosted-protease inhibitor regimen at screening (with plasma HIV RNA < 400 copies/mL at screening) \\nwilling to modify antiretroviral therapy, in accordance with the randomisation assignment \\nno previous exposure to etravirine \\nsubjects in good health upon medical history, physical exam, and laboratory testing in the opinion of the investigator \\nhave no serologic evidence of active HBV infection evidenced by negative hepatitis B surface antigen \\nfemale subjects who are heterosexually active and of childbearing potential (i.e., not surgically sterile or at least two years post menopausal) must practice contraception as follows from screening through completion of the study: \\nbarrier contraceptives (condom, diaphragm with spermicide) \\nIUD or Depo PLUS a barrier contraceptive \\nfemale subjects of childbearing potential must have a negative pregnancy test.',\n",
       " 'Age 19 years of older\\nModerate or severe claudication (Rutherford category 2 or 3)\\nCritical limb ischemia (Rutherford category 4 or 5)\\nPatients with signed informed consent\\nTarget lesion length =150 mm by angiographic estimation\\nStenosis of more than 50% in femoropopliteal artery\\nAt least one patent (less than 50 percent stenosed) tibioperoneal runoff vessel.',\n",
       " 'Patients scheduled for supine-positioned elective craniotomy for supratentorial malignant and non-malignant brain tumors 3 cm or larger (measured as the largest diameter in any plane on MR images)\\nASA (American Society of Anesthesiologist) status 1-3 (27)\\nWritten informed consent from participating patients',\n",
       " 'symptomatic Dupuytrens contracture with palpable cord, involving MCP, total contracture size over 30 degrees',\n",
       " 'Subjects admitted to the hospital with acute or chronic medical illnesses or for elective and emergency surgical illness or trauma\\nKnown history of Type 2 diabetes mellitus for >3 months\\nTreated with either diet alone, any combination of oral antidiabetic agents, non-insulin injectables or insulin therapy\\nBlood glucose levels between >140 mg and <400 mg/dL without laboratory evidence of diabetic ketoacidosis',\n",
       " 'Must have pathologically confirmed invasive adenocarcinoma or ductal carcinoma in situ of the breast.',\n",
       " 'Patients must have undergone segmental mastectomy (i.e., lumpectomy).',\n",
       " 'Patients must not have received prior radiation therapy to the breast.',\n",
       " 'Patients must not have active local-regional disease prior to registration.',\n",
       " 'Patients must not be pregnant because of the potential for fetal harm as a result of radiation treatment.',\n",
       " 'Women of child-bearing age will be given a serum pregnancy test prior to study entry to ensure they are not pregnant.',\n",
       " 'They will also be counseled on the importance of avoiding pregnancy and hormonal contraception while undergoing radiation therapy.',\n",
       " 'Patients must not have a serious medical or psychiatric illness which prevents informed consent or compliance with treatment.',\n",
       " 'All patients must be informed of the investigational nature of this study and give written informed consent in accordance with institutional and federal guidelines.',\n",
       " '1.',\n",
       " 'Male and female recipients of all races, â\\x89¥18 years of age.',\n",
       " '2.',\n",
       " 'Patients undergoing primary or subsequent deceased-donor or living donor kidney transplantation.',\n",
       " '3.',\n",
       " 'Subject and/or guardian must be able to provide informed consent.',\n",
       " '4.',\n",
       " 'Subject and/or guardian must be able to comply with the study protocol.',\n",
       " 'Any patients that will be submitted to phacoemulsification surgery in the Hospital de Clinicas of State University of Campinas (BRAZIL)\\nPatients over 18 years old\\nPatients who are able to perform SD-OCT\\nPatients who sign the consent form',\n",
       " '=18-40 year old women\\nBV+ by Amsel criteria and Nugent score OR history of BV in the prior 6 months\\nWilling to use the NuvaRing as directed\\nNot intending or wishing to become pregnant over the course of the study\\nCapable of providing written informed consent',\n",
       " '>/= 18 years old\\nAtrial fibrillation or flutter on electrocardiogram\\nHeart rate >110 beats/min\\nSystolic blood pressure >/= 90 mmHg',\n",
       " 'Patients presenting with ST-elevation acute myocardial infarction (STEMI) within 12 hours of their symptom onset in whom TIMI-3 flow was established in infarct related artery (IRA) after balloon angioplasty or thrombectomy.',\n",
       " '18 years old or older.',\n",
       " 'ADHD is diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5 criteria).',\n",
       " 'Substance Use Disorder is diagnosed according to DSM-5 criteria.',\n",
       " 'Qb-score 1.3 or higher on at least one of the weighted summary parameters QbActivity, QbInattention or QbImpulsivity on the QbTest.',\n",
       " 'Participants are given their written informed consent to participate in the study.',\n",
       " 'Age = 18 years\\nLaparoscopic cholecystectomy\\nEmergent/elective\\n=2 risk factors: diabetes mellitus, age =70 years, BMI =30, fascial enlargement',\n",
       " 'Newborns weighing 1.5kg or more at birth',\n",
       " '18 years of age or older\\ncapable of providing informed consent',\n",
       " 'Inclusion criteria includes all U.S. HCA hospitals with an adult ICU;\\nNote: Unit of randomization is the hospital, but the participants are hospital adult ICUs\\nAll patients within adult ICUs are included, including rare patients <18 years and >=12 years.',\n",
       " 'women\\nproven pelvic floor dysfunction\\ninformed consent',\n",
       " 'Provide written, signed and dated informed consent prior to initiating any study-related activities.',\n",
       " 'Male or female >18 years of age at the time of screening\\nFitzpatrick Skin phototype IV-VI, non-white race/ethnicity, including but not limited to - --African Americans, Asians, Pacific Islanders and Hispanics.',\n",
       " 'Clinical diagnosis of chronic plaque-type psoriasis of the body\\nPlaque psoriasis with =2% Body Surface Area (BSA) involvement (may include scalp involvement), PASI Score = 2, IGA mod 2011 score of 2 or greater (based on scale of 0-4)\\nFemales of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline.',\n",
       " 'While using investigational product and for at least 28 days after last application of investigational product, FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options d\\nMust be in general good health as judged by the Investigator, based on medical history and physical examination.',\n",
       " '1. age 18-65 years, inclusive \\n2. diagnosis of moderate to severe AT, confirmed by Dr. Wilson using clinical symptoms and exam findings consistent with chronic AT (>6 month duration) - which includes pain while palpating the intratendinous swelling part of the Achilles tendon and relief of pain when tendon placed under tension - and pre-procedure US \\n3. self-reported AT-related pain for at least 6 months and VAS (Visual Analog Scale) pain >5 (0-10 scale) \\n4. self-reported failure of eccentric exercise protocol (at least 75% completion) \\n5. self-reported failure of at least 2 of the 3 most common treatments for AT (NSAIDS, rest/ice or taping) \\n6. patient considered surgery but decided to wait and/or refused surgery -',\n",
       " '1.',\n",
       " 'Fasting glucose > 7.0 or have diabetes medication; \\n2.',\n",
       " 'Male, 35-80 years; female, postmenopausal to 80 years; \\n3.',\n",
       " 'Agree to participant in the trial.',\n",
       " 'Mexican-american\\nFemale\\nBMI 30-42\\nwillingness to complete protocol\\npre-diabetic\\nEnglish or Spanish literate',\n",
       " 'Patients undergoing ambulatory hand surgery for carpal tunnel and trigger finger, under local anesthesia with or without sedation.',\n",
       " 'Cervical spine injury with functional loss in the upper extremity\\nGreater than 4 months out from C-spine injury\\nStable motor recovery\\nMedically stable\\nInternational Classification for Surgery of the Hand in Tetraplegia of 0-5 at 6 months\\nGrade 0 finger/thumb extension at 6 months\\nSubjects fluent in English or when not fluent, an appropriate translator is present',\n",
       " 'Patients undergoing surgery on shoulder, humerus, or clavicle',\n",
       " 'asthma or COPD',\n",
       " \"Horner's Syndrome\\nHistory of taking an alpha blocker (tamsulosin/ terazosin/doxazosin/alfuzosin/silodosin) medication\",\n",
       " 'Participant aged 19 or over\\nAvailable for the entire duration of the study and willing to participate on the basis of the information provided in the FIU duly read and signed.',\n",
       " 'Adult patients\\nKidney transplant recipients\\nPatients treated by a calcineurin inhibitor and mycophenolic acid\\nViremia >= 3 log UI/ml\\nPatients who have given written informed consent\\nNegative pregnancy test (blood Ã\\x9f-HCG dosage)',\n",
       " 'Primary total hip arthroplasty (THA)',\n",
       " 'Habitual dietary sodium intake > 3400mg per day',\n",
       " 'Type 2 diabetes\\nAge 18 - 75 years\\nAnti-GAD antibodies negative (Glutamic Acid Decarboxylase)\\nC-peptide levels = 1.5 ng/mL\\nFasting blood glucose > 126 mg/dl\\nHbA1c 8.0 - 10.5 %\\nBMI 25.0 - 45.0 kg/m2\\nPrevious therapy with BBIT (basal insulin and at least once daily bolus insulin)',\n",
       " 'Presents to the Emergency Department (ED) and meets the clinical definition for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)\\nKnown or suspected gram-positive infection.',\n",
       " 'primigravida, singleton pregnancy, maternal age 18-35 years, and pregnancy duration 16-20 weeks at the time of study inclusion.',\n",
       " 'patients were 18 years old or more,\\nnaive to HCV treatment,\\nHCV genotype 4,\\ncompensated liver disease.',\n",
       " 'heart failure NYHA II-IV\\nprevious treatment with diuretics\\nage>18 years',\n",
       " 'Patients in the cardiothoracic intensive care after cardiac surgery with cardiopulmonary bypass\\nAcute kidney injury, defined as increase in S-creatinine 50% or 27 mol/L\\nNormal S-creatinine before surgery',\n",
       " 'Subjects who the investigator believes can and will comply with the requirements of the protocol (i.e.',\n",
       " 'return for follow-up visits, and able to converse with study personnel)\\nAge 18 years or older\\nUndergoing major cardiac surgery using cardiopulmonary bypass',\n",
       " 'patients = 70 years of age, undergoing a noncardiac surgical procedure under general anesthesia, with an anticipated duration of postoperative admission of at least 2 days.',\n",
       " 'Adult (>18 years of age and older) patients who have or will have undergone surgical resection or biopsy of a supratentorial brain tumor and are able to consent for themselves.',\n",
       " 'Able to be randomized prior to or up to 48 hours after surgery.',\n",
       " 'Bloodstream infection with Enterobacter spp., Serratia marcescens, Providencia spp., Morganella morganii or Citrobacter freundii (i.e.',\n",
       " 'likely AmpC-producer), and susceptibility to 3rd generation cephalosporins (i.e.',\n",
       " 'ceftriaxone, cefotaxime or ceftazidime), meropenem and piperacillin-tazobactam from at least one blood culture draw.',\n",
       " 'This will be determined in accordance with laboratory methods and susceptibility breakpoints defined by protocols used in the recruiting site laboratories..\\nNo more than 72 hours has elapsed since the first positive blood culture collection.',\n",
       " 'Patient is aged 18 years and over (>=21y in Singapore).',\n",
       " '(1)= 45 years old;\\n(2)A diagnosis or previous diagnosis of essential hypertension, including anyone currently taking antihypertensive drugs; or for those who have not taken antihypertensive drugs within the last 2 weeks, two consecutive examinations were conducted at least one day apart, and both sitting blood pressure (mean value of 3 measurements) met the following criteria: diastolic blood pressure (DBP) =90 mmHg or systolic blood pressure (SBP) =140 mmHg (the second blood pressure was measured at V1);\\n(3)If a study participant is a woman of childbearing age, she agrees to use a reliable contraceptive method during the trial;\\n(4)Voluntarily participates and has signed an informed consent form.',\n",
       " '(1)Completed MTHFR C677T gene polymorphism detection in run-in period or MTHFR C677T genotype already known in advance;\\n(2)Exhibited good tolerance to enalapril and good overall medication compliance (>80%) in run-in period or previously exhibited good tolerance and adherence to ACEI drugs in previous medication history.',\n",
       " '(3)Voluntarily continues to participate in this study.',\n",
       " 'After the investigator has taken the decision to use human insulin or insulin analogues to treat the subject, any type 2 diabetic previously inadequately controlled with two or more OADs is eligible for the study \\nThe selection of the subjects will be at the discretion of the individual investigator',\n",
       " 'Age â\\x89¥ 18 years (Age â\\x89¥ 12 years for patients with bone sarcomas).',\n",
       " 'Histologically confirmed diagnosis of unresectable, recurrent, and/or metastatic high grade soft-tissue or bone sarcoma of one of the following subtypes: soft tissue sarcomas (leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH and synovial sarcoma), and bone sarcomas (Ewing sarcoma, osteosarcoma, and chondrosarcoma [de-differentiated or mesenchymal]).',\n",
       " 'ECOG Performance Status of 0 or 1.',\n",
       " 'At least one site of measurable disease on CT/MRI scans as defined by RECIST 1.1.',\n",
       " 'Baseline imaging must be performed within 30 days of dosing.',\n",
       " 'At least one site of accessible disease for pre- and post-treatment core biopsies for at least 20 patients per arm on the expansion cohorts.',\n",
       " 'Patients may have received 1-3 prior systemic therapies in the metastatic setting.',\n",
       " 'Adequate organ function within 14 days of dosing \\nMust be willing to provide and have available archival tissue for PD-L1 testing.',\n",
       " 'Written, voluntary informed consent.',\n",
       " 'Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 120 days after last study drug administration.',\n",
       " 'Women of childbearing potential include pre-menopausal women and women within the first 2 years of the onset of menopause.',\n",
       " 'Women of childbearing potential must have a negative pregnancy test â\\x89¤ 72 hours prior to Day 1 of study.',\n",
       " 'Effective methods of birth control include: surgically sterile, barrier device (condom, diaphragm), contraceptive coil, intrauterine device (IUD), and abstinence.',\n",
       " 'Life expectancy of >12 weeks.',\n",
       " 'Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of CNS metastatic disease and are without evidence of clinical progression for at least 4 weeks prior to screening, have no evidence of new or enlarging brain metastases, and are off steroids for at least 7 days before first dose of pembrolizumab.',\n",
       " 'Above 18 years of age\\nSymptomatic, permanent AF of at least three months duration\\nResting heart rate =80 bpm\\nSigned informed consent',\n",
       " 'BMI = 35\\ntype 2 diabetes\\nHbA1c = 6,5 % or fasting glycemia =7mmol/l or non-fasting glycemia =11mmol/l\\nable to consent',\n",
       " 'Male or female, 18 years of age or older.',\n",
       " 'Study eye with clinically significant diabetic macular edema (DME) with central subfield thickness â\\x89¥ 350Âµm on spectral domain OCT\\nBest corrected visual acuity (BCVA) of 20/50 to 20/320 ETDRS equivalent (65 letters to 23 letters) in the study eye, with BCVA decrement primarily attributable to DME.',\n",
       " 'Treatment naÃ¯ve, i.e., no previous anti-VEGF treatment in the study eye or no anti-VEGF treatment in the 45 days prior to study enrollment.',\n",
       " \"In the investigator's opinion, the subject still has significant intraretinal fluid with room for improvement in both macular edema and BCVA.\",\n",
       " 'Intra-Ocular Pressure (IOP) is under control (i.e., IOP â\\x89¤ 25 mm in the study eye) and study eye is not receiving any IOP lowering drops.',\n",
       " 'Willing and able to return for all study visits.',\n",
       " 'Able to meet the extensive post-op evaluation regimen.',\n",
       " 'Understands and signs the informed consent form.',\n",
       " 'Need for long-term oral anticoagulation;\\nPatient has provided written informed consent.',\n",
       " 'Males and females of 18 years of age or older at the time of the vaccination\\nSevere chronic kidney disease (Stage 4 and 5)',\n",
       " 'Age 18-65\\nscheduled to receive ISB and general anesthesia as a day surgery patient for rotator cuff repair and acromioplasty, as a part of planned routine care',\n",
       " 'Women above 18 years of age with biopsy proven, clinically stage 1 or 2 breast cancer who will be undergoing partial mastectomy with SLNBx at Memorial Health',\n",
       " 'All adult patients with chronic myeloid leukaemia in any phase (chronic, accelerated or blastic) who undergo allogeneic stem cell transplantation between 01/01/2010 and 30/09/2013 and have been previously treated with Nilotinib or Dasatinib, regardless of their response to these drugs.',\n",
       " 'Liver cirrhosis\\nAge between 18 and 70 years\\nEsophageal varices with high bleeding risk: more than F2 and red color sign\\nNo previous history of upper gastrointestinal bleeding\\nNo previous history of endoscopic, radiologic, or surgical therapy for varices or ascites\\nDo not take beta-blocker, ACE inhibitor, or nitrate\\nChild-Pugh score <12',\n",
       " 'Age 1-59 months,\\nPlan to remain in study area greater than 6 months\\nDischarged from hospital following non-trauma related admission',\n",
       " 'Acute Myocardial Infarction Undergoing Primary percutaneous coronary intervention.',\n",
       " \"Women who are in their first 5 years of menopause \\nHave a T score between -1 and -2.49 at the femoral neck, total hip, or L1-L4 spine \\nBe 19 years of age or older \\nHave their health care provider's permission to enroll in the study.\",\n",
       " 'Eligible patients must meet the following criteria to be enrolled in the study: \\n1.',\n",
       " 'Newly diagnosed, stage IV squamous cell lung cancer.',\n",
       " 'This includes patients who present with disseminated metastases, and those with a malignant pleural or pericardial effusion (i.e., formerly stage IIIB in the 6th TNM staging system).',\n",
       " '2.',\n",
       " 'Patients who have received prior adjuvant therapy for early-stage lung cancer are eligible if at least 12 months have elapsed from that treatment.',\n",
       " '3.',\n",
       " 'Histologically confirmed squamous cell bronchogenic carcinoma.',\n",
       " 'Patients whose tumors contain mixed non-small cell histologies are eligible, as long as squamous carcinoma is the predominant histology.',\n",
       " 'Mixed tumors with small cell anaplastic elements are not eligible.',\n",
       " 'Cytologic specimens obtained by brushings, washings, or needle aspiration of the defined lesion are acceptable.',\n",
       " '4.',\n",
       " 'Patients with previous radiotherapy as definitive therapy for locally advanced non-small cell lung cancer are eligible, as long as the recurrence is outside the original radiation therapy port.',\n",
       " 'Radiation therapy must have been completed >4 weeks prior to the initiation of study treatment.',\n",
       " 'Patients who have received chemo/radiation for locally advanced NSCLC are not eligible.',\n",
       " 'Patients who have received palliative radiation therapy for symptomatic metastases must have completed treatment >14 days prior the initiation of the study treatment.',\n",
       " '5.',\n",
       " 'Presence of evaluable (measureable or non-measurable) disease.',\n",
       " '6.',\n",
       " 'ECOG Performance Status of 0 or 1.',\n",
       " '7.',\n",
       " 'Laboratory values as follows: \\nAbsolute neutrophil count (ANC) >1,500/microL and platelets >100,000/microL (â\\x89¤72 hours prior to initial treatment).',\n",
       " 'Hemoglobin >9 g/dL (Note: Patients may be transfused or receive erythropoietin to maintain or exceed this level).',\n",
       " 'Bilirubin < ULN.',\n",
       " 'Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) â\\x89¤2.5 times the upper limit of normal if no liver involvement or â\\x89¤5 times the upper limit of normal with liver involvement.',\n",
       " 'Creatinine <2.0 mg/dL, or creatinine clearance >40 mL/min (as calculated by the Cockcroft-Gault method.',\n",
       " '8.',\n",
       " 'Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to start of treatment.',\n",
       " 'Women of childbearing potential or men with partners of childbearing potential must use effective birth control measures during treatment and at least 6 months after the last dose of the study treatment.',\n",
       " 'If a woman becomes pregnant or suspects she is pregnant while participating in this study, she must agree to inform her treating physician immediately.',\n",
       " 'Sexually active men must agree to use a medically acceptable form of birth control during treatment and at least 6 months after the last dose.',\n",
       " 'If a female partner becomes pregnant during the course of the study the treating physician should be informed immediately.',\n",
       " '9.',\n",
       " '>18 years of age.',\n",
       " '10.',\n",
       " 'Ability to understand the nature of this study, give written informed consent, and comply with study requirements.',\n",
       " '11.',\n",
       " 'Patients entering this study must be willing to provide tissue from a previous tumor biopsy (if available) for correlative testing.',\n",
       " 'An exception to this is when the national/local regulations prohibits some of the key activities of this research like the export of samples to third countries, storage of coded samples or global gene expression profiling without a pre-specified list of target genes.',\n",
       " 'If tissue is not available, a patient will still be eligible for enrollment into the study.',\n",
       " 'Patients undergoing total knee arthroplasty under spinal anaesthesia\\n45y or older\\nASA 1-3\\nBMI 18-35',\n",
       " 'Persistent primary or recurrent trans-sphincteric anal fistula',\n",
       " 'Age 60 years or older.',\n",
       " 'Current diagnosis of major depressive disorder (DSM-IV-TR), single episode, recurrent or chronic, without psychotic features, as detected by MINI and clinical exam.',\n",
       " 'Minimum MADRS score = 15.',\n",
       " 'Mini-Mental State Exam = 24.',\n",
       " 'Fluent in English.',\n",
       " 'generally healthy grade 1-2 school children\\nwith written parental consent\\nwith at least 1 sound and fully erupted permanent first molar',\n",
       " 'American Society of Anesthesiologist (ASA) status I-II adult patients undergoing elective laparoscopic cholecystectomy.',\n",
       " 'Elective surgery for thoracic aneurysm',\n",
       " 'DSM-IV or DSM-5 diagnosis of schizophrenia or schizoaffective disorder\\nMale or Female\\nAge: 18 to 65 years\\nCaucasian or Non-Caucasian\\nSmoke at least 10 cigarettes daily\\nUrine cotinine level ?',\n",
       " '100 ng/ml (NicAlert(r) reading ?',\n",
       " '3)\\nAgrees to wear a head mounted display (HMD) for up to 45 minutes\\nAble to complete the Evaluation to Sign Consent (ESC) with minimum score of 80%',\n",
       " 'planned sequential both-sided lower third molar extraction (split-mouth) with osteotomy (with or without upper molar extraction in local anesthesia)\\nable to understand the study and the NRS scale',\n",
       " 'Male participants between 18 and 40 years-old\\nWritten informed consent signed by the participant',\n",
       " 'Vestibular schwannoma advised to surgical treatment\\nNo measurable remaining vestibular function',\n",
       " 'Male\\n18 years of age\\nPresenting with hernia requiring surgical intervention',\n",
       " 'Children aging between 3 and 6 years\\npresenting good health conditions\\nwhose parents or legal guardians accept and sign the consent form\\nwith at least one occlusal or occlusal proximal caries lesion in primary molars\\nonly occlusal and/or occlusal-proximal surfaces with caries lesions with dentin involvement',\n",
       " 'Patients both sexes\\nAge between 31 and 60 years\\nDiagnosis of diabetes according ADA criteria:',\n",
       " 'Clinical diagnosis of calculous cholecystitis.',\n",
       " '1.',\n",
       " 'Males and females age â\\x89¥18 years in second relapse or refractory.',\n",
       " '2.',\n",
       " 'Males and females age â\\x89¥60 years in first relapse or refractory.',\n",
       " '3.',\n",
       " 'Must have baseline bone marrow sample taken.',\n",
       " '4.',\n",
       " 'Morphologically documented primary AML or AML secondary to myelodysplastic syndrome (MDS with â\\x89¥20% bone marrow or peripheral blasts), as defined by the World Health Organization (WHO) criteria, confirmed by pathology review at treating institution.',\n",
       " '5.',\n",
       " 'Able to swallow the liquid study drug.',\n",
       " '6.',\n",
       " 'ECOG performance status of 0 to 2 \\n7.',\n",
       " 'In the absence of rapidly progressing disease, the interval from prior treatment to time of AC220 administration will be at least 2 weeks for cytotoxic agents or at least 5 half-lives for noncytotoxic agents.',\n",
       " 'The use of chemotherapeutic or antileukemic agents other than hydroxyurea is not permitted during the study with the possible exception of intrathecal (IT) therapy at the discretion of the Investigator and with the agreement of the Sponsor.',\n",
       " '8.',\n",
       " 'Persistent chronic clinically significant non-hematological toxicities from prior treatment must be â\\x89¤Grade 1.',\n",
       " '9.',\n",
       " 'Prior therapy with FLT3 inhibitors is permitted, except previous treatment with AC220.',\n",
       " '10.',\n",
       " 'Serum creatinine â\\x89¤1.5 Ã\\x97 ULN and glomerular filtration rate (GFR) > 30 mL/min \\n11.',\n",
       " 'Serum potassium, magnesium, and calcium levels should be at least within institutional normal limits.',\n",
       " '12.',\n",
       " 'Total serum bilirubin â\\x89¤1.5 Ã\\x97 ULN \\n13.',\n",
       " 'Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) â\\x89¤2.5 Ã\\x97 ULN \\n14.',\n",
       " 'Females of childbearing potential must have a negative pregnancy test (urine Î²-hCG).',\n",
       " '15.',\n",
       " 'Females of childbearing potential and sexually mature males must agree to use a medically accepted method of contraception throughout the study.',\n",
       " '16.',\n",
       " 'Written informed consent must be provided.',\n",
       " '1.',\n",
       " 'Male and female subjects must be 18 years of age or older and ambulatory.',\n",
       " '2.',\n",
       " 'Females of child-bearing potential (FOCP) must have a negative serum beta human chorionic gonadotropin (HCG) pregnancy test.',\n",
       " '3.',\n",
       " 'A documented history of severe Symptomatic Orthostatic Hypotension (SOH) that, in the judgment of the treating physician, has required treatment with midodrine HCl , and has been at a stable dose for at least 3 months.',\n",
       " '4.',\n",
       " 'The subject has manifested at least 1 of the following symptoms while standing or had a medical history of 1 of the following when not treated for orthostatic hypotension (OH): dizziness, lightheadedness, feeling faint, or feeling like they might black out.',\n",
       " 'American Society of Anesthesiologists Classification I-III\\nNormal cognitive function in order to sign written, informed consent and to understand trial protocol\\nAgreement to the trial protocol, including the randomized manner',\n",
       " 'Age = 18 years of either gender\\nWritten informed consent must be obtained before any intravitreal injection of bevacizumab is performed\\nVisual impairment predominantly due to abnormal new vessel ingrowth and/or macular edema.',\n",
       " 'The presence of fluid (intraretinal, subretinal or sub-RPE) detected clinically or on the ocular coherence tomography.',\n",
       " 'Post menopausal women with a history of estrogen positive breast cancer who are receiving aromatase inhibitors for at least one month.',\n",
       " 'Patients must complain of mild to moderate arthralgia.',\n",
       " 'Ability to understand and sign informed consent.',\n",
       " 'Patients meet criteria for low to moderate risk for moderate exercise based oon the ACSM guidelines.',\n",
       " 'patient 18 years old and more\\nwith multiple sclerosis according to the criteria of Mac Donald 2010 : relapsing-remitting (RR), secondary-progressive (SP) or primary-progressive (PP)\\nfor which treatment with dimethyl-fumarate has been prescribed\\nfollowed at the Rothschild Foundation in the Neurology Department\\nhaving given written consent to participation in the study',\n",
       " 'Ability to understand and the willingness to sign a written informed consent document\\nAge= 18 and= 75 years\\nClinical/ Histological/ cytological/ Imaging examination proven Oral/Oropharynx Squamous-cell carcinoma (Tongue, buccal mucosa, mouth floor, hard palate, Molar area), the depth of invasion > 4mm in preoperative assessment\\nIn line with clinical stage I / II stage (T1-2 N0 M0; AJCC 2010) and receiving surgical resection\\nKPS= 70\\nNormal bone marrow reserve function and normal liver, kidney function\\nExpected survival period= 6 months',\n",
       " 'Patients older than 18 years\\nClassification of the American Society of Anesthesiologists (ASA I-III)\\nNo cognitive deficits\\nSigned informed consent prior to surgery',\n",
       " 'Body mass index (BMI): 18 â\\x89¤ BMI â\\x89¤ 32 kg/mÂ² \\nPostmenopausal state revealed by: \\nMedical history, if applicable (natural menopause at least 12 months prior to first study drug administration; or surgical menopause by bilateral ovariectomy at least 3 months prior to first study drug administration), in addition: in women < 65 years old, follicle stimulating hormone (FSH) > 40 IU/L',\n",
       " 'women and men between 18 - 80 years of age\\ntype 2 diabetes mellitus\\nearly to moderate stage diabetic retinopathy (ETDRS: 20 (microaneurysms only) to 35 (microaneurysms/ hemorrhages and/or hard exsudates)) in one or both eyes\\nstable HbA1c (Â± 0.5%) for at least 12 weeks\\nantidiabetic treatment with either diet, metformin, DPP4, GLP1, pioglitazone, acarbose, or respective combinations\\nHbA1c = 6.5 and = 10.0 %\\nbody mass index < 46 kg/m2\\noffice blood pressure = 150/95 mmHg (confirmed on a second day; 24h ambulatory blood pressure measurement (ABPM) is allowed to check accuracy of office values; inclusion with 24h mean blood pressure = 145/90 mm Hg is possible); patients with hypertension should be treated according to current treatment guidelines\\nat least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral oophorectomy\\nhysterectomy\\n= 50 years and in postmenopausal state > 1 year\\n< 50 years and in postmenopausal state > 1 year with serum follicle stimulating hormone (FSH) > 40 IU/l and serum estrogen < 30 ng/l or a negative estrogen test, both at screening or women of childbearing potential with a negative serum beta human chorionic gonadotropin (Ã\\x9f-hCG) pregnancy test at screening who agree to meet one of the following criteria from the time of screening, during the study and for a period of 4 days following the last administration of study medication:\\ncorrect use of one of the following accepted contraception methods: hormonal contraceptives (combined oral contraceptives, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release), intrauterine device (IUD/IUS) or a double barrier method, e.g.',\n",
       " 'condom and occlusive cap (diaphragm or cervical/vault caps) with spermicide (foam, gel, film, cream or suppository)\\ntrue abstinence (periodic abstinence and withdrawal are not acceptable methods of contraception)\\nsexual relationship only with female partners\\nsterile male partners\\nsigned written informed consent and willingness to comply with treatment and follow-up procedures\\ncapability of understanding the investigational nature, potential risks and benefits of the clinical trial',\n",
       " 'current diagnosis of narcolepsy with cataplexy OR healthy control',\n",
       " 'Children receiving amoxicilline-clavulanic acid (50-90 mg/kg/day, twice daily) due to acute otitis media or acute sinusitis',\n",
       " 'patients who underwent successful TAVI\\nwith any approved TAVI device\\nvia transfemoral access\\nwith use of any of the approved vascular closure devices\\nprovided written informed consent',\n",
       " 'Patients with biopsy-proven metastatic carcinoid tumors or other neuroendocrine tumors (Islet cell, Gastrinomas and VIPomas) with at least one measurable lesion (other than bone) that has either not been previously irradiated or if previously irradiated has demonstrated progression since the radiation therapy \\nThe patient has no major impairment of renal or hepatic function, as defined by the following laboratory parameters: total bilirubin <1.5 X ULN; AST, ALT<2.5X ULN (<5 X ULN if liver metastases are present) \\nPatients on Sandostatin Lar (long acting somatostatin analogue) must be on a stable dose for 30 days prior to study entry and short acting somatostatin analogues must be judged to be on a clinically stable dose by the investigator prior to study entry \\nMust have a life expectancy of greater than three (3) months \\nKarnofsky Performance Status > 60 \\nFemale patients must have a negative serum pregnancy test at screening.',\n",
       " '(Not applicable to patients with bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal.)',\n",
       " 'age=65 years\\ndiagnosis with mantle cell lymphoma\\nAnn Arbor stage II,III or IV\\nECOG=1 or if ECOG=2 but recover after pretreatment.',\n",
       " 'full term singleton pregnant women\\nScheduled for elective Cesarean Delivery\\nAged between 18 and 40 years',\n",
       " 'history of significant bleeding (i.e.',\n",
       " 'bleeding which required intervention or hospitalization), even in the absence of anticoagulation treatment at the time of the bleeding event, or\\na cardioembolic event, which occurred on anticoagulation, or\\na high risk profile of the patient, defined as a CHA2DS2-VASc score = 3 and a HAS-BLED score = 2',\n",
       " 'Current DSM-IV diagnosis of cannabis dependence, >1 week detoxified and abstinent;\\nAble to provide written informed consent and to comply with study procedures.',\n",
       " 'Dutch speaking (Dutch as primary language).',\n",
       " 'Be scheduled for trans-jugular liver biopsy the day of the ultrasound procedure.',\n",
       " 'Be at least 21 years of age.',\n",
       " 'Be medically stable.',\n",
       " 'If a female of child-bearing potential, must have a negative pregnancy test.',\n",
       " 'Be conscious and able to comply with study procedures.',\n",
       " 'Have read and signed the IRB-approved Informed Consent form for participating in the study.',\n",
       " 'Symptomatic patients with heart failure (men and women) aged >18 years,\\nFunctional class II, III or IV by the New York Heart Association (NYHA)\\nLeft ventricular ejection fraction <35%\\nIschemic and nonischemic etiology\\nType B natriuretic peptide (BNP) >150 pg/ml (or pro-BNP [N-terminal-proBNP] = 600 pg / ml) or if the patient was hospitalized for cardiac decompensation within the preceding 12 months, BNP >100 pg/ml (or N-terminal-proBNP = 400 pg / ml)',\n",
       " \"moderate to severe Crohn's Disease (basic HBI = 7) with stenosis\",\n",
       " 'Male or female subjects aged =18 to =65 years\\nGeneral good health as established by medical history and physical examination\\nWritten informed consent\\nFemales of childbearing potential must agree to use an efficacious hormonal or barrier method of birth control during the study.',\n",
       " 'Abstinence is acceptable.',\n",
       " 'Available for all visits scheduled in this study.',\n",
       " 'full term\\nsingleton pregnant women\\nscheduled for elective cesarean delivery',\n",
       " 'Single unit implant rehabilitation\\nMaxilla and mandible\\nMust accept treatment plan\\nMust sign informed consent\\ndental extraction performed at least 3 month prior\\nMust have at least 6 mm of residual bone\\nAbsence of oral lesions\\nkeratinized tissue must be present',\n",
       " 'Patients with a confirmed diagnosis of: \\n1.',\n",
       " 'Stage 4 colon cancer either s/p metastasectomy or post-initial chemotherapy or maintenance \"standard of care\", either involving 5-fluorouracil/leucovorin (5-FU/LV) alone or continual bevacizumab alone.',\n",
       " 'Patients in maintenance cohort must have had 2 consecutive CT scans showing stable disease and not be experiencing significant prior treatment-related toxicity above Grade 1.',\n",
       " '2.',\n",
       " 'Pancreas cancer, either s/p resection and adjuvant chemotherapy or locally advanced pancreas cancer s/p chemotherapy and radiation.',\n",
       " 'Initial chemotherapy or radiation therapy may have been stopped between 2 weeks and 2 months prior to study start, and patients must have recovered from prior treatment related toxicity to grade 1 or less.',\n",
       " 'Prior surgery, including tumor resection or metastasectomy must have been performed at least 4 weeks prior to study enrollment.',\n",
       " \"No concomitant anti-cancer treatment is allowed \\nAge >/= 18 years \\nPerformance status of 0-1 \\nAdequate hepatic, bone marrow, and renal function \\nPartial thromboplastin time (PTT) must be </= 1.5 x upper normal limit of institution's normal range and INR (International Normalized Ratio) < 1.5.\",\n",
       " 'Life expectancy >/= 4 months for maintenance cohorts and >/= 6 months for adjuvant cohorts \\nWomen of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and must not be lactating.',\n",
       " 'Subject is capable of understanding and complying with protocol demands and able to sign and date the informed consent',\n",
       " 'treatment-naive patients with B-cell lymphoma\\nHBsAg positive at baseline\\ntreated with rituximab-based immunochemotherapy\\nlife expectancy of more than 3 months',\n",
       " 'Provision of fully informed consent prior to study specific procedures.',\n",
       " 'Patients must be >= 19 years of age\\nRET fusion positive or FGFR2 fusion/other FGFR mutation Refractory solid tumor and/or specific sensitivity to Sunitinib by Avatar scan that has progressed following standard therapy or that has not responded to standard therapy or for which there is no standard therapy.',\n",
       " 'ECOG Performance status0-2\\nHave measurable or evaluated disease based on RECIST 1.1 as determined by investigator.',\n",
       " 'Absolute neutrophil count >= 1.5 x 109/L, Hemoglobin >= 9g/dL, Platelets>=100 x 109/L Bilirubin <= 1.5 x upper limit of normal AST/ALT <= 2.5 X upper limit of normal(5.0 x upper limit of normal, for subject with liver metastases) Creatinine<= 1.5 X UNL\\nPatients of child-bearing potential should be using adequate contraceptive measures should not be breast feeding and must have a negative pregnancy test prior to start of dosing\\nAdequate heart function',\n",
       " 'satisfying DSM-V criteria for ED and for half of the patients in addition \\nhave a history of childhood trauma.',\n",
       " '3-17 years\\nweight </= 100kg\\nscheduled for urologic or orthopedic procedure necessitating intrathecal morphine\\nability to use verbal or pictorial pain assessment tools and techniques\\ninformed consent and (if applicable) assent',\n",
       " 'Adult outpatients (18 years or older)\\nroutinely referred for small bowel video capsule endoscopy (CE)',\n",
       " 'Before participate in the study, patients must understand the treatment plan and willing to participate in the study.',\n",
       " 'Patients must have signed an approved informed consent.',\n",
       " 'Histopathologic confirmed squamous cell carcinoma of head and neck ,including oral cavity, oropharynx, larynx, or hypopharynx.',\n",
       " 'Ages=65 years,Not limited to gender.',\n",
       " 'ECOG performance status =2.',\n",
       " 'Patients with surgical contraindication or reject to surgery.',\n",
       " 'Postoperative TNM(primary tumor,regional nodes,metastasis) staging III~IV, positive surgical margin.',\n",
       " 'without evidence of distant metastases.',\n",
       " 'No contraindication to chemoradiotherapy.',\n",
       " 'Life expectancy > 3 months.',\n",
       " 'Available Organ function: white blood cell=3.5Ã\\x97109/L, Neutrophils =1.5Ã\\x97109/L, Hemoglobin =80g/L, Blood platelet>100Ã\\x97109/L; Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST)= 2.5 upper limit of normal(ULN); Total bilirubin (TBIL) <1.5 ULN;serum creatinine=1.5 ULN; creatinine clearance of = 50ml/min',\n",
       " 'South Australian secondary school students in years 10, 11, and 12 in 2017\\nWritten parental consent for those under the age of 18\\nWritten student consent assent for those under the age of 18 (or if 18 years old and older consent for themselves)\\nAvailable at school for at least the first pharyngeal swab and willing to comply with study procedures',\n",
       " 'Healthy patients age 18 and older\\nBreech presentation\\nSingleton gestation .scheduled for ECV desiring CSE.',\n",
       " 'Probable or definite diagnosis of autoimmune hepatitis according to the International Autoimmune Hepatitis Study Group criteria\\nFirst presentation of AIH requiring treatment according to the current EASL guidelines\\nAge = 18 years\\nMust provide informed consent and agree to comply with the trial protocol',\n",
       " 'All patients admitted to the ICU in septic shock\\nAll patients that develop septic shock while in the ICU',\n",
       " 'Aged over 18\\nPrimary symptom of chest pain\\nNo contraindication to CTA\\nWilling and able to provide written informed consent',\n",
       " 'ASA I and II women\\n18-45 yrs old\\nSingleton pregnancy\\nCervical cerclage 1st or 2nd trimester of pregnancy undergoing with spinal anesthesia\\nHeight 150 - 180 cm\\nBMI = 40 kg/m2.',\n",
       " 'males and females greater than or equal to 18 years of age\\ncurrent regular user of e-cigarettes (use at least once daily for the past 30 days) with nicotine strength > 6mg/ml\\nhealth medical history\\nabstinent from any tobacco/nicotine use for 4 hours prior to imaging',\n",
       " 'Age between one year and 18 years\\nSepsis due to MDR or minimally susceptible gram-negative bacteria\\nHistory of MDR gram-negative infection or sepsis due to organisms sensitive to colistin.',\n",
       " 'Culture result consistent with MDR gram negative for this febrile neutropenic episode.',\n",
       " 'Patient in sepsis and colistin was administered empirically to increase antibiotic coverage.',\n",
       " '1.',\n",
       " 'Women 18 to 40 years of age inclusive who can give written informed consent \\n2.',\n",
       " 'Available for all visits and consent to follow all procedures scheduled for the study \\n3.',\n",
       " 'Agree to daily application of gel and monitoring as per Daily Monitored Adherence (DMA) method \\n4.',\n",
       " 'Healthy and self-reported sexually active \\n5.',\n",
       " 'HIV-negative as determined by a HIV rapid test at time of enrollment \\n6.',\n",
       " 'On a stable form of contraception and willing to continue on this stable method of contraception, OR, Have undergone surgical sterilisation at least 3 months prior to enrollment \\n7.',\n",
       " 'In the absence of the use of exogenous hormone(s), have a self-reported regular menstrual cycle defined as having a minimum of 21 days and a maximum of 36 days between menses \\n8.',\n",
       " 'Upon pelvic/speculum examination and colposcopy at the time of enrollment, the cervix and vagina appear normal as determined by the investigator \\n9.',\n",
       " 'Asymptomatic for genital infections at the time of enrollment \\n10.',\n",
       " 'Willing to refrain from use of vaginal products or objects within 14 days prior to enrollment and for the duration of the study \\n11.',\n",
       " 'Willing to answer acceptability and adherence questionnaires throughout the study \\n12.',\n",
       " 'Willing to refrain from participation in any other research study for the duration of this study \\n13.',\n",
       " 'Willing to provide adequate locator information for study retention purposes and be reachable per local standard procedures',\n",
       " 'Intrauterine fetal death as confirmed by absence of cardiac motion on ultrasound by Attending physician at the time of admission to the hospital.',\n",
       " 'Estimated gestational age greater than 20 weeks\\nHemodynamically stable and appropriate for induction of labor as per primary clinical health team in house\\nWomen with one prior low transverse cesarean delivery',\n",
       " 'Men or women, 18 to 65 years old with a BMI of 35 kg/m2 or greater who will be undergoing bariatric surgery (VSG and RYGB)\\nSigned written informed consent\\nWomen of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug\\nWomen must not be breastfeeding',\n",
       " 'patients with FEV1 / FVC <70%',\n",
       " 'patients undergoing venous malformation embolization operation through general anesthesia.',\n",
       " 'aged 18-65 years old.',\n",
       " 'operating time varies 1-4h,and extubation after the operation.',\n",
       " 'Age greater than or equal to 18 years\\nHave RA, as defined by the 1987 revised American College of Rheumatology criteria\\nIn sustained clinical remission for the last 6 months while receiving treatment with either etanercept, infliximab, or adalimumab, and greater than or equal to 1 DMARD (methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, minocycline, cyclosporine, azathioprine, gold, penicillamine).',\n",
       " 'DAS28 should be less than 2.6 on each visit over the preceding 6 months, with at least one visit 2-4 months before enrollment.',\n",
       " 'If there is no visit 6 months before enrollment, the nearest visit in the 6-12 month period before enrollment should be considered and have a DAS28 less than 2.6.',\n",
       " 'Subjects chronically infected with HCV Genotype 1 \\nHCV RNA viral load of â\\x89¥ 10*5* IU/mL (100,000 IU/mL) at screening',\n",
       " 'Adult kidney transplant recipients > 18 y.o.',\n",
       " 'Kidney Transplant recipients, after the first episode of cytomegalovirus infection, using the current immunosuppressive regimen: azathioprine or mycophenolate, tacrolimus and prednisone.',\n",
       " 'Women at any age with early stage breast cancer (stage I-II) and American Society of Anesthesiologists (ASA) score of I-II.',\n",
       " 'Informed consent of parent(s) or legal guardian; informed consent or assent of subject as applicable.',\n",
       " 'Male or female children between the ages of 10 and 35 years with congenital heart disease that has been palliated with a Fontan circulation.',\n",
       " 'Ability of perform a maximal exercise test as defined by a respiratory exchange ratio (RER) greater than 1.0 at the time of maximal exercise',\n",
       " 'Age over 18 years\\nPatients with rectal cancer stage: cT1-2-3, cN0-1, cM0.',\n",
       " 'Tumor equal or below 10 cm from the anal verge, candidates to (ETM) low anterior resection and anastomosis, with or without preoperative chemo-radiotherapy.',\n",
       " 'Adenocarcinoma of low or moderate differentiation\\nASA I, II, III.',\n",
       " 'Scheduled to undergo revision total knee arthroplasty',\n",
       " '> 18 years old\\nAcute symptomatic BV\\nSigned informed consent\\nInsufficient knowledge of German\\nIlliteracy\\nPregnancy\\nAcute illness\\nKnown allergies against ingredients of the investigational products',\n",
       " 'Informed consent\\nDiagnosis of type 2 diabetes (HbA1c > 48 mmol/mol)\\nAge older than 30 years',\n",
       " 'Current diagnosis of otolaryngeal cancer and undergoing surgery with general anesthesia\\nCompetent to provide informed consent',\n",
       " 'Scheduled for bilateral varus rotational osteotomy (VRO) with or without associated soft tissue and osseous procedures',\n",
       " 'Symptomatic primary knee osteoarthritis with failed conservative treatment at least 3 months\\nKellgren-Lawrence grade I-III\\nGave informed consent\\nCan do questionnaires',\n",
       " 'Male \\nAge between 18 and 49 years old; \\nWilling to provide name, address, telephone and other contact information in order to be contacted, whenever needed (example: in case of missing any scheduled visit, contact for confirmation of scheduling a visit, urgent safety notifications); \\nWilling to strictly follow the study protocol; \\nCapacity for understanding and signing in the Informed Consent Form; \\nTo understand the impossibility of participating in another clinical trial during the time of participation in the study, until 6 months after its conclusion; \\nIntellectual level which allows to filling in the diaries for registering of symptoms at home; \\nWilling to undergo to serological testing to HIV, HBV and HCV; \\nBeing in good health, with no significant medical history; \\nPhysical examination at screening period without clinically significant changes; \\nLab examination at screening period within the normal ranges, determined by the laboratory or abnormal values, grading below 1 or 2, according to medical decision.',\n",
       " '1.',\n",
       " 'Patient is over 18 years old.',\n",
       " '2.',\n",
       " 'Patient is scheduled for a non-emergency procedure.',\n",
       " '3.',\n",
       " 'Subject signs and dates a written informed consent form (ICF) and indicates an understanding of the study procedures.',\n",
       " 'Age = 15 years old\\nHospitalization with acute undifferentiated fever (temperature > 37.5 C, tympanic) =14 days or patients admitted to hospital with a history of fever = 14 days who subsequently develop fever within 24 hours of admission\\nClinically suspected scrub typhus: defined as acute undifferentiated fever with no clear focus of infection and negative malaria blood smear and/or negative malaria RDT.',\n",
       " 'Patients may have one, none, or a combination of other clinical findings such as eschar, rash, lymphadenopathy, headache, myalgia, cough, nausea and abdominal discomfort.',\n",
       " 'A positive scrub typhus RDT (Scrub Typhus IgM RDT, InBios International, Seattle, WA, USA) and/or positive PCR-based detection of O. tsutsugamushi DNA from the admission blood sample\\nWritten informed consent and/or, written informed assent as required\\nAble to take oral medication',\n",
       " 'Corneal ulcer that is smear positive for either bacteria or filamentous fungus\\nPinhole visual acuity worse than 20/70 in the affected eye\\nNot treated already with antimicrobial medications at presentation\\nAge over 18 years\\nBasic understanding of the study as determined by the physician\\nCommitment to return for follow up visits',\n",
       " 'Patients are of American Society of Anesthesiologists (ASA) physical status I and II, aged 8-14 years old, of both gender, with suspected acute appendicitis scheduled for laparoscopic appendicectomy.',\n",
       " 'Undergoing mid-urethral sling surgery\\nHave symptoms of both stress and urgency urinary incontinence\\nAble to consent, fill out study documents, and complete all study procedures and follow-up visits\\nAt least 18 years of age\\nEnglish speaking\\nBe able and willing to learn clean intermittent self catheterization technique',\n",
       " '18 years or older patients who are proven to be infected by Helicobacter pylori based on positive in Urea Breath Test or positive in histopathologic examination of biopsy in antrum and corpus of gaster through esophagoduodenoscopy.',\n",
       " 'Aged 18 years or older\\nPreviously taken one or more statins\\nWithdrawn from statins because of perceived side effects\\nDeveloped side effects within 2 weeks of initiation\\nClinical indication for statins for primary or secondary prevention of cardiovascular disease or dyslipidaemia, on either no medication or non-statin lipid lowering therapy (e.g, ezetimibe)',\n",
       " \"The patients signed the written informed consent\\nThe patients present with operable unilateral invasive breast cancers without distant metastasis(stage I, II, and III)\\nThe breast tumor's positive ER/PR rate is <1%, and positive ER-beta1 rate is =10% by IHC.\",\n",
       " 'The patients have no history of neoadjuvant hormone therapy.',\n",
       " 'The patients have normal cardiac functions by echocardiography.',\n",
       " \"The patients' ECOG scores are =0-2.\",\n",
       " 'Female patient who is = 18yrs, and = 65yrs.',\n",
       " 'The patients are non-pregnant, and disposed to practice contraception during the whole trial.',\n",
       " 'The patients underwent neoadjuvant chemotherapy plus surgery or directly modified radical mastectomy or breast-conserving surgery (plus sentinel lymph node biopsy or axillary lymph node dissection) after diagnosis of breast cancer.',\n",
       " 'The patients underwent chemotherapy, radiation therapy or targeted therapy(herceptin) after surgery according to the 2013 NCCN guideline.',\n",
       " \"The results of patients' blood tests are as follows:\",\n",
       " 'Healthy\\nMale\\n>7 Metabolic Equivalents\\nWritten informed consent\\nChronic pain syndrome\\nDrug abuse\\nAlcohol abuse\\nSuspicion of neurologic dysfunction at tested sites\\nOngoing treatment with antidepressants\\nOngoing treatment with analgesics\\nPretreatment with any CYP3A inducers or inhibitors\\nKnown allergy to tested drugs\\nElevated eye pressure\\nObstructive uropathy\\nHeart disease\\nPulmonary disease\\nNeurological disease\\nPsychiatric illness',\n",
       " 'Diagnosis of emphysema confirmed by CT scan.',\n",
       " 'If a report of past CT scan is not available at site documenting then a CT scan is to be performed at screening \\nMale or female patients at least 18 years of age.',\n",
       " 'Able and willing to sign an informed consent.',\n",
       " 'Patient with record of congenital AAT deficiency of phenotype PiZZ (homozygote) or other rare phenotypes related to AAT deficiency and with AAT serum level â\\x89¤ 11 micromole.',\n",
       " 'For patients receiving IV AAT augmentation therapy the serum AAT level threshold does not apply.',\n",
       " 'FEV1/SVC <70% of predicted value post bronchodilator (SVC is slow VC) and FEV1 < 80% of predicted value post-bronchodilator \\nHistory of at least two moderate or severe exacerbations that required change in treatment (antibiotics, systemic steroids, hospitalization) in the last 18 months prior to date of screening , with at least one of these occurring within the last 12 months prior to screening.',\n",
       " 'Ability to comply with completion of electronic diary.',\n",
       " 'Ability to self-administer inhaled AAT.',\n",
       " \"No significant abnormalities in serum hematology, serum chemistry and serum inflammatory / immunogenic markers according to the Principal Investigator's judgment, taking into considerations the potential effects of the AAT deficiency.\",\n",
       " \"No significant abnormalities in urinalysis according to the Principal Investigator's judgment, taking into considerations the potential effects of the AAT deficiency.\",\n",
       " 'No significant abnormalities in ECG per investigator judgment.',\n",
       " 'Negative for HBsAg and for antibodies to HCV, HIV-1.',\n",
       " 'AAT deficient patients who are either naÃ¯ve (not receiving IV augmentation therapy) or AAT deficient patients (receiving IV augmentation therapy), if they have been stable on regular therapy for at least 3 months prior to the screening visit and are willing to continue the same regime throughout this trial.',\n",
       " 'Note that only sites in Germany can recruit patients who are currently being treated with IV AAT.Patients who stopped IV augmentation treatment 6 months prior to screening date and will not re-start this treatment for the course of the study will be considered NaÃ¯ve.',\n",
       " 'Non-pregnant, non-lactating female patients, whose screening pregnancy test is negative and who are using contraceptive methods deemed reliable by the investigator, or who are at least 2 years post-menopausal or surgically sterilized.',\n",
       " 'Diagnosis of sacroiliitis\\nAge 18 to 80 years old\\nChronic low back pain\\nSI joint pathology is the predominant source of pain\\nPositive Fortin Finger Test (PMT)\\nJoint anatomy is identifiable using ultrasonography\\nPatient has no other comorbidities that contraindicate the procedure\\nPatient has attempted physical therapy and corticosteroid injections with local anesthetic -Previous injections of lidocaine and corticosteroid provided at least minor immediate relief\\nPatient must not have had a corticosteroid injection in the SI joint within the last three months\\nPatient must consent to the procedure',\n",
       " 'All children scheduled for outpatient MRI scans with expected duration of scan between 30 minutes and 75 minutes.',\n",
       " 'Aged 5 years to less than 12 years at Visit 1.',\n",
       " 'At least 15 (25%) children of the total study population must be aged 5 to less than 8 years.',\n",
       " 'Male or pre-menarchial female subjects.',\n",
       " 'Subjects must be pre-adolescent without any signs of puberty (Tanner Stage 1).',\n",
       " 'Normal range for their height and weight.',\n",
       " 'Weight and height measurements should fall within the percentile range 3-97% of normal values for age according to Danish growth charts.',\n",
       " 'Have a documented diagnosis of persistent asthma, as defined by the National Institutes of Health for at least 3 months prior to the Screening Visit.',\n",
       " 'A pre-bronchodilatory forced expiratory flow in 1 second (FEV1) at Visit 1 (Screening) >=80% predicted.',\n",
       " 'There should be no Short acting beta-agonist (SABA) use within 4 hours of this measurement.',\n",
       " 'Using one of the following asthma therapies prior to entry into the study: SABA inhaler alone (e.g.',\n",
       " 'salbutamol) on an as required basis and/or Regular non-inhaled corticosteroid (ICS) controller medications for asthma (e.g.',\n",
       " 'cromones or leukotriene receptor antagonists) and/or Previously treated with ICS (equipotent to inhaled budesonide <=400 micrograms (mcg) total daily dose).',\n",
       " 'There must be no ICS use within 2 weeks of Visit 1 (Screening).',\n",
       " 'Able to replace their current SABA treatment with study supplied rescue SABA provided at Visit 1 for use as needed for the duration of the study.',\n",
       " 'Written informed consent from at least one parent/care giver (legal guardian) and accompanying informed assent from the subject (where the subject is able to provide assent) prior to admission to the study: (1) If applicable, subject must be able and willing to give assent to take part in the study according to the local requirement.',\n",
       " \"The study investigator is accountable for determining a child's capacity to assent to participation in a research study, taking into consideration any standards set by the responsible independent ethics committee (IEC).\",\n",
       " '(2) Subject and their legal guardian(s) understand that the study requires them to be treated on an outpatient basis.',\n",
       " '(3) Subject and their legal guardian(s) understand that they must comply with study medication and study assessments including recording of peak expiratory flow and rescue SABA use, attending scheduled study visits, and being accessible by a telephone call.',\n",
       " 'Male or Female.',\n",
       " 'No age restriction.',\n",
       " 'Diagnosed with an infection related stone.',\n",
       " 'Medically fit for definitive surgical management of stone.',\n",
       " 'Life expectancy greater than one year.',\n",
       " 'Stone free after definitive surgical therapy defined as fragments less than 3mm.',\n",
       " 'Signed written informed consent.',\n",
       " 'Age 18 to 65.',\n",
       " 'Normal and healthy (immune competent) as determined by medical history, physical exam, vital signs and clinical laboratory tests during the screening period.',\n",
       " 'If all lab results for quantitative IgA immunoglobulin level are lower than 15% below normal range, the subject may not proceed further in the screening process.',\n",
       " 'Subject must meet all required subject suitability criteria that pertain to normal source plasma donors.',\n",
       " 'Negative HIV serology during screening period.',\n",
       " 'Subject must have been previously immunized for smallpox, at =3 years prior to commencement of screening assessments, and vaccination history must be confirmed by oral or written history and the presence of a visible pathognomonic smallpox vaccination scar.',\n",
       " 'Female subjects of childbearing potential must agree to use highly effective birth control methods.',\n",
       " 'Ultrasound confirmed complete mole',\n",
       " 'primary total knee replacement surgery\\nASA (american society of anesthesiologists) class 1-3',\n",
       " 'Primary B-NHL, PTCL (ALK+ anaplastic large cell lymphoma and NK(natural killer cell )/T cell lymphoma were excluded) or HL patients confirmed by histopathology;\\nAges =18 years old, < 80 years old;\\nECOG (Eastern Cooperative Oncology Group)score: 0-2\\nAt least one measurable lesion;\\nExpected survival time=3 months;\\nLiver function: transaminase=2.5Ã\\x97 upper limit of normal value,bilirubin=1.5Ã\\x97upper limit of normal value;\\nRenal function: serum creatinine is 44-133 mmol/L;\\nRoutine blood test:WBC=3.0Ã\\x97109/L,Neutrophils=1.5Ã\\x97109/L,Hb=100g/L,Platelet=80Ã\\x97109/L; LVEF=50%;\\nNew York Heart Association (NYHA) heart function classification is I-II grade\\nsigned informed consent.',\n",
       " 'Age = 18 years\\nAmerican Society of Anesthesiologists Classification I-III\\nNormal cognitive function in order to sign written, informed consent and to understand trial protocol\\nAgreement to the trial protocol, including the randomized manner',\n",
       " 'major depressive episode in type2 bipolar disorder or bipolar disorder NOS.',\n",
       " '(MADRS more than 20 point)\\n18years to 65years\\nsubjects who sign the informed consent document',\n",
       " 'Age 18 or older.',\n",
       " 'Patients diagnosed with acromegaly with GH-secreting pituitary adenoma on sellar MRI, meeting the biochemical criteria outlined above (refer to 1.',\n",
       " 'Diagnosis of acromegaly) and with typical acromegalic features.',\n",
       " 'No prior use of somatostatin analogues.',\n",
       " 'Adequate hepatic and renal function\\nProvision of a signed written informed consent',\n",
       " 'Women be at least 18 years of age\\nHave symptoms of vaginal odor and or/discharge\\nMeet the clinical (Amsel) criteria for BV\\nWilling to participate in research',\n",
       " 'ASA (American Society of Anesthesiologists) class 1 & 2,\\nundergoing day-case knee arthroscopy',\n",
       " '1.',\n",
       " 'Males and females â\\x89¥ 18 years old.',\n",
       " '2.',\n",
       " 'Clinical diagnosis of type 1 diabetes for at least one year.',\n",
       " '3.',\n",
       " 'The subject will have been on insulin pump therapy for at least 3 months and currently using a fast actin insulin analog (Lispro, Aspart or Guilisine).',\n",
       " '4.',\n",
       " 'Last (less than 3 months) HbA1c â\\x89¤ 10%.',\n",
       " '5.',\n",
       " 'Currently using carbohydrate counting as the meal insulin dose strategy.',\n",
       " 'adult female partner\\naged 18 to 40 years.',\n",
       " 'scheduled for elective cesarean section.',\n",
       " 'Subject was previously enrolled in a selected company sponsored feeder trial, and has received at least 1 dose of radium 223 dichloride or placebo in the feeder trial',\n",
       " 'Diagnosis of DSM 5 Anxiety Disorder\\nStable medical history and general health\\nOn stable anti-parkinsonian therapy for 2 weeks before enrollment',\n",
       " 'Pregnant women admitted to Women health hospital with a diagnosis of severe pre-eclampsia',\n",
       " 'Metabolic Syndrome (ATP III)\\nModerate to severe OSA',\n",
       " 'All infertile women treated with intracytoplasmic sperm injection (ICSI)/Fertilization in Vitro and Embryo Transfer (FIVET)\\nLess than or equal to (<=) 1 previous failed embryo transfer\\nEumenorrheic normo-gonadotropic women\\nBasal follicle-stimulating hormone (FSH) <=12 International unit per liter (IU/L)\\nAnti-mullerian hormone (AMH) greater than (>) 1.1 nanogram per milliliter (ng/mL)\\nOvarian Reserve: number of antral follicles 2 millimeter (mm) between 6 <= antral follicle count (AFC) <= 16\\nFollicles > 16 mm at the triggering day between 5-14\\nBody Mass Index (BMI) between 18 <= BMI <= 27 kilogram per meter square (kg/m^2)\\nIndication for Fresh Embryo transfer\\nNormal uterine cavity on ultrasound exam (e.g., no presence of hydrosalpinx)\\nUndergoing Assisted Reproductive Technique (ART) and oocyte maturation by human chorionic gonadotropin (HCG) triggering\\nProgesterone (P4) serum level at the HCG triggering day <= 1.5 ng/mL (Day O/Randomization)\\nEstradiol (E2) <= 3000 picogram/milliliter (pg/mL) at the human chorionic gonadotropin (HCG) triggering day (Day 0/Randomization)\\nSubjects must have read and signed the Informed Consent Form prior to study-specific-procedures not part of standard of care\\nOther protocol defined inclusion criteria could apply',\n",
       " 'Age = 65 years with one additional stroke risk factor (hypertension, diabetes, heart failure history of or left ventricular ejection fraction <0.40), previous stroke or transient ischemic attack).',\n",
       " 'Atrial fibrillation and not on oral anticoagulation (OAC) therapy but eligible\\nAtrial fibrillation on sub-optimal OAC',\n",
       " 'Healthy adults 30- 65 years old,\\nBMI 25-35 kg/m2,\\nnondiabetic as defined by fasting plasma glucose <126 mg/dL\\nLipids: one group with an LDL =/>130 and Triglycerides < 150 mg/dL The 2nd group will have and LDL=/>130 mg/dL and Triglycerides =/>150 mg/dL but less than 400 mg/dL.',\n",
       " 'Meibomian Gland Dysfunction\\nEligible for heat treatment\\nOcular Surface Disease Index (OSDI) >12\\nQuality or expressibility score =20 years old: >1 or >20 years old: =1\\nNon-invasive tear film break-up time (NITBUT) <10 s in at least one eye\\nSchirmer-1 test >5 mm after 5 min',\n",
       " 'Informed consent as documented by signature (see informed consent form)\\nPrimary ITP according to the definition of Rodeghiero et al.',\n",
       " '(52) and a platelet count of <30x109/l\\nAge range: 18-45 years\\nPreviously treated patients, with failure or intolerance to first-line therapy, or relapse after first-line therapy, i.e.',\n",
       " 'corticosteroids, intravenous immunoglobulin (IVIG), or anti-D immunoglobulins',\n",
       " 'Chronic hepatitis B,\\nAntiviral experienced,\\nCurrently on long term TDF anti-HBV treatment,\\nHBV DNA < 6 log IU/ml (LLOD)\\nAble to sign the consent form of anticipating in the study',\n",
       " 'Primary periampullary tumor\\nR0, R1 resection\\nChronic pancreatitis requiring pancreatoduodenectomy',\n",
       " 'Patients aged of 18 and over,\\nSatisfying the 1987 American College of Rheumatology (ACR) criteria for RA\\nReceiving a prescription of Adalimumab 40 mg subcutaneous every two weeks.',\n",
       " 'Motor complete tetraplegia for at least 3 months\\nAge from 18 to 74 years\\nBody mass index (BMI) from 18 to 35kg/m2\\nInformed consent as documented by signature',\n",
       " 'Women with expected difficult IUD insertion like nulliparous women and women with previous cesarean section.',\n",
       " 'age <2 years\\nindication of general anesthesia with tracheal intubation\\ninhalational induction scheduled\\nwritten informed consent of both parents',\n",
       " 'Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.',\n",
       " 'A male or female aged 61 years or above at the time of the first vaccination.',\n",
       " 'Written informed consent obtained from the subject.',\n",
       " 'Healthy subjects or subjects with well controlled underlying disease.',\n",
       " 'HbA1c > 13.0 %\\nNo treatment with insulin or oral agents for 6 months\\n20 = Age < 80 years',\n",
       " 'No response to more than one antiarrhythmic drug, or unwilling to receive long-term drug treatment.',\n",
       " 'Can provide informed consent form expressing willingness to participate in the study and comply with follow-up tests and evaluation procedures.',\n",
       " 'Aged 18-80 years.',\n",
       " 'Aged 18 years or older\\nScheduled for invasive coronary angiography',\n",
       " '1.',\n",
       " 'Patients â\\x89¥ 18 years-old from \"Instituto TeletÃ³n Santiago\" and \"Hospital ClÃ\\xadnico Mutual de seguridad\".',\n",
       " '2.',\n",
       " 'C5 to T12 spinal cord injury, classified as ISNCSCI grades C and D \\n3.',\n",
       " 'Traumatic and non-traumatic, non-progressive lesions \\n4.',\n",
       " 'Onset > 6 months \\n5.',\n",
       " 'Ability to ambulate with or without assistive devices \\n6.',\n",
       " 'Ability to follow verbal or visual commands \\n7.',\n",
       " 'Signed informed consent',\n",
       " 'non-valvular atrial fibrillation\\nnondiabetic patients\\ntype 1 and 2 diabetic patients',\n",
       " 'All patients admitted to the Duke CICU, who require intubation and sedation for mechanical ventilation that is expected to be >24 hours in duration will be included, unless they meet the specified exclusion criteria.',\n",
       " 'Patients intubated within one hour prior to care transition to the CICU will also be screened for inclusion.',\n",
       " 'Women must be postmenopausal (i.e.12 months without menstrual period), or surgically sterile, i.e.',\n",
       " 'women of child bearing potential are not allowed to be included into the study.',\n",
       " 'In cases of doubt a pregnancy test should be performed.',\n",
       " '(NB -post menopausal women currently receiving hormone replacement are permissible) \\nAcute myocardial infarction < 12 h defined as: \\n1.',\n",
       " 'Angina or equivalent symptoms > 20 min and \\n2.',\n",
       " 'ST elevation in 2 contiguous ECG leads (= 2 mm precordial lead, = 1 mm limb lead).',\n",
       " 'This ECG recording serves as baseline ECG, i.e.',\n",
       " 'ECG I.',\n",
       " 'Planned primary percutaneous coronary intervention \\nThe subject has given written informed, dated consent to participate in the study',\n",
       " 'Pregnant patients who require a scheduled or non-urgent cesarean birth\\nPatient able to receive neuraxial analgesia\\nPatient able to give verbal and written consent for both cesarean birth and study',\n",
       " 'Nonsurgical neonates and babies up to age 6 months with INR 1.5 or more who are deemed clinically to need plasma infusion.',\n",
       " 'Patients undergoing laparoscopic assisted donor nephrectomy\\nPatients that have elected to have a nerve block\\n18 years of age or older\\nPatients of ASA status I - III',\n",
       " 'Age 3 to 18 years on day of surgery\\ndiagnosis of spinal deformity\\nundergoing elective posterior spine multi-level instrumentation surgery',\n",
       " 'Type 1 diabetes according to ADA criterias <5 years.',\n",
       " 'Age= 18 years and less than 70 years.',\n",
       " 'Non-obese: defined as BMI less than 28 kg/m2\\nPositive for at least one of the anti-islet autoantibodies: GADA, IA2A, ZnT8A\\nFasting or postprandial plasma C-peptide more than 100 pmol/L\\nWritten informed consent from the patient or family representative.',\n",
       " 'Planned non-cardiac surgery at least after 12 months of implantation of drug eluting stent\\nLow or intermediate risk level surgery\\nWritten informed consent',\n",
       " 'Diagnosis of sickle cell disease \\nClinically significant disease defined as at least 1 painful episode per year averaged over the previous 3 years or a history of priapism, stroke, acute chest syndrome, avascular necrosis, multi-organ failure or the need for chronic narcotic medications for pain from sickle cell disease \\nMust have failed a previous attempt at treatment with hydroxyurea defined as the inability to achieve a significant absolute increase in % fetal hemoglobin or the inability to tolerate hydroxyurea treatment due to severe side effects such as but not limited to myelosuppression, gastrointestinal symptoms, edema or hepatic enzyme elevations or have contraindications to hydroxyurea \\n18 years of age or older \\nHematologic laboratory values as outlined in the protocol \\nNon-hematologic laboratory values as outlined in the protocol \\nMust agree not to donate blood or other bodily fluid while taking the study drug and for 28 days thereafter \\nWomen of child-bearing potential (WCBP) must have a negative serum pregnancy test 72 hours or less prior to starting treatment \\nWomen of child-bearing potential and men must agree to use 2 forms of adequate contraception prior to study entry and for the duration of study participation',\n",
       " '1.',\n",
       " 'Age: 18 years and older.',\n",
       " '2.',\n",
       " 'Sex: Male and non-pregnant, non-lactating female \\n1.',\n",
       " 'Women of childbearing potential must have negative serum (Beta HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administration.',\n",
       " 'If dosing is scheduled on Sunday or Monday, the HCG pregnancy test should be given within 48 hours prior to dosing of each study period.',\n",
       " 'An additional serum (Beta HCG) pregnancy test will be performed upon completion of the study.',\n",
       " '2.',\n",
       " 'Women of childbearing potential must practice abstinence or be using an acceptable form of contraception throughout the duration of the study.',\n",
       " 'Acceptable forms of contraception include the following: \\n(1) intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study period, or (2) barrier methods containing or used in conjunction with a spermicidal agent, or (3) postmenopausal accompanied with a documented postmenopausal course of at least one year or surgical sterility (tubal ligation, oophorectomy or hysterectomy).',\n",
       " '3.',\n",
       " 'During the course of the study, from study screen until study exit - including the washout period, women of childbearing potential must use a spermicide containing barrier method of contraception in addition to their current contraceptive device.',\n",
       " 'This advice should be documented in the informed consent form.',\n",
       " '3.',\n",
       " 'Weight: At least 60 kg (132 lbs) for man and 48 kg (106 lbs) for women and within 15% of Ideal Body Weight (IBW), as referenced by the Table of \"\"Desirable Weights of Adults\"\" Metropolitan Life Insurance Company, 1999 (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).',\n",
       " '4.',\n",
       " 'All subjects should be judged normal and healthy during a pre-study medical evaluation (physical examination, laboratory evaluation, 12-lead ECG, hepatitis B and hepatitis C tests, HIV test, and urine drug screen including amphetamine, barbiturates, benzodiazepine, cannabinoid, cocaine, opiates, phencyclidine, and methadone) performed within 14 days of the initial dose of study medication.',\n",
       " 'Females 18-65 years old who undergoing colposcopic directed biopsy',\n",
       " 'Participants having H. pylori related chronic gastritis with/without peptic ulcers who are aged greater than 20 years old and are willing to received eradication therapy.',\n",
       " 'Confirmed diagnosis (clinical and histological features) of Hailey Hailey or Darier diseases.',\n",
       " 'Moderate to very severe lesions located in large folds \\nPatient aged 18 ans or more \\nPatient with health coverage \\nPatient who have signed the consent form \\nPatient proficient into filling out the questionnaires.',\n",
       " 'all adult patients with a nasal or facial skin/soft tissue defect requiring reconstruction limited to or including a full-thickness skin graft',\n",
       " 'Subject or legal representative has voluntarily signed the informed consent approved by the Institutional Review Board,\\nHip fracture surgery scheduled under general anesthesia\\nSubject is 65 years or older on the day of surgery',\n",
       " 'acute myocardial infarction or \\nischemic cardiomyopathy with or without previous myocardial infarction or \\ndilated cardiomyopathy due to valvular heart disease, hypertensive heart disease, history of myocarditis (no active myocardial infection present)',\n",
       " 'Patients diagnosed with primary biliary cholangitis\\nTreated with Ursodeoxycholic Acid in West China Hospital for at least 6 month and suboptimal response to Ursodeoxycholic Acid',\n",
       " 'selective operation of inguinal hernia repair<U+3001>orthopedics operation or general surgery operation in children\\naged 3-9 years\\nASA I - II\\nenter the operating room by himself without parents\\nnormal liver and kidney function\\nno history of anesthesia medication allergy.',\n",
       " '=18 years old, men or post-menopausal women (women with no periods for 12 months or more, or those who have had a surgical menopause)\\nTreated hypertensive patients with an average daytime ambulatory blood pressure measurement (ABPM) <150/95mmHg on stable doses of one or more antihypertensive medication (at least one of which should be; an ACE inhibitor, angiotensin receptor blocker or diuretic) for 3 months, or untreated hypertensive patients with an average daytime ABPM =135/85 but <150/95.',\n",
       " 'Adult subjects aged 18 years or older\\nScheduled for elective posterior lumbar spinal fusion surgery between 1 and 3 levels',\n",
       " '18-50 ages\\nSingleton pregnancy\\nCervical length <=25mm between 18(0) and 23(6) weeks',\n",
       " 'Acute Coronary Syndrome group: 40 patients with type 1 myocardial infarction within 21 days prior to the imaging visit and invasive coronary angiography with angiographic evidence of at least a 50% stenosis in one or more coronary arteries.',\n",
       " 'Only patients undergoing PCI will be included in the study.',\n",
       " 'Stable Ischemic Heart Disease group: 40 patients who have undergone invasive coronary angiography within 21 days prior to the imaging visit, with history of typical angina prior to the angiogram, but no prior myocardial infarction or coronary revascularization.',\n",
       " 'have no prior CAD associated event (no prior myocardial infarction, acute coronary syndrome, coronary angiogram, or PCI),\\nhave CAC between 10 to <1000, and\\nmatch to patients in the ACS group by gender, age by decile, and CAC category (using CAC categories of 10 to <100, 100 to <400, 400 to <1000).',\n",
       " \"Controlled hypertension: systolic BP < 150 and diastolic BP < 90 mmHg in persons aged 60 years or older, systolic BP < 140 and diastolic BP < 90 mmHg in persons 40 through 59 years according to the JNC 8th guideline\\nEvidence of diastolic dysfunction showing E/E' > 10\\nThe patient agrees to the study protocol and the schedule of clinical and echocardiographic follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site\",\n",
       " 'Patients needed to pericardiocentesis during RFCA for paroxysmal or persistent atrial fibrillation.',\n",
       " 'Patients = 18 years of age\\nSubjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol\\nEstablished diagnosis of UC and moderate-to-severe disease activity, defined as a Mayo score of 6-12, with an endoscopic subscore =2.',\n",
       " 'Patients had an inadequate response to, or had failed to tolerate, 1 or more of the following conventional therapies: oral 5-aminosalicylates, oral corticosteroids, azathioprine (AZA), and/or 6-mercaptopurine (6MP); or corticosteroid dependent (ie, an inability to taper corticosteroids without recurrence of UC symptoms).',\n",
       " 'Patients concurrently treated with oral 5-aminosalicylates or corticosteroids were to receive a stable dose for at least 2 weeks before baseline, and patients receiving AZA and/or 6MP were to receive a stable dose for at least 4 weeks before baseline.',\n",
       " 'Patients were required to maintain stable doses of their concomitant UC medications during the study.',\n",
       " 'Female subjects of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 6 months thereafter OR\\nSurgical sterilized female patients with documentation of prior hysterectomy, tubal ligation or complete bilateral oophorectomy OR\\nPostmenopausal women with postmenopausal defined as permanent cessation >1 year of previously occurring menses.',\n",
       " \"Female subjects' serum pregnancy test performed at the screening visit and urine pregnancy test performed at the baseline visit must be negative.\",\n",
       " 'Subjects have following investigations within 1 month prior to enrolment.',\n",
       " 'Routine bloods including U&E, FBC, LFTs, inflammatory markers (CRP) and albumin will be measured.',\n",
       " \"Medical history, concomitant medications\\nIntradermal reaction to Tuberculin (PPD skin test) or Mycobacterium tuberculosis antigenspecific interferon-gamma release assay (IGRA)\\nTB screening: chest X-Ray unless performed in the last 6 months\\nStool examination for enteric pathogens including Clostridium difficile\\nInclusion/exclusion criteria\\nInformed consent\\nMayo score (including sigmoidoscopy unless performed in previous 3 months)\\nPatient's weight and height and abdominal circumference\",\n",
       " 'Severe or uncontrolled infection.',\n",
       " 'Sensitive to the product or other genetically engineered biological products from Escherichia coli strains.',\n",
       " 'Mental or nervous system disorders.',\n",
       " 'Severe heart, lung and central nervous system disorders.',\n",
       " 'Pregnant or lactating women.',\n",
       " 'TBIL(total bilirubin ), ALT(alanine aminotransferase),AST(glutamic-oxalacetic transaminase) > 2.5Ã\\x97ULN(upper limit of normal); if it were caused by liver metastases, TBIL, ALT,AST >5Ã\\x97ULN.',\n",
       " 'Cr(creatinine) >1.5Ã\\x97ULN.',\n",
       " '35-75 years old;\\ndiagnosed as type 2 diabetes according to the criteria of the World Health Organization in 1999.',\n",
       " 'Major spine surgery scheduled as part of clinical care\\n18-80 years',\n",
       " 'Biopsy-proven LN Class III/IVÂ±V (ISN/RPS 2003), with biopsy performed within 12 weeks of randomization.',\n",
       " 'Positive anti-dsDNA.',\n",
       " 'Active LN with proteinuria (urine protein/creatinine ratio >1.0 or 24-hr urine protein >1.0 g at baseline), with or without hematuria.',\n",
       " \"Both 'incident' (i.e.\",\n",
       " \"new) patients and 'flare' patients can be included.\",\n",
       " 'a very high cardiovascular risk and LDL-cholesterol> 1.8 mmol / l\\na high cardiovascular risk and LDL-cholesterol> 2.5 mmol / l\\nPatient with a high or very high cardiovascular risk treated by lipidlowering therapy with statin',\n",
       " 'Diagnosed Iron deficiency anemia.',\n",
       " 'H-pylori positive cases.',\n",
       " 'Second trimester pregnancy.',\n",
       " 'Previous diagnoses of COPD and HF under optimized clinical treatment as judged by the accompanying physician\\nReduced left ventricular ejection fraction (<50%)\\nNon-reversible airway obstruction (post-bronchodilator FEV1/FVC < 0.7 and FEV1 < 80 %)\\nRespiratory muscle weakness (Pi,max < 70cmH2O)\\nPersistent dyspnea on daily life (Baseline Dyspnea Index focal score <or= 8).',\n",
       " 'Written informed consent\\nAge =18 years\\nHas undergone first time isolated CABG due to an episode of acute coronary syndrome (STEMI, NSTEMI, unstable angina) within 6 weeks before surgery',\n",
       " 'Men and women aged 18-45 years.',\n",
       " 'Diagnosis of functional dyspepsia, based on the Rome IV criteria (2016).',\n",
       " 'GIS score of at least 6.',\n",
       " 'Negative H. pylori test .',\n",
       " 'Availability of a signed patient information sheet (Informed Consent form) for participation in the clinical trial.',\n",
       " 'Patients who agree to use an effective method of contraception throughout the clinical trial.',\n",
       " 'self-reported healthy adults between the ages of 18-60 who are fluent in English.',\n",
       " 'Diagnosis of uncomplicated gastroschisis\\nGestational age >33 weeks at time of delivery\\nWeight >1900g at time of delivery\\nTransfer of patient to Riley Hospital for Children prior to any abdominal surgery',\n",
       " 'Over 18 years of age; Systemically healthy; Non-smoking;\\nWith good oral hygiene;\\nAbsent irreversible pulpal alteration;\\nWith the presence of a non-carious cervical lesion (LCNCs) that needs to be restored.',\n",
       " 'This lesion should be non-carious, non-retentive, with at least 1 mm and up to 3 mm depth, should involve both enamel and dentin of vital teeth without mobility, and present hypersensitivity;\\nPresence a natural tooth of the same position of the restored tooth, but in the opposite arch of the same jaw to be considered for the positive control;\\nPeriodontal parameters : Depth Probing (PS), Visible Plaque Index (IPV), Gingival Index (GI) and Probing Bleed Index (SS).',\n",
       " 'The normal included were: PS = 1 to 3 mm, GI = 0, IPV = score 0 e SS = score 0.',\n",
       " 'First or second single kidney (cadaveric or living donors) transplant recipients.',\n",
       " 'Considered for a standard immunosuppressive protocol.',\n",
       " 'Must be capable of giving written informed connect for participation in the study for 24 months.',\n",
       " 'Women with a singleton pregnancy undergoing cesarean section after 37 weeks of gestation.',\n",
       " 'Unilateral leg pain secondary to lateral stenosis, disc protrusion or herniated disc.',\n",
       " 'Age between 18 and 80 years.',\n",
       " 'Moderate to severe pain (NVS>4).',\n",
       " 'Right proficient oral and written language.',\n",
       " 'healthy\\nno allergy known to these drugs\\nsecond trimester abortion',\n",
       " 'Adult patients (18years old or older) undergoing living-donor or deceased-donor liver transplantation',\n",
       " 'HBsAg and HBeAg positive for more than 6 months, HBV DNA detectable with ALT level abnormal lasted for three months and at least time190 IU/L or liver puncture biopsy demonstrated apparent inflammation, never treated before enrolled.',\n",
       " \"age =18 at screening\\nnot intending to move away from the clinic's catchment area for the next 2 years\\nHIV-1 antibody negative\\nreports commercial sex work\\ncontact information is provided\\nwritten informed consent\",\n",
       " 'Male and female patients, age 18-75 yrs.',\n",
       " 'COPD diagnosed according to GOLD, FEV1 40-80% predicted, SpO2 =92% at 750 m.\\nBorn, raised and currently living at low altitude (<800m).',\n",
       " 'Written informed consent.',\n",
       " 'Subject is 65 years old who is able and willing to give an informed consent.',\n",
       " 'Patients undergoing planned trans-femoral TAVI.',\n",
       " 'Calculated eGFR below 60ml/min/1.73m2 (MDRD)',\n",
       " 'patients with a diagnosis of either cervical, thoracic, or lumbar facet or sacroiliac joint pain who have responded to medial branch blocks and are already scheduled for bilateral radiofrequency ablations\\nage greater than 18 years old\\nEnglish speaking',\n",
       " 'Women with POI: For the purpose of the research women is considered to have POI if she is aged less than 40 years and has amenorrhea of at least 4 month with FSH level above 25 IU/L (repeated twice >4 weeks apart).',\n",
       " 'Male and female subjects between 40-85 years old will be enrolled.',\n",
       " 'Younger subjects are not included as the risk for brain amyloid lesions is too low\\nAll subjects will speak English as their first language or demonstrate proficiency in English (defined as reaching a scaled score of > 11 on the WAIS vocabulary test).',\n",
       " 'All subjects will have normal cognition at baseline: a Clinical Dementia Rating CDR=0, Global Deterioration Scale GDS<2.',\n",
       " 'All subjects will be in good general health and able to participate in the LP and imaging exams.',\n",
       " 'This determination is made by the study neurologist and reviewed at a consensus meeting for each subject.',\n",
       " 'Female with a persisting pregnancy of unknown location: \\nA pregnancy of unknown location is defined as a pregnancy in a woman with a positive pregnancy test but no definitive signs of pregnancy in the uterus or adnexa on ultrasound imaging.',\n",
       " 'A definitive sign of gestation includes ultrasound visualization of a gestational sac with a yolk sac (with or without an embryo) in the uterus or in the adnexa.',\n",
       " 'Ultrasound must be performed within 7 days prior to randomization.',\n",
       " 'Persistence of hCG is defined as at least 2 serial hCG values (over 2-14 days), showing < 15% rise per day, or < 50% fall between the first and last value.',\n",
       " 'Patient is hemodynamically stable, hemoglobin >10 mg/dL \\nGreater than or 18 years of age',\n",
       " 'Localized intermediate-risk or high-risk prostate cancer cT3\\nGleason score = 7 (3+4 and/or 4+3) and/or\\nPSA = 20 ng/ml\\nintact preoperative erectile function with an IIEF = 21 (IIEF-6).',\n",
       " 'Patients with diagnosis of cerebral palsy.',\n",
       " \"Patients' curator must be able to give voluntary consent.\",\n",
       " 'Methadone-maintained cocaine-dependent patients use between 1g to 2g a day; 1 to 3 times a week',\n",
       " 'A formal diagnosis of Autism or Pervasive Developmental Disorder not otherwise specified (PDD-NOS), given by a child neurologist.',\n",
       " 'Age: 10-18 years.',\n",
       " 'A signed parental consent form.',\n",
       " 'Body Mass Index (BMI) = 35 kg/m2\\nHbA1c = 5.7%\\nAbility to speak and understand English',\n",
       " 'A diagnosis of VTE in outpatient clinic or as discharge diagnosis after hospitalization.',\n",
       " 'A claimed prescription of a NOAC from a Danish pharmacy within 14 days of discharge or outpatient clinic visit.',\n",
       " 'Adults (18 and older) with physiologically confirmed SA or mild-moderate asthma and followed by an asthma specialist for at least 6 months.',\n",
       " 'Must agree to have regular clinic visits (minimum 3-4 per year for SA, 1-2 for mild-moderate asthma).',\n",
       " 'Must have good compliance with medications Patients with asthma and COPD.',\n",
       " 'diabetes mellitus type 1',\n",
       " \"Major subjects of over 40 years (mean age of Meniere's disease 40 to 50 years)\\nInformed consent signed\\nMedical examination performed prior to participation in research\\nPatients without history of inner ear disease\\nRecipient of a French social security scheme\",\n",
       " 'suspicion of nonfunctional P-NET on primary CT (i.e hypervascularity) or MRI\\nsigned informed consent',\n",
       " 'Diagnosed with Beta-Thalassemia Major and receiving regular blood transfusion and on iron chelating therapy.',\n",
       " 'Weight: equal to or over 35 kg.',\n",
       " 'Normal renal function.',\n",
       " 'F; age 18 to 70\\nAmerican Society of Anesthesiologists (ASA) I e II;\\nbreast cancer ( DIN 2 e 3, o LIN 2 e 3 sec.',\n",
       " 'Tavassoli) scheduled for nipple-sparing mastectomy, simple mastectomy, skin-sparing mastectomy, skin-reducing mastectomy c, lymphnode biopsy and axillary dissection;\\nimmediate sub-pectoral prosthetic reconstruction;\\nsigned informed consent.',\n",
       " 'Participants having H. pylori related chronic gastritis with/without peptic ulcers who are aged greater than 20 years old and are willing to received eradication therapy.',\n",
       " 'Healthy children aged 6 months to 72 months',\n",
       " 'successful left atrial appendage occlusion with Amulet device within 37 days prior to randomization.',\n",
       " \"treatment with dual antiplatelet therapy (clopidogrel and acetylsalicylic acid) between left atrial appendage closure and randomization\\nparticipant's age 18 years or older at the time of signing the informed consent form\\nparticipant is willing to follow all study procedures; especially randomized antiplatelet treatment regimen and follow-up visits with transesophageal echocardiography when applicable\\nparticipant is willing to sign the study informed consent form\",\n",
       " 'Age greater than 18 \\nPlanned thoracoscopy with low probability(by surgeon estimate) of conversion to open procedure',\n",
       " 'Aged =18 years\\nClinical diagnosis of acute coronary syndrome\\nIn the opinion of the attending clinician requires dual anti-platelet therapy with aspirin and a P2Y12 receptor antagonist\\nResident in Scotland with a Community Health Index (CHI) number\\nThe attending clinician has equipoise regarding the duration of therapy\\nProvision of informed consent',\n",
       " 'Of either gender, aged â\\x89¥19 and â\\x89¤70 years \\nAtopic dermatitis subjects who are coincident with Hanifin and Rajka diagnosis criteria \\nSubacute and chronic atopic subjects who have atopic dermatitis symptoms continually at least 6 months \\nSubjects with over moderate atopic dermatitis (SCORAD score > 20) \\nSubjects who understand and voluntarily sign an informed consent form',\n",
       " 'Need of lower third molar surgeries',\n",
       " 'NA',\n",
       " 'Children with clinical diagnosis of PWS;\\nAge range: 7 to 14 years-old;\\nVoluntarily participated and Written informed consent signed',\n",
       " 'Age range: 14 to 65 years-old;\\nClinically diagnosed of Port-wine Stain;\\nPatients receiving hemoporfin based upon the clinical judgment of the investigator;\\nWritten informed consent signed and agreed to receive periodic follow-up',\n",
       " '18 years of age or older;\\nSuffer from schizophrenia/schizoaffective disorder meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria;\\nHave a total baseline score on the Brief Psychiatric Rating Scale (BPRS) = 45;\\nBe capable and willing to provide written informed consent to participate in this study;\\nAgree to abide by the study protocol and its restrictions and be able to complete all aspects of the study, including all visits and tests',\n",
       " 'HIV controlled on therapy for at least 12 weeks\\nViral load < 200 copies\\nBMI >27 to 45\\nDiagnosis of DM type 2 with A1-C >7 to 15\\nParticipants must be willing to comply with all study related procedures',\n",
       " '18 years of age or older \\nHistologically confirmed diagnosis of melanoma, breast cancer or gynecologic cancer at MSKCC \\nHave one of the following disease histories: \\nNewly-diagnosed or recurrent (local, regional, metastatic) malignant melanoma or breast cancer patients in whom SLN mapping is indicated \\nResidual clinically or radiographically evident tumor, including primary cutaneous and mucosal melanomas \\nPrior radiation therapy, chemotherapy, or surgery in patients requiring flap reconstruction in the head and neck region.',\n",
       " 'Newly diagnosed patients with previous excisional biopsy.',\n",
       " 'OR \\nNewly-diagnosed gynecologic cancer patients in whom SLN mapping and surgical excision is indicated OR \\nNormal baseline cardiac function based upon pre-operative evaluation \\nAt the discretion of the operating surgeon, ANC>1000/mcl and platelets>100,000/mcl.',\n",
       " \"At the discretion of the operating surgeon, Bilirubin level of < 2.0 mg/dl in the absence of a history of Gilbert's disease (or pattern consistent with Gilbert's).\",\n",
       " 'For melanoma patients, If patients have a history of malignancy other than melanoma, and other skin cancers in the past five years, their inclusion is up to the discretion of the physician.',\n",
       " 'All patients of childbearing and child-creating age must be using an acceptable form of birth control \\nWomen who are pre-menopausal must have a negative serum pregnancy test',\n",
       " 'At least 18 years of age \\nNo more than 20 wk of gestation \\nGiven Ante-natal Cards of the Ghana Health Service \\nCompleted the initial routine ante-natal examination at the clinics \\nHIV negative or status unknown (as from the Ante-natal card) \\nFree from chronic disease e.g.',\n",
       " 'malignancy requiring frequent medical attention (as from the Ante-natal card) \\nResiding in the Manya Krobo or Yilo Krobo district \\nPrepared to sign an informed consent \\nLiving in the area throughout the duration of the study \\nAcceptance of home visitors',\n",
       " 'Patient >18 years of age\\nPatient presents with acute coronary syndrome (ACS) or stable coronary artery disease (CAD)\\nPatient is eligible for PCI\\nPatient is willing and able to provide informed written consent\\nPatient not able to receive 12 months of dual anti-platelet therapy\\nFailure of index PCI\\nPatient or physician refusal to enroll in the study\\nPatient with known CYP2C19 genotype prior to randomization\\nPlanned revascularization of any vessel within 30 days post-index procedure and/or of the target vessel(s) within 12 months post-procedure\\nAnticipated discontinuation of clopidogrel or ticagrelor within the 12 month follow up period, example for elective surgery\\nSerum creatinine >2.5 mg/dL within 7 days of index procedure\\nPlatelet count <80,000 or >700,000 cells/mm3, or white blood cell count <3,000 cells/mm3 if persistent (at least 2 abnormal values) within 7 days prior to index procedure.',\n",
       " 'History of intracranial hemorrhage\\nKnown hypersensitivity to clopidogrel or ticagrelor or any of its components\\nPatient is participating in an investigational drug or device clinical trial that has not reached its primary endpoint\\nPatient previously enrolled in this study\\nPatient is pregnant, lactating, or planning to become pregnant within 12 months\\nPatient has received an organ transplant or is on a waiting list for an organ transplant\\nPatient is receiving or scheduled to receive chemotherapy within 30 days before or after the procedure\\nPatient is receiving immunosuppressive therapy or has known immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematous, etc.)',\n",
       " 'Patient is receiving chronic oral anticoagulation therapy (i.e., vitamin K antagonist, direct thrombin inhibitor, Factor Xa inhibitor)\\nConcomitant use of simvastatin/lovastatin > 40 mg qd\\nConcomitant use of potent CYP3A4 inhibitors (atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) or inducers (carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, and rifapentine)\\nNon-cardiac condition limiting life expectancy to less than one year, per physician judgment (e.g.',\n",
       " 'cancer)\\nKnown history of severe hepatic impairment\\nPatient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions\\nPatient has an active pathological bleeding, such as active gastrointestinal (GI) bleeding\\nInability to take aspirin at a dosage of 100 mg or less\\nCurrent substance abuse (e.g., alcohol, cocaine, heroin, etc.)',\n",
       " 'Current height less than 5th percentile AND/OR\\nPredicted adult height (based on bone age) more than 10 cm below target height (mid parental height)\\nEvidence of puberty: physical signs and serum luteinizing hormone > 0.3 IU/L and testosterone > 15 ng/dl',\n",
       " '18 - 64 years old\\nAble to give consent\\nunprotected sex (in past 6 months) with 1 or more men of unknown HIV status\\nevaluated for an STI within 6 months prior to screening\\nsex in last 6 months with an HIV-infected partner\\nIDU with report of using previously used or shared needles in past 6 months or has been in a methadone, buprenorphine, or suboxone treatment program in past 6 months or engaging in high-risk sexual behaviors\\nindividuals engaging in transactional sex (i.e sex for money, drugs, or housing)\\nInfrequently uses condoms during sex with 1 or more partners of unknown HIV status who are known to be at substantial risk of HIV infection (IDU or bisexual male partner)\\nCrCl = 60 ml/min\\nHIV- uninfected women desiring PrEP',\n",
       " 'At least 18 years of age\\nSigned informed consent\\nAfrican American race\\nHistory of a solitary renal transplant\\nStable tacrolimus dose for at least 2 weeks prior to randomization',\n",
       " 'The treating physician has chosen Ventavis as a suitable long-term treatment for the patient \\nPatient with primary pulmonary hypertension (i.e.',\n",
       " 'Idiopathic Pulmonary Arterial Hypertension or Familial Pulmonary Arterial Hypertension) and classified as NYHA functional class III (NYHA = New York Heart Association) \\nNo prior treatment with Ventavis or other active treatments for primary pulmonary hypertension within 6 weeks of date of study inclusion (unless otherwise advised by Bayer Schering Pharma)',\n",
       " \"Diagnosis of idiopathic Parkinson's disease that is optimally treated (motor fluctuations <20% of subject's awake time).\",\n",
       " 'Subjects may be on levodopa therapy but must be stable at the time of entry into the study\\nSexually active (i.e.',\n",
       " '=1 attempt/week) males, 40 - 64 years of age (inclusive) at time of screening\\nDiagnosis of moderate erectile dysfunction (defined according to the NIH Consensus Development Panel on Impotence) for more than 6 months and demonstrating and incomplete response to tadalafil alone\\nSubject demonstrating an IIEF-5 drug-free baseline score that is = 10 but = 16, and an IIEF-5 tadalafil-alone baseline score that is = 18\\nSubject in a stable heterosexual relationship for at least 6 months.',\n",
       " '(2)\\nSubject motivated to seek treatment for erectile dysfunction.',\n",
       " 'Subject with a total serum testosterone level = 300 ng/dL, with or without supplementation\\nHoehn and Yahr Scale score of 1 - 3\\nPatient able to consent and comply with protocol requirements',\n",
       " 'Axial spondyloarthritis (ASAS criteria) and radiologic sacroiliitis as detected either by MRI or X-ray.',\n",
       " 'All subjects underwent a detailed history and systemic physical examination including neurologic and musculoskeletal evaluations.',\n",
       " 'To rule out any confounding etiologies, basic diagnostic laboratory tests including complete blood count and acute phase reactants (erythrocyte sedimentation rate and C-reactive protein) were performed.',\n",
       " 'The patients diagnosed as having acute non-specific low back pain according to history and physical examinations were invited to participate and will be informed about the purpose and course of the study.',\n",
       " \"A primary complaint of pain in the area between the 12th rib and buttock crease without leg pain\\nFemale or male, 20 - 80 years of age\\nLow back pain of less than six weeks' duration; and at least moderate pain intensity (NRS<U+2267>4)\",\n",
       " 'Postmenopausal women\\nAge 60-80 years\\nT-score according to DXA: <-2.5\\nindication for osteoporosis therapy according to international guidelines',\n",
       " 'Women aged 20-49; \\nHaving a regular menstrual cycle of which the menstrual period is between day 3-7, and the period between day 25-35; \\nExcluding internal and surgical disease (after having variety of physical examination such as electrocardiogram/hepatic and renal function/blood routine and urine routine).',\n",
       " 'Age 18 years or older\\nSymptomatic or asymptomatic coronary artery disease patients\\nMLA(minimal luminal area)<4mm2\\nplaque burden>70%\\nLipid-rich plaque on NIRS(Intracoronary Near-Infrared Spectroscopy) (defined as maxLCBI4mm>315)\\n2 target vulnerable lesions\\nEligible for percutaneous coronary intervention with Absorb Bioresorbable Vascular Scaffold or Everolimus Eluting Stent\\nWilling and able to provide informed written consent\\nReference vessel diameter 2.75-4.0\\nLesion length = 40',\n",
       " 'Referred for surgery for open reduction and internal fixation for ankle fracture',\n",
       " 'subjects older than 35 years\\ndiagnosis of moderate to very severe COPD (FEV1 <80% predicted), according to the GesEPOC criteria, established at least 3 months\\ncurrent or former smoker with an accumulated consumption >10 packs x year\\nhospital admission for COPD exacerbation',\n",
       " \"Parkinson disease diagnosed by United Kingdom Parkinson's disease Society Brain Bank Criteria\\nPostural instability and gait disturbance phenotype\\nHoehn and Yahr stage = 3\\nMini-Mental status examination = 24\",\n",
       " \"Diagnosis of sleep disordered breathing or obstructive sleep apnea\\nChildren undergoing elective tonsillectomy or adenotonsillectomy at Children's Healthcare of Atlanta Egleston location\\nParent or legal guardian willing to participate, and able to understand and sign the provided informed consent\",\n",
       " 'LVAD on warfarin requiring temporary interruption of anticoagulation for procedures',\n",
       " 'Patients older than 18 years\\nIschemic symptoms or evidence of myocardial ischemia (inducible or spontaneous) in the presence of >50% de novo stenosis located in native coronary vessels',\n",
       " 'Perimenopausal women complaining of abnormal uterine bleeding (menorrhagia, metrorrhagia, polymenorrhoea or polymenorrhagia) without local gynecological cause.',\n",
       " 'Failure of medical treatment for at least 3 months.',\n",
       " 'Clinical Administered PTSD Scale 5 Monthly version Criteria A and >30 points',\n",
       " 'NA',\n",
       " 'CHB patients who had received single NAs for more than 12 months.',\n",
       " 'Hepatitis B e antigen (HBeAg)-negative.',\n",
       " 'Hepatitis B surface antigen (HBsAg) positive and <1000 IU/mL.',\n",
       " 'Hepatitis B virus DNA <100 IU/mL.',\n",
       " 'CKD patients classified as Stage 3 and 4 of National Kidney Foundation Classification with estimated glomerular filtration rate (GFR) between 15 and 59 mL/min/1.73 m2 according to the Modification of Diet in Renal Disease (MDRD) formula based on serum creatinine, age, gender, and race.',\n",
       " 'Men and women 35 to 70 years of age',\n",
       " 'Patients undergoing SSRF at Denver Health Medical Center',\n",
       " 'Patients aged at least 18 years\\nPatients with chronic heart failure present for at least 12 months\\nConfirmed presence of iron deficiency\\nSerum haemoglobin of 9.5 to 14.0 g/dL',\n",
       " '1.',\n",
       " 'Subjects must have recurrent or persistent platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with measureable disease (as defined by RECIST 1.1.)',\n",
       " 'after first or second line platinum-based chemotherapy, for which treatment with PLD is indicated.',\n",
       " 'Platinum-based therapy is defined as treatment with carboplatin, cisplatin or another organoplatinum compound.',\n",
       " 'Platinum-resistant is defined as having a platinum-free interval (PFI) of < 12 months after first- or second-line platinum-based chemotherapy, or having disease progression while receiving second-line platinum-based chemotherapy.',\n",
       " 'Subjects are allowed to have received, but are not required to have received: \\none additional cytotoxic regimen and/or PARP inhibitor for management of recurrent or persistent disease.',\n",
       " 'biologic therapy (e.g., bevacizumab) as part of their primary treatment regimen or part of their treatment for management of recurrent or persistent disease.',\n",
       " '2.',\n",
       " 'Histologic documentation of the original primary tumor.',\n",
       " '3.',\n",
       " 'Documented radiographic disease progression < 12 months after the last dose of first- or second-line platinum-based chemotherapy.',\n",
       " '4.',\n",
       " 'Subjects in Phase 2 must have disease amenable to biopsy and must be willing to undergo pre- and post-treatment tumor biopsies.',\n",
       " 'Optional for Phase 1.',\n",
       " 'Note: archival tissue will be requested for all subjects preferably from primary tumor site prior to cancer treatment; however, archival tissue is not a requirement for study entry.',\n",
       " '5.',\n",
       " 'ECOG performance status of 0 or 1.',\n",
       " '6.',\n",
       " 'Laboratory parameters for vital functions should be in the normal range.',\n",
       " 'Laboratory abnormalities that are not clinically significant are generally permitted, except for the following laboratory parameters, which must be within the ranges specified, regardless of clinical significance: \\nHemoglobin: â\\x89¥ 9 g/dL \\nNeutrophil count: â\\x89¥ 1.5 x 109/L \\nPlatelet count: â\\x89¥ 100,000/mm3 \\nSerum creatinine, â\\x89¤ 1.5x Institutional Upper Limit of Normal (ULN), or Creatinine Clearance â\\x89¥ 50 mL/min (by Cockcroft-Gault formula) \\nSerum bilirubin: â\\x89¤ 1.2 mg/dL \\nAST/ALT: â\\x89¤ 2.5 x ULN \\nAlkaline phosphatase: â\\x89¤ 2.5 x ULN \\n7.',\n",
       " 'Age â\\x89¥18 years.',\n",
       " '8.',\n",
       " 'Able and willing to give valid written informed consent.',\n",
       " '9.',\n",
       " 'Body weight > 30 kg',\n",
       " 'diagnosis of ADHD\\nparental permission and/or teen consent/assent as appropriate\\nbetween 16-25 years of age\\nIQ greater than or equal to 70\\npermit or license to drive\\nability to read and understand English',\n",
       " 'Subjects aged 18 years or older, at the time of signing the informed consent.',\n",
       " 'Subjects with documented physician diagnosis of asthma as their primary respiratory disease.',\n",
       " 'ACT score <20 at screening visit.',\n",
       " 'Non-smokers (never smoked or not smoking for >6 months with <10 pack years history (Pack years = [cigarettes per day smoked/20] multiplied by number of years smoked).',\n",
       " 'Male or female subjects will be included.',\n",
       " 'A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: (i) Not a woman of childbearing potential (WOCBP).',\n",
       " '(ii) A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 5 days] after the last dose of study treatment.',\n",
       " 'Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and protocol.',\n",
       " 'Subject understands and is willing, able, and likely to comply with study procedures and restrictions.',\n",
       " 'Subject must be able to read in a language supported by the smart phone app in their region.',\n",
       " 'Subject must have been on maintenance therapy (Fixed dose combination ICS/LABA) for 3 months, cannot have changed dose in the month prior to screening and be able to change to an equivalent dose of RELVAR/BREO for the duration of the study.',\n",
       " 'Other background asthma medication such as anti-leukotrienes and oral corticosteroids are permitted provided the dose has been stable for 1 month prior to screening.',\n",
       " 'Subject must be able to change to Salbutamol/Albuterol MDI rescue for the duration of the study and judged capable of withholding albuterol/salbutamol for at least 6 hours prior to study visits.',\n",
       " 'Subject must have their own Android or iPhone operating system (IOS) smart phone and a data package suitable for the installation and running of the app and sending and receiving data.',\n",
       " 'Data used by the CIS is approximately 1 megabyte (MB) per month as a maximum; this is less data than a 1 minute video streamed from YouTube (2MB).',\n",
       " 'Subjects must be willing and able to download the app on their personal smart phone and keep it turned on for the duration of the study.',\n",
       " 'This will also require Bluetooth to be turned on for duration of the study.',\n",
       " 'Subjects will also have to turn on mobile data for the app for the duration of study; unless travelling and when extra data roaming costs could be incurred.',\n",
       " 'ACT score <20 at randomization visit (visit 2).',\n",
       " \"presence of typical HF symptoms and signs\\nLV ejection fraction = 50\\nelevated levels of NT-proBNP (at least >125 pg/ml)\\nechocardiographic structural (a left atrial volume index > 34 mL/m2 or a left ventricular mass index =115 g/m2 for males and =95 g/m2 for females) or functional alterations (E/e'=13 and a mean e' septal and lateral wall < 9 cm/s).\",\n",
       " 'All patients admitted at the Gynecological emergency Unit at Hospital de ClÃ\\xadnicas de Porto Alegre scheduled for uterine evacuation with <12 weeks of gestation.',\n",
       " 'Age greater than 18\\nNOSE score greater than 55\\nNasal septal deviation on exam',\n",
       " 'Adult men and women> 18 years old\\nPresence of sustained ventricular tachycardia with HR> 120 bpm\\nSystolic blood pressure> 90 mmHg\\nNo signs of poor peripheral perfusion\\nAbsence of dyspnea\\nAbsence of severe angina\\nSigned consent form',\n",
       " 'Patients scheduled for thyroidectomy with general anesthesia in the University of Chile Clinical Hospital',\n",
       " 'A positive history of chronic claudication,\\nExercise-limiting claudication established by history and direct observation during a screening walking test administered by the evaluating vascular surgeon,\\nArterial occlusive disease per ankle Brachial index measurements and/or other imaging modalities,\\nStable blood pressure regimen, stable lipid regimen, stable diabetes regimen and risk factor control for 6 weeks.',\n",
       " 'Male or female = 18 years of age at Visit 1.',\n",
       " 'Sweat chloride equal or greater than 60 mEq/L by quantitative pilocarpine iontophoresis test.',\n",
       " 'Two well-characterized mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene\\nAbnormal nasal potential difference (NPD) as measured by a change in NPD in response to a low chloride solution and isoproterenol of less than -5 mV.',\n",
       " 'Documentation of the presence of an acute pulmonary exacerbation, based on CF Foundation guidelines, as diagnosed by a faculty member of the Denver Adult CF Program.',\n",
       " 'Respiratory culture(s) demonstrating evidence of Pseudomonas aeruginosa or Achromobacter species airway infection.',\n",
       " 'Subject is able to produce sputum, undergo phlebotomy, and provide written consent.',\n",
       " \"The subject's treating physician has determined that they should receive either tobramycin or colistin intravenously as one of the designated agents for their APE treatment.\",\n",
       " 'Subjects who are able to receive either tobramycin or colistin as part of their antibiotic regimen will be randomized into one of three arms.',\n",
       " 'If a treating physician deems that a subject cannot receive tobramycin due to vestibular toxicity, ototoxicity or bacterial resistance, the subject will be randomized to either standard or PK-adjusted colistin.',\n",
       " 'Menopausal women with breast cancer treated and using tamoxifen or aromatase inhibitor.',\n",
       " 'With hot flashes and with or without active sexual life.',\n",
       " 'Male or female between, and including, 6-12 weeks (42 to 90 days) of age at the time of the first vaccination.',\n",
       " 'Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol \\nWritten informed consent obtained from the parent or guardian of the subject.',\n",
       " 'Free of obvious health problems as established by medical history and clinical examination before entering into the study.',\n",
       " 'Born after a gestation period between 36 and 42 weeks.',\n",
       " 'Completed \"ALO-IIT-012(PEAK study)\", without major protocol deviations.',\n",
       " 'Male, or female, 19 years to 75 years.',\n",
       " 'Female with childbearing potential who has a negative urine pregnancy test result at study start and willing to continue practice appropriate birth control during the entire duration of study\\nSubjects completed PEAK can be included within 30 days after End Of the Study\\nSubjects completed PEAK can be included if their treatment is the same as randomized even after 30 days of End Of the Study.',\n",
       " 'Epilepsy partial seizure subjects.',\n",
       " 'Currently taking 1 to 3 antiepileptic drugs.',\n",
       " 'Patients on regular hemodialysis 3sessions/wk.',\n",
       " 'Recent catheter insertion at beginning of the study.',\n",
       " 'Both males and females.',\n",
       " 'Age group = 18 ys.',\n",
       " '1.',\n",
       " 'Age 18 years or older \\n2.',\n",
       " 'Diagnosis of venous leg ulcer(s), as clinically determined by the investigator by a positive venous reflux test (venous refilling <20 seconds) using Doppler ultrasound for at least 4 weeks prior to screening day, which have not adequately responded to conventional ulcer therapy.',\n",
       " '3.',\n",
       " 'Designated venous leg ulcer meets the following criteria at both the screening and baseline visits.',\n",
       " 'If the patient has multiple ulcers, at least one ulcer must meet the following criteria at both the screening and baseline visits: \\n1.',\n",
       " 'Present for at least 4 weeks \\n2.',\n",
       " 'CEAP Classification Stage 6 \\n3.',\n",
       " 'Surface ulcer with an area > 15cm2 post debridement \\n4.',\n",
       " 'Viable, granulating wound (investigator discretion) \\n4.',\n",
       " 'Ulcers that extend through the epidermis but not through the muscle, tendon, or bone (Stage II or III ulcers as defined by the IAET).',\n",
       " '5.',\n",
       " 'Female patients of childbearing potential must have a negative pregnancy test at screening and must agree to use hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence throughout until 2 weeks after the last administration of study drug \\n6.',\n",
       " 'Signed informed consent',\n",
       " 'type 2 diabetic, age 18 and over, informed consent,',\n",
       " 'Provision of written informed consent (by patient or appropriate designee according to local regulations) prior to any study specific procedures.',\n",
       " 'Aged 18 years or older, male or female.',\n",
       " 'History of stable angina pectoris with angiographic evidence of CAD (diameter stenosis = 50%) in major, i.e., left main, left anterior descending, left circumflex, and right coronary arteries.',\n",
       " 'History of previous myocardial infarction (MI)\\nHistory of coronary revascularization, i.e., percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG), not including the elective PCI during the index hospitalization\\nDocumented history of type 2 diabetes mellitus.',\n",
       " 'Post-procedural residual diameter stenosis of the treated lesions < 20% in patients with stent implantation or < 50% in those with balloon angioplasty\\nPost-procedural thrombolysis in myocardial infarction (TIMI) grade 3 flow in treated vessels\\nNegative cardiac troponin test before the index elective PCI.',\n",
       " 'Taking Clopidogrel 75 mg daily dose for at least 7 days or taking Clopidogrel 75 mg daily dose for less than 7 days but with 300 to 600 mg Clopidogrel loading dose before PCI.',\n",
       " 'Taking acetylsalicylic acid (ASA) 100 mg daily treatment for at least 7 days or taking ASA 100 mg daily dose for less than 7 days but with 300 mg ASA loading dose before PCI.',\n",
       " 'have a negative urine or blood pregnancy test at enrolment and prior to randomization;\\ncurrently be using a hormonal contraceptive and agree to continue its use in addition to using double-barrier local contraception (i.e., intra-uterine device plus spermicidal and condom for male partner) from screening through study completion.',\n",
       " 'scheduled for Nuss procedure for pectus excavatum correction\\nat least 13 years old at the time of the procedure',\n",
       " 'Histologically confirmed primary breast cancer\\nPlanned to start docetaxel component of FEC-D or AC-D, or first cycle of; dose-dense AC-T, TC, FEC-D or TAC chemotherapy\\n=19 years of age\\nAble to provide verbal consent',\n",
       " 'aged = 6 months\\nsign the informed consent form\\nthe legal guardians participate in all the planned follow-up and be able to comply with all research procedures\\nthe subjects have completed the basic immunization of 2 needle recombinant hepatitis B vaccine, there is no inoculation history of EV71 vaccine, and no history of EV71 infection\\nthe last vaccination intervals = 14 days\\ntemperature = 37<U+2103>\\naged = 6 months\\nsign the informed consent form\\nthe legal guardians participate in all the planned follow-up and be able to comply with all research procedures\\nthere is no inoculation history of EV71 vaccine, and there is no history of EV71 infection\\nthe last vaccination intervals = 14 days\\ntemperature = 37<U+2103>\\naged = 8 months\\nsign the informed consent form\\nthe legal guardians participate in all the planned follow-up and be able to comply with all research procedures\\nthere is no inoculation history of EV71 vaccine, and there is no history of EV71 infection\\nthe last vaccination intervals = 14 days and the last attenuated live vaccine intervals=28days\\ntemperature = 37<U+2103>\\naged = 8 months\\nsign the informed consent form\\nthe legal guardians participate in all the planned follow-up and be able to comply with all research procedures\\nthere is no inoculation history of EV71 vaccine, and there is no history of EV71 infection\\nthe last vaccination intervals = 14 days and the last attenuated live vaccine intervals = 28 days\\ntemperature = 37<U+2103>',\n",
       " 'Scheduled to undergo bilateral palatine tonsillectomy as the only procedure',\n",
       " 'Between the age of 25 to 65 at baseline\\nBe willing to participate in a smoking cessation program\\nBe willing to attend all clinic visits\\nMust be currently smoking at least Â½ pack/day at baseline (confirmed with cotinine level and CO Smokerlyzer\\n>5 pack-year history of smoking\\nGlobal Initiative for Chronic Obstructive Lung Disease (GOLD) 0: FEV1=0.80 and FEV1/FVC>0.70 Forced Expiratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC)\\nGOLD 1: FEV1=0.80 and FEV1/FVC < 0.70\\nGOLD 2: 0.50=FEV1<0.80 and FEV1/FVC < 0.70\\nBe willing to abstain from using any nicotine patches, e-cigarettes, or marijuana for the duration of the study.',\n",
       " 'Male or female patients = 18 and = 85 years of age\\nWomen of child bearing potential must test negative on standard pregnancy test (urine or serum)\\nPatients with body weight = 55 kg and = 140 kg and body mass index (BMI) = 18 kg/m2\\nPatients diagnosed severe sepsis / septic shock at admission on Intensive Care Unit who can be enrolled within 90 min after admission OR patients diagnosed severe sepsis / septic shock during Intensive Care Unit stay who can be enrolled within 90 min after diagnosis\\nPatients where antibiotic therapy has already been started (prior to randomization)\\nPatient who are fluid responsive.',\n",
       " 'Fluid responsiveness is defined as increase of > 10% in mean arterial pressure (MAP) after passive leg raising (PLR)\\nSigned informed consent by patient, legal representative or authorized person or deferred consent',\n",
       " 'Adult males and females who are 18 years of age or older.',\n",
       " 'Evidence or suspicion of upper gastrointestinal bleed (GIB)\\nPatient with known or suspected cirrhosis\\nUpper GIB secondary to bleeding esophageal varices as show by esophageal endoscopy, requiring endoscopic band ligation (EBL) at presentation\\nWilling and able to provide informed consent for study, or have a Legally authorized representative (LAR) provide consent if the patient is unable to do so',\n",
       " 'women previously diagnosed with generalized vulvodynia \\nwomen previously diagnosed with localized vestibulodynia,',\n",
       " '18 years or older\\nChest radiograph showing new opacities.',\n",
       " 'Cough\\nProduction of sputum\\nTemp >38,0 Â°C or <36,0 Â°C\\nAudible abnormalities by chest examination compatible with pneumonia\\nLeukocytosis (>10.000 cells/mm3), leftward shift (>10%) or leucopenia (<4000 cells/mm3)\\nC-reactive protein > 15 mg/l (three fold higher than the upper limit of normal)',\n",
       " 'Children aged 3-16 with a parent/guardian (hereafter termed parent) reported history of allergy to a penicillin antibiotic in which the reported allergic reaction occurred at least six months prior to the current PED visit.',\n",
       " 'Only children well enough to be discharged to home at the conclusion of the PED visit are eligible.',\n",
       " 'Scheduled back surgery',\n",
       " 'Non-affective psychosis \\nPremorbid IQ of over 70 \\nA service user of the early intervention service \\nAged 18 or over (up to the age of 35 which is the limit for the early intervention service) \\nPsychiatrically stable enough to attend to completion (no hospitalisations or medication changes in last 4 weeks)',\n",
       " 'Patients undergoing surgery with general anesthesia,\\nPatients weighing = 80 pounds who are not -intubated prior to surgery,\\nPatients who are able to give informed consent.',\n",
       " 'Subject are at least 18 years of age \\nSubject has confirmed Pulmonary Hypertension and Interstitial Lung Disease \\nSubject are able to complete study procedures, such as spirometry, and Pulmonary Exercise test.',\n",
       " \"Possible or probable Alzheimer's disease (National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria), with Mini-Mental State Exam (MMSE) score of 10-26 inclusive; MMSE scores above 26 in those who nevertheless meet criteria for AD may be allowed with Steering Committee approval on a case by case basis \\nClinically significant apathy for at least four weeks for which either 1) the frequency of apathy as assessed by the Neuropsychiatric Inventory (NPI) is 'Very frequently', or 2) the frequency of apathy as assessed by the NPI is 'Frequently' or 'Often' AND the severity of apathy as assessed by the NPI is 'Moderate' or 'Marked' \\nA medication for apathy is appropriate, in the opinion of the study physician \\nProvision of informed consent for participation in the study by patient or surrogate (if the patient is unable to provide informed consent) and caregiver \\nAvailability of primary caregiver, who spends greater than ten hours a week with the patient and supervises his/her care, to accompany the patient to study visits and to participate in the study \\nSufficient fluency, of both the patient and caregiver, in written and spoken English to participate in study visits, physical exams, and outcome assessments \\nNo change to AD medications within the month preceding randomization, including starting, stopping, or dosage modifications \\nTreatment with stable doses of selective serotonin reuptake inhibitor antidepressants(SSRIs) is appropriate if stable for 3 months prior to randomization.\",\n",
       " 'Other psychotropics(with the exclusion of antipsychotics), if stable for 3 months, may be allowed only with Steering Committee approval on a case by case basis.',\n",
       " 'Age between 20 and 80 years\\nPatients undergoing percutaneous coronary intervention and need to take dual antiplatelet therapy continuously at least 12weeks\\nModified Lanza Score grade 0-1 measured by upper gastrointestinal endoscopy\\nmild gastrointestinal symptom\\nCreatinen in blood = 3mg/dl\\nBUN = 50mg/dl\\nBirilubin = 3mg/dl\\nAST and ALT = 80U/L',\n",
       " 'Patients aged =50 years with DM2 and symptomatic PAD diagnosed clinically (according to Fontaine criteria, stage IIa or IIb and III) and by measuring the <U+0391><U+0392><U+0399>.',\n",
       " 'Subjects = 19 or = 75 years of age\\nSubjects undergoing treatment for type 2 diabetes\\nSubjects undergoing treatment of statin for hypercholesterolemia\\nFasting LDL-C = 250mg/dL at the screening visit\\nFasting LDL-C =70mg/dL or = 160mg/dL at the randomization visit\\nFasting TG<500mg/dL',\n",
       " 'Diagnosis of diabetes mellitus according to World Health Organization criteria ( treatment with insulin or an oral hypoglycemic agent, twice random glucose measurements major than 200 mg/dl, or a fasting glucose major than 140 mg/dl)\\nUlcer located on the legs or feet, stage III or IV (Wagner Classification System)\\nThe subject agrees to comply with study protocol requirements and all follow up visit requirements.',\n",
       " '1.',\n",
       " 'Signed informed consent \\n2.',\n",
       " 'Healthy subjects aged between 18 years and 45 years inclusive \\n3.',\n",
       " 'Weighing at least 50 kg \\n4.',\n",
       " 'Volunteers must be hospitalized on Days 1-4, 7-9, and 17-20 for pharmacokinetic assessments for each biomarker and TPV/r (Days 7-9 and 17-20) \\n5.',\n",
       " 'Volunteers must be willing to complete all study-related activities \\n6.',\n",
       " 'Each volunteer must have a valid social security number \\n7.',\n",
       " 'Each volunteer must have acceptable medical history, physical examination and laboratory test',\n",
       " 'Males and females 21 years of age or older;\\nUndergoing elective primary, resurfacing arthroplasty, revision, or second stage re-implantation total hip replacement;\\nUndergoing elective primary, revision, or second stage re-implantation total or uni compartmental knee replacement;\\nPatient has necessary mental capacity to participate and is able to comply with study protocol requirements;\\nPatient is willing and able to give informed consent; and\\nPatient is willing to be randomized and participate.',\n",
       " 'Males and females aged between 18 to 75 years.',\n",
       " \"Adult patient under guardianship with consent obtained and the legal guardian's authorisation obtained.\",\n",
       " 'Single stroke having occurred more than 6 months before (previous TIA is accepted).',\n",
       " 'Capable of understanding instructions and participating in the definition of a therapeutic goal (Boston Diagnostic Aphasia Examination (BDAE) < 3).',\n",
       " 'Having previously undergone BTI.',\n",
       " 'The last injection must have been performed at least 4 months prior to inclusion.',\n",
       " 'Affiliation to the French social security regime or a similar regime.',\n",
       " 'Patient (or the legal guardian if under guardian adult patient) has signed the informed consent form.',\n",
       " 'patients aged >18, <75, left ventricle ejection fraction (LVEF) >50%, multivessel coronary disease detected by coronarography, indication to receive a CABG, stable CAD.',\n",
       " 'All diabetics and non diabetics.',\n",
       " '.',\n",
       " 'Inclusion criteria are American Society of Anesthesiologists (ASA) physical status I-III, age between 18 and 70 years and body mass index (BMI) between 20 and 35 kg/m2.',\n",
       " 'Male and female adolescent patients, aged 13 to 17 years, diagnosed with RLS based on the IRLSSG consensus criteria (Allen RP 2014) (Appendix 2).',\n",
       " 'Total RLS severity score of 15 or greater on the IRLS rating scale at Visit 1 (screening) and at Visit 2 (baseline) (Appendix 8).',\n",
       " 'RLS symptoms for at least 4 of 7 consecutive evenings/nights during the screening period.',\n",
       " 'Body weight greater than 33.4 kg and a healthy weight using age-based body mass index (BMI) range 5th-85th percentile at screening and baseline.',\n",
       " 'Appendix 3 contains BMI-for-age charts that can be consulted.',\n",
       " 'Estimated creatinine clearance of at least 60 mL/min (using the Cockcroft-Gault equation) at screening only.',\n",
       " 'Signed patient and parent Institutional Review Board (IRB)-approved informed consent/assent form (as applicable) before any study-related procedures are performed.',\n",
       " 'Phase 1 Specific Patient at least 18yrs of age with histologically confirmed CLL/SLL or B-cell Non-Hodgkin lymphoma (DLBCL, FL, MCL, MZL, lymphoplasmacytic lymphoma).',\n",
       " 'Phase 2a Inclusion \\nHistological evidence: FL Grade 1-3A/iNHL, with relapsed or refractory disease (iNHL includes LPL/WM, MZL); aNHL, defined as DLBCL, FL Grade 3B, MCL, and transformed NHL with relapsed disease; CLL/SLL, PTCL, or CTCL (with MF/SS) with relapsed or refractory.',\n",
       " 'Received BCR and/or BCL2 inhibitors were intolerant or had relapsed/refractory disease afterwards.',\n",
       " 'Prior treatment for lymphoid malignancy for progressive /refractory disease \\nâ\\x89¥ 1 prior regimen (min 2 cycles) with antibody conjugate, cytotoxic chemotherapy, or TKI alone or in combination.',\n",
       " \"Measureable disease defined as: â\\x89¥ 1 lesion â\\x89¥ 1.5 cm single dimension via CT, CT/PET with nodal or mass lesions; Quantifiable circulating tumor cells; or for WaldenstrÃ¶m's macroglobulinemia presence of IgM l > 2X ULN; For CTCL: mSWAT > 0 \\nAbility to provide diagnostic reports \\nGeneral Inclusion \\nECOG Score of 0 or 1.\",\n",
       " 'Hematologic ANC > 1000/uL and platelet > 75,000/uL, \\nSerum creatinine of < 1.5 ULN or calculated CrCl of > 50 mL/min \\nBilirubin < 20.0mg/dL (if Gilberts then < 2.5 mg/dL) and AST/AST < 2.5 ULN',\n",
       " '1.',\n",
       " 'Subject has a history of GTC seizures, either primary GTC or partial onset seizures with secondary generalization.',\n",
       " '2.',\n",
       " 'Is being admitted to a hospital for routine vEEG monitoring related to seizures.',\n",
       " '3.',\n",
       " 'Male or female between the ages of 2-99.',\n",
       " '4.',\n",
       " 'Has an upper arm circumference which is adequate for proper fit of the EMG monitor (at least 14cm).',\n",
       " '5.',\n",
       " 'If female and of childbearing potential, has a negative pregnancy test.',\n",
       " '6.',\n",
       " 'Can understand and sign written informed consent, or will have a parent or a legally authorized representative (LAR) who can do so, prior to the performance of any study assessments.',\n",
       " '7.',\n",
       " 'Subject and/or Primary Caregiver must be competent to follow all study procedures.',\n",
       " '8.',\n",
       " 'Is able to read, speak, and understand English.',\n",
       " 'Elective Cardiac surgery\\nAmerican Society of Anesthesiologists physical status class I-III',\n",
       " 'Chronic hepatitis B (HBsAg positive > 6 months)\\nHBeAg negative within six months prior to initiation of peginterferon alfa-2a\\nHBV DNA < 200 IU/ml during nucleos(t)ide analogue (except Telbivudine) treatment within one month prior to initiation of peginterferon alfa-2a\\nCompensated liver disease\\nAge > 18 years\\nWritten informed consent',\n",
       " 'Histologically or cytologically confirmed adenocarcinoma of the breast with locally advanced or metastatic disease, and a candidate for chemotherapy.',\n",
       " 'Human epidermal growth factor receptor 2 (HER2)-positive.',\n",
       " 'No prior chemotherapy for their metastatic breast cancer (MBC).',\n",
       " 'Measurable disease.',\n",
       " 'Age â\\x89¥ 18 years.',\n",
       " 'For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly effective, non-hormonal form of contraception or 2 effective forms of non-hormonal contraception by the patient and/or partner.',\n",
       " 'Contraception use must continue for the duration of study treatment and for at least 6 months after the last dose of study treatment.',\n",
       " 'Male patients whose partners are pregnant should use condoms for the duration of the study.',\n",
       " 'CHB patients who had received NAs for more than 12 months.',\n",
       " 'Hepatitis B e antigen (HBeAg)-negative and anti-HBeAg positive.',\n",
       " 'Hepatitis B surface antigen (HBsAg) positive and <1500 IU/mL.',\n",
       " 'Hepatitis B virus DNA not detectable(Roche Cobas).',\n",
       " 'Healthy Volunteers: \\nAge of at least 18 years \\nExistence of a contraceptive method for women of child-bearing age \\nPerson affiliated to social security or beneficiary of such a scheme \\nSigned consent form \\nSystemic sclerosis patients: \\nSystemic sclerosis meeting the EULAR criteria.',\n",
       " 'Presence of at least 2 ischemic digital cutaneous ulcerations on two different fingers, with digital ulcers classified as \"active ulcers\" according to the North American working group definition: epithelial denudation is clearly Visible at one place and the bed of de-epithelialized ulcer can be seen; Ulcerations distal to the proximal interphalangeal joint, not associated with calcinosis or bony relief.',\n",
       " 'Ulcers whose major axis measured with the electronic caliper is â\\x89¥ 2 mm \\nAge greater than or equal to 18 years \\nExistence of a contraceptive method for women of reproductive age \\nA person who is or is a beneficiary of social security \\nInformed and signed consent signed by the patient or his / her legal representative.',\n",
       " 'Age greater than or equal to 18 years old\\nRequirement for vasoactive drugs via a central venous catheter for the treatment of shock.',\n",
       " 'Shock will be defined as mean arterial pressure less than 70 mmHg or systolic blood pressure less than 100 mmHg despite administration of at least 1000 mL of crystalloid or 500 mL of colloid, unless there is an elevation in the central venous pressure to > 12 mmHg or in the pulmonary artery occlusion pressure to > 14 mmHg coupled with signs of tissue hypoperfusion (e.g.',\n",
       " 'altered mental state, mottled skin, urine output < 0.5 mL/kg body weight for one hour, or a serum lactate level of > 2 mmol per liter).',\n",
       " 'Currently smoke at least ten cigarettes a day\\nHave been smoking for at least one year\\nMeet criteria for schizophrenia, schizoaffective disorder, or another psychotic disorder based on structured clinical interview\\nCan speak and write fluent conversational English\\nAre between 18 and 70 years of age\\nAre willing to make a smoking cessation attempt\\nScore 26 or higher on the Montreal Cognitive Assessment',\n",
       " 'Pediatric patients with deep dental decay in primary molars\\nTeeth with signs and symptoms of reversible pulpitis',\n",
       " 'breast cancer\\nundergoing unilateral mastectomy with or without axillary node dissection\\nreceived adequate oral and written information about the study and signed an informed-consent form',\n",
       " 'Present to ED primary for management of LBP, defined as pain originating between the lower border of the scapulae and the upper gluteal folds.',\n",
       " 'Flank pain, that is pain originating from tissues lateral to the paraspinal muscles, will not be included.',\n",
       " 'Musculoskeletal etiology of low back.',\n",
       " 'Patients with non-musculoskeletal etiologies such as urinary tract infection, ovarian cysts, or influenza like illness will be excluded.',\n",
       " 'The primary clinical diagnosis, at the conclusion of the ED visit, must be a diagnosis consistent with non-traumatic, non-radicular, musculoskeletal LBP.',\n",
       " 'Patient is to be discharged home.',\n",
       " 'Patients admitted to the hospital are more likely to be treated with parenteral medication and therefore are not appropriate for this study.',\n",
       " 'Age 18-64 Enrollment will be limited to adults younger than 65 years because of the increased risk of adverse medication effects in the elderly.',\n",
       " 'Non-radicular pain.',\n",
       " 'Patients will be excluded if the pain radiates below the gluteal folds in a radicular pattern.',\n",
       " 'Pain duration <2 weeks (336 hours).',\n",
       " 'Patients with more than two weeks of pain are at increased risk of poor pain and functional outcomes.',\n",
       " '(9)\\nPrior to the acute attack of LBP, back pain cannot occur more frequently than once per month.',\n",
       " 'Patients with more frequent back pain are at increased risk of poor pain and functional outcomes.',\n",
       " '(9)\\nNon-traumatic LBP: no substantial and direct trauma to the back within the previous month\\nFunctionally impairing back pain: A baseline score of > 5 on the Roland-Morris Disability Questionnaire',\n",
       " \"Male or female =18 years of age at Visit 1\\nDocumentation of a CF diagnosis\\nEnrolled in the Cystic Fibrosis Foundation National Patient Registry (CFFNPR) prior to Visit 1 (US sites only)\\nAt the time of Visit 1, there is a plan to initiate IV antibiotics for a pulmonary exacerbation\\nPerformed spirometry at Visit 1 and Visit 2 and willing to perform spirometry at Visit 3\\nCompleted the CRISS questionnaire at Visit 1 and Visit 2 and willing to complete the Cystic Fibrosis Respiratory Symptoms Diary (CFRSD) questionnaire at Visit 3\\nWilling to adhere to a specific treatment duration determined by initial response to treatment and subsequent randomization\\nWilling to return for follow up Visit 3\\nWritten informed consent obtained from the subject or subject's legal representative\",\n",
       " 'Women with singleton pregnancy.',\n",
       " 'History of preterm labor and/or midtrimester miscarriage in a previous pregnancy.',\n",
       " 'Cervical length of 15-25 mm by transvaginal sonography (TVS) at 16-24 weeks of gestation.',\n",
       " 'Mild-to-moderate RDS;\\nPostnatal age 2 to 48 hours;\\nGestational age 27 0/7 to 36 6/7 weeks;\\nTreated with nasal CPAP modalities = 5 cm H2O and FiO2 between 0.30 and 0.60 for at least 2 hours to maintain SpO2 90-95%;\\nInformed consent',\n",
       " 'histologically confirmed metastatic cancer that is not amenable to surgery or radiation therapy with curative intent \\nmeasurable lesion by CT or other techniques according to RECIST',\n",
       " 'Patients with a histologically or cytologically proven diagnosis of NSCLC \\nUnresectable (locally advanced) stage IIIa or IIIb disease \\nInitial radiotherapy field of treatment to encompass greater than or equal to 30% of the esophagus \\nLife expectancy greater than or equal to 6 months \\nEstimated weight loss less than or equal to 10% in the 3 months before study randomization \\nMeasurable disease \\n18 years of age or older \\nEastern Cooperative Oncology Group (ECOG) performance status of 0 - 2 \\nHemoglobin (hgb) greater than or equal to 10 g/dL without transfusional support or growth factor use in the 4 weeks before study randomization \\nAbsolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L without growth factor use in the 2 weeks before study randomization \\nPlatelet count greater than or equal to 100 x 10^9/L \\nSerum bilirubin less than or equal to 1.5 x institutional upper limit of normal (ULN) \\nSerum creatinine less than or equal to 2.0 mg/dL (Note: Patients with a serum creatinine greater than or equal to 1.4 and less than or equal to 2.0 mg/dL must demonstrate a 24-hour urinary creatinine clearance greater than or equal to 50 mL/min) \\nFemales of childbearing potential: negative serum or urine pregnancy test \\nPatient must give written informed consent before participating in any study-specific procedure, randomization, or receiving investigational product.',\n",
       " 'Patients with reproductive capability must agree to practice adequate contraception methods.',\n",
       " 'Recipient is Age = 18 years\\nSerum ALT within normal limits with no history of liver disease\\nLack of sensitization (i.e.',\n",
       " 'PRA < 20%) that would be expected to result in a high likelihood of needing aggressive immunosuppression to treat rejection',\n",
       " 'Born at University of New Mexico Hospital\\nGreater than 34 weeks gestation\\nPrimary in-utero drug exposure was opioids other than buprenorphine\\nMaternal or infant urine drug screen positive for methadone and/or opioids on admission',\n",
       " 'Diagnosis of Type 1 diabetes (for at least a year)\\nOn multiple daily insulin injections, including basal long-acting insulin and rapid-acting insulin before each meal.',\n",
       " 'HbA1c < 75 mmol/mol (9.0%)\\nParticipant and/or parent/legal guardian willing and able to give informed consent for participation in the study.',\n",
       " 'Family have a freezer in which to safely store the test meals.',\n",
       " \"In the Investigator's opinion, is able and willing to comply with all trial requirements.\",\n",
       " 'Patient age >= 18 years\\nZubrod performance status of 0-3\\nT1-3 N0 M0 adenocarcinoma of the prostate\\nProstate volume = 100 cc\\nSigned study-specific consent form\\nExtension of local tumor to involve adjacent organs other than seminal vesicles (T4)\\nProstate volume > 100 cc\\nNodal involvement\\nMetastatic disease\\nPrior pelvic radiotherapy except as part of combination therapy for prostate cancer\\nHistory of scleroderma\\nPatients with psychiatric or addictive disorder that would preclude obtaining informed consent',\n",
       " 'Non-ventilated Patients over the age of 65',\n",
       " 'Men or women aged 18 years or older\\nPatients presenting for CMR with the clinical diagnosis of hypertrophic cardiomyopathy based on left ventricular wall thickness of at least =15 mm in the absence of any other cardiac or systemic cause of hypertrophy\\nPatients presenting for CMR with the clinical diagnosis of idiopathic dilated cardiomyopathy based upon left ventricular ejection fraction =40%, LV end-diastolic diameter =55 mm or left ventricular end-systolic diameter =45 mm, and the absence of coronary stenoses on angiography.',\n",
       " 'Patients presenting for CMR evaluation of chest pain but without evidence of obstructive coronary artery disease either by coronary angiography or stress testing.',\n",
       " 'Patient must meet 1987 ACR criteria\\nAge > 18 years of age\\nBaseline DAS28/Erythrocyte Sedimentation Rate (ESR) >=3.2\\nStable concomitant Disease Modifying Anti-Rheumatic Drugs (DMARDs)\\nStable prednisone <10mg or equivalent\\nPower Doppler score of >=10',\n",
       " 'Having been diagnosed with primary OCD as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-) criteria;Cleaning or checking as primary OCD symptoms\\nYale-Brown Obsessive-Compulsive Scale (Y-BOCS) score of = 16\\nNever receiving adequate treatment or stop receiving treatment for at least 8 weeks\\nHaving an education degree of high school or above\\nAccepting to participate in the study',\n",
       " 'Subjects scheduled for laparoscopic unilateral inguinal hernia repair\\nASA 1 or2.',\n",
       " 'Age >18 years.',\n",
       " 'Men and women aged > 18 years\\nAngiographically confirmed acute massive pulmonary embolism with involvement of Central pulmonary arteries.',\n",
       " 'endovascular mechanical thrombus fragmentation + thrombolytic therapy (using recombinant tissue activator of plasminogen), performed for treatment of the above-mentioned pulmonary embolism in less than 48 hours before randomization.',\n",
       " 'The patient should be randomized no earlier than 24 hours after procedures endovascular mechanical thrombus fragmentation + thrombolytic therapy\\nWritten informed consent signed by patient.',\n",
       " 'Age 65 - 79\\nHistory of coronary artery disease (MI/heart attack, stroke, heart failure, or peripheral artery disease)\\nCancer, with no active treatment in the last year\\nMCI (MoCA >18<26 -inclusive of 1 point if <12 years of education Group 2\\nDecline physical function (walking speed < 1 m/s) Group 3 (Either or both)\\nAbdominal obesity (>88cm women, >102cm men) AND hypertension (treated or resting blood pressure >140/90\\nAbdominal obesity (>88cm women, >102cm men) AND hyperlipidemia (treated or fasting total cholesterol >240 English literacy Willing to provide informed consent',\n",
       " 'Male and female individuals between ages of 18 to 70 years old \\nMultiple contiguous gingival recession defects on a minimum of two adjacent teeth, exhibiting 3mm or more recession on at least one of those teeth \\nNo prior surgical treatment in the sites planned for therapy \\nMinimum of 2 mm of keratinized gingiva \\nAbsence of cervical restorations extending to the CEJ \\nMiller class 1, 2 and 3 recession defects will be included \\nAvailability to undergo treatment and return for follow up visits at specified post-operative intervals',\n",
       " 'Patient with spontaneous intracranial hemorrhage or traumatic intracranial hemorrhage or patient requiring neurological surgery\\nCoagulation disorder defined by PT less than 60%',\n",
       " 'Aged between 18-70 years\\nMeets the Diagnostic and Statistical Manual (DSM) IV and DSM-V diagnostic criteria for generalised anxiety disorder (GAD) based on structured interview (Mini International Neuropsychiatric Interview-Plus 6 [MINI-Plus 6].',\n",
       " 'Note that while the MINI-Plus 6 uses the DSM-IV criteria, the same criteria are used in the DSM-V).',\n",
       " 'Presents with anxiety (Hamilton Anxiety Rating Scale = 18) at the time of study entry\\nFluent in written and spoken English\\nProvides a signed copy of the consent form\\nPrimary diagnosis other than GAD\\nPresentation of moderate to severe depressive symptoms (Montgomery-Asberg Rating Scale: MADRS = 18 at time of study entry or = 24 at any time during study)\\nPresentation of suicidal ideation (= 3 on MADRS suicidal thoughts domain at time of study entry or at any time during study)\\nCurrent diagnosis of bipolar disorder or schizophrenia on structured interview (MINI Plus)\\nCurrent substance/alcohol use disorder on structured interview (MINI Plus) Page 21 of 39 Commercial-in-Confidence\\nCurrently taking an antidepressant, mood stabiliser, antipsychotic, anticonvulsant, warfarin or thyroxin, or current regular use (more than 2 days per week) of a benzodiazepine or opioid-based analgesic\\nCurrent use of a psychotropic nutraceutical (e.g.',\n",
       " \"St John's wort)\\nPrevious intolerance to kava\\nThree or more failed trials of pharmacotherapy for the current GAD episode\\nRecently commenced psychotherapy (within four weeks of study entry)\\nKnown or suspected clinically unstable systemic medical disorder\\nDiagnosed hepato-biliary disease/inflammation\\nElevated liver enzymes at baseline blood test\\nPregnancy or breastfeeding, or trying to conceive\\nNot using medically approved contraception (including abstinence) if female and of childbearing age\\nUnable to participate in all scheduled visits, treatment plan, or other trial procedures according to the protocol (except for the optional genetic component)\",\n",
       " 'a crown-rump length = 6mm and no cardiac activity OR\\na crown-rump length <6mm and no fetal growth at least one week later OR\\nAt least one week after diagnosis OR a discrepancy of at least one week between crown-rump length and calendar gestational age\\nIntra-uterine pregnancy\\nWomen aged above 16 years\\nHemodynamic stable patient\\nNo signs of infection\\nNo signs of incomplete abortion\\nNo contraindications for mifepristone or misoprostol',\n",
       " 'Singleton pregnancy;\\n8-22 weeks gestation\\nPrevious pregnancy complicated by gestational diabetes',\n",
       " '=32 weeks gestational age at birth\\n=6 weeks postnatal age at randomization\\nRemains hospitalized after birth (has never been discharged home)\\nTreating clinician deems infant eligible to receive 2-month vaccines\\nEnglish- or Spanish-speaking parent(s)/legally authorized representative(s) (LAR(s))\\nNot planned for discharge within 60 hours of study entry\\nThe parent/guardian must be willing and capable of providing permission for their child to participate through the written informed consent process',\n",
       " 'Children aged 0-59 months living with families registered in the rural Bandim Health Project Health and Demographic Surveillance Site are included, provided a parent/guardian consent.',\n",
       " 'Has a cataract and is expected to undergo clear corneal cataract surgery with phacoemulsification and implantation of a posterior chamber intraocular lens \\nHas a potential post-operative pinhole corrected Snellen VA of at least 20/200 or better in both eyes',\n",
       " 'Age = 18 years and NYHA (New York Heart Association) functional class II, III and IV',\n",
       " 'between 7 to 70 years of age\\nfluent in English or Spanish\\nplans to receive care in the Community Health Center during the next year\\npresents with signs and symptoms of a SSTI\\nwilling/able to provide informed consent',\n",
       " '1.',\n",
       " 'Presence of bacteremia due solely to: \\nS. aureus on at least 1 blood culture within 72 hours of beginning study drug (Cohort A) OR \\nMRSA on a baseline blood culture and on at least 1 additional blood culture after at least 72 hours of vancomycin and/or daptomycin treatment (Cohort B).',\n",
       " '2.',\n",
       " 'Male or female â\\x89¥ 18 years of age.',\n",
       " '3.',\n",
       " 'If female of childbearing potential must be willing to practice sexual abstinence or dual methods of contraception during treatment and for at least 30 days after the last dose of study drug.',\n",
       " '4.',\n",
       " 'Expectation of survival for at least 2 months.',\n",
       " 'Inpatient or outpatient age 8-19 years inclusive; participants must live with a parent, guardian, or caregiver;\\nFluent in English;\\nDiagnosed or told by a clinician that they have any of the following bipolar spectrum disorders (BSD): bipolar I, bipolar II, unspecified bipolar and related disorders, Disruptive Mood Dysregulation Disorder (DMDD), cyclothymic disorder, other specified bipolar and related disorders, as well as mood disorder not otherwise specified (if diagnosed in the past as per DSM-IV);\\nBody mass index >85%ile for age and sex by standard growth charts;\\nReceived a new or ongoing prescription for at least one SGA (i.e., olanzapine, clozapine, risperidone, quetiapine, aripiprazole, ziprasidone, iloperidone, lurasidone, paliperidone, brexpiprazole or cariprazine) that is not prescribed as a PRN medication;',\n",
       " 'age 18 years or older\\npatients undergoing invasive procedures via the radial or femoral arteries',\n",
       " 'Irritable Bowel Syndrome (IBS) (ROME III criteria): subtype with diarrhea or mixed form\\nage 18-65 years',\n",
       " 'Children 7-17 with moderate to severe pain requiring around the clock treatment with an opioid analgesic.',\n",
       " 'Be an experienced opioid user, defined as any subject treated with opioid therapy, equivalent or equal to >20 mg per day of morphine, for a period of 3 consecutive days immediately prior to first day of dosing.',\n",
       " 'Age over 18 years,\\nGeneral Condition WHO 0, 1 or 2,\\nASA Class I and II, eligible for endoscopic or surgical treatment with curative intent,\\nHistological diagnosis of high grade glandular epithelial neoplasia (Vienna 4-1 to 4-46), possibly multifocal or stage 0 (Tis, N0, M0),\\nEndoscopic and histological confirmed diagnosis of intestinal metaplasia,\\nHistological diagnosis confirmed by two endoscopies with biopsies and two pathological readings; biopsies should be carried out according to the protocol of the SFED (four-quadrant biopsies every cm) with at least once acetic acid for staining.',\n",
       " \"Operators describe Barrett's esophagus using he SFED planimetric model.\",\n",
       " 'The final exam will be no more than two months before the date of treatment and should have been achieved in investigator establishment,\\nMinimum 1 cm,\\nMaximum 12 cm.',\n",
       " 'the resected lesion must have been well differentiated and confined to the mucosa (m2 maximum) on histological analysis,\\nresection should be more than two months,\\nresection must have been macroscopically complete laterally,\\nresection must have been histologically complete in depth,\\nresection must have been histologically complete laterally with regard to the microinvasive cancer, that is to say with a clear margin of safety (margin may be high-grade dysplasia provided that the latter has not macroscopic translation),\\nAt least one endoscopic and histologic follow-up should be conducted with dye in a period of less than two months before the date of treatment, and at the investigator establishment.',\n",
       " 'Patient may take an inhibitor of proton pump equivalent to 2 times 40 mg of esomeprazole,\\nNo mediastinal or celiac, or suspected metastatic lymph nodes by EUS,\\nAffiliation to a social security system or similar,\\nLack of participation in another clinical study,\\nInformed consent signed.',\n",
       " 'NA',\n",
       " 'Accepted for CABG surgery\\nTreatment with Ticagrelor within 48 hours',\n",
       " 'Patients with T2DM and CAS as defined below: \\nClinical definitions \\nT2DM: Diagnosed according to the WHO criteria [53].',\n",
       " 'CAD:Presence of any one of the following: Angina plus positive exercise tolerance test, enzyme and/or Q wave positive myocardial infarction, angiographic evidence ( >50% stenosis of one vessel), percutaneous or surgical coronary revascularisation.',\n",
       " 'Aged between 18 and 75 \\nProvided written consent for participation in the trial prior to any study-specific procedures or requirements.',\n",
       " 'Male and females between ages 18-85 years of age\\nSCI ( =1 month of injury)\\nASIA A, B,C and D\\nSCI above L5\\nAble to perform a visible contraction with dorsiflexor and hip flexor muscles (allowing testing of largely impaired patients)\\nAble to ambulate a few steps with or without an assistive device\\nMale and females between ages 18-85 years of age\\nAble to walk and complete lower-limb tests with both legs',\n",
       " 'patients with severe left ventricle dysfunction with an ejection fraction (EF)=40%, being scheduled for revascularization.',\n",
       " 'Female \\nAge â\\x89¥18 years \\nPatients with a lesion > 0.5 cm in largest diameter size, initially scored BI-RADSÂ® 3, 4a, 4b or 4c in B-mode ultrasound \\nInformed consent about histological examination (core cut biopsy (CCB), vacuum-assisted biopsy (VAB), fine needle aspiration (FNA) or surgery) has already been given in the course of clinical routine \\nSigned informed consent of study participation',\n",
       " 'Cases (with a history of TBI): \\n1.',\n",
       " 'Ages 50-95 years \\n2.',\n",
       " 'History of traumatic brain injury of sufficient severity to have resulted in medical attention (ascertained via the Ohio State University TBI Identification Questionnaireâ\\x80\\x94OSU TBI-ID, and based on DoD/VA criteria) \\n3.',\n",
       " 'Residence in AFRH-Washington D.C. or the Veterans Home of California-Yountville \\n4.',\n",
       " 'MMSE score â\\x89¥ 20 \\n5.',\n",
       " ...]"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "inc_data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "2600"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(inc_data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "for exc_file in exc_file_paths:\n",
    "    with open(exc_file, \"r\", encoding=\"unicode_escape\") as f:\n",
    "        data = sent_tokenize(f.read())\n",
    "        exc_data.extend(data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Research exemption requested\\nHistory of PCV-13 vaccination\\nHistory of cochlear implant\\nCerebrospinal Fluid (CSF) leak\\nCongestive Heart Failure (CHF)\\nDiabetes Mellitus (DM)\\nChronic Kidney Disease (CKD)\\nHuman Immunodeficiency Virus (HIV)\\nCommon Variable Immune Deficiency (CVID)\\nPatients who have received the PPSV23 vaccine in the last 5 years\\nWomen who are pregnant will also be excluded from the study by performing 2 point of care urine pregnancy tests ( prior to vaccinations)',\n",
       " 'Patients having had an ophthalmic surgical procedure within 6 months of the beginning of the study.',\n",
       " 'Patients with a diagnosis of glaucoma\\nAny abnormality of the cornea which may prevent reliable applanation tonometry\\nKnown allergy/ hypersensitivity reaction to Brimonidine\\nContra-indication to Brimonidine including patients on monoamine oxidase inhibitors (MOA)\\nPatients unwilling or unable to provide informed consent\\nPatients with anticipated difficult airway management (as this may require medications and/or airway manipulations resulting in increased IOP)',\n",
       " 'Women of child-bearing potential that do not practice adequate contraception.',\n",
       " 'Pregnant or lactating.',\n",
       " 'Received more than one primary chemotherapy regimen.',\n",
       " 'Concomitant or previous malignancies with the exception of adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, incidental carcinoid, or other cancer from which the patient has been disease free for 5 years.',\n",
       " 'Active uncontrolled infection requiring antibiotics.',\n",
       " 'Concurrent severe medical problems unrelated to the malignancy which would limit full compliance with the study.',\n",
       " 'Received radiation to more than 10% of bone.',\n",
       " 'Prior treatment with topotecan or gemcitabine.',\n",
       " 'Hypersensitivity to camptothecin or nucleoside analogues.',\n",
       " 'Use of an investigational agent within 30 days.',\n",
       " 'Ongoing acute kidney injury Stage 2/3\\nHistory of kidney transplant',\n",
       " 'Pregnant and/or nursing mothers.',\n",
       " 'Allergy to bupivacaine.',\n",
       " 'History of drug/alcohol abuse.',\n",
       " 'Severe cardiovascular, hepatic, renal disease or neurological impairment.',\n",
       " 'History of constipation\\nPre-existing use of narcotics or opioids\\nPre-existing renal or hepatic failure\\nMental illness, mental retardation, or inability to participate in informed consent due to mental status\\nPre-existing dementia\\nAllergy to any protocol medication\\nEmergency operation\\nSubjects who are incarcerated or wards of the state\\nMinors\\nSubjects with inflammatory bowel disease, active colitis, or pre-existing intra-abdominal inflammation.',\n",
       " 'Diverticulitis without active infection/inflammation will not be excluded.',\n",
       " 'Patient has history of loose or watery stools\\nPatient has both clinically significant findings and unexplained clinically significant alarm symptoms\\nPatient has symptoms of or been diagnosed with a medical condition that may contribute to abdominal pain\\nPatient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments',\n",
       " 'score level D on the SIGAM mobility grade \\nhave experienced 1 or more falls in the last month before the study \\nhave a residual limb length which does not allow for seven inches clearance of bracket attachment for the PowerFoot \\nthe residual limb must be stable in volume (no change in socket or socket padding in last 6 months) and without pain that limits function \\nthe sound-side (contralateral) lower extremity must be free of impediments that affect gait, range of motion, or limb muscle activity \\nAny diagnosed cardiovascular, pulmonary, neurological, and/ or orthopedic conditions that would interfere with subject participation',\n",
       " 'immunization with PPV23 within the last year\\nany confirmed or suspected immunodeficiency condition, including human immunodeficiency virus (HIV) infection, haematological malignancy, or a congenital immunodeficiency\\nhistory of allergic disease or reactions likely to be exacerbated by any component of the vaccine\\nhistory of allergic disease likely to be stimulated by the vaccination\\nhistory or records of immunosuppressive therapy (with the exception of topical corticosteroids) for more than 14 days and within 6 months of vaccination\\nhistory or evidence of administration of immunoglobulins and/or any blood products during the study period or within the three months preceding the study vaccine\\nuse of any other investigational or non-registered drug or vaccine during the study period or within 30 days preceding the study vaccine\\nadministration of a vaccine during the period starting one month before the dose of vaccine and ending one month after\\npregnancy',\n",
       " 'Purulent infection \\nRefusal to participate \\nAllergy to tested material',\n",
       " 'A history of life-threatening asthma defined for this protocol as an asthma episode that required intubation, hypercapnea requiring non-invasive ventilatory support, respiratory arrest, hypoxic seizures or asthma-related syncopal episode(s).',\n",
       " 'Subjects with a history of asthma exacerbation requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or a depot corticosteroid injection or emergency room attendance (within 3 months) or requiring hospitalization for asthma (within 6 months) prior to screening.',\n",
       " 'Significant, non-reversible active pulmonary disease (e.g.',\n",
       " 'cystic fibrosis, bronchiectasis, tuberculosis).',\n",
       " \"Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of Visit 1 and led to a change in asthma management or, in the opinion of the Investigator, is expected to affect the subject's asthma status or the subject's ability to participate in the study.\",\n",
       " 'Any fracture in the leg to be measured within 6 months prior to the screening visit.',\n",
       " 'Any metabolic disorders or other diseases that may impact on normal growth patterns.',\n",
       " 'No major surgery requiring general anaesthesia for at least 3 months prior to the screening visit.',\n",
       " 'No febrile illnesses with temperature >39 degree celsius for more than five consecutive days within the week preceding the Screening Visit.',\n",
       " \"Any significant abnormality or medical condition identified at the screening medical assessment (including serious psychological disorder) that in the Investigator's opinion, preclude entry into the study due to risk to the subject or that may interfere with the outcome of the study.\",\n",
       " 'Clinical visual evidence of candidiasis at Visit 1 (Screening).',\n",
       " 'Use of any of the prohibited medications listed in protocol.',\n",
       " 'Strenuous physical exercise within 3 hours of Visit 1 (Screening) \\nDrug allergies: Any adverse reaction including immediate or delayed hypersensitivity to any intranasal, inhaled, or systemic corticosteroid therapy.',\n",
       " 'Known or suspected sensitivity to the constituents of the ELLIPTA Inhaler (i.e., lactose, FF).',\n",
       " 'Milk Protein Allergy: History of severe milk protein allergy.',\n",
       " 'The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).',\n",
       " 'Exposure to more than 4 investigational medicinal products within 12 months prior to the first dosing day.',\n",
       " 'Unable to use the ELLIPTA inhaler and peak flow meter correctly.',\n",
       " 'An affiliation with the Investigator site: the parents/guardians or child is an immediate family member of the participating Investigator, sub-Investigator, study coordinator, or employee of the participating Investigator.',\n",
       " 'The Parent or Guardian has a history of psychiatric disease, intellectual deficiency, substance abuse or other condition (e.g.',\n",
       " 'inability to read, comprehend or write) which may affect: validity of consent to participate in the study; adequate supervision of the subject during the study; compliance of subject with study medication and study procedures (e.g.',\n",
       " 'completion of daily diary, attending scheduled clinic visits); subject safety and well-being.',\n",
       " 'Children in care: Children who are wards of the government or state are not eligible for participation in this study.',\n",
       " 'Serious suicidal tendency\\nThe score of the sixth item of HAMA =3\\nThe score of HAMD =21\\nPregnant or lactating women\\nHistory of allergic or hypersensitivity to tandospirone\\nSerious or unstable cardiac, renal, neurologic, cerebrovascular, metabolic, or pulmonary disease\\nSecondary anxiety disorders\\nDrug or alcohol dependence within 1 year\\nPatients currently taking benzodiazepine drugs\\nDrivers and dangerous machine operators\\nParticipated in other clinical studies in the last 30 days\\nPatients with clinically significant ECG or laboratory abnormalities\\nPatients with a history of epilepsy\\nPatients with abnormal TSH concentration',\n",
       " 'HPN < 12 months\\nmetabolically unstable\\ncancer as the reason for intestinal failure',\n",
       " 'allergic to dexmedetomidine, similar active ingredients or excipients\\nG-6-PD deficiency\\na history of arrhythmia, bronchial and cardiovascular diseases, abnormal liver function and so on\\na history of use of alpha 2 receptor agonists or antagonists.',\n",
       " 'Preoperative renal failure (defined as a serum creatinine > 2.0 mg/dL.)',\n",
       " 'American Society of Anesthesiologists Physical Status IV or V\\nPulmonary disease necessitating home oxygen therapy\\nAllergy to methadone, hydromorphone, or ketamine\\nPreoperative recent history of opioid or alcohol abuse\\nSignificant liver disease\\nInability to use a PCA device or speak the English language',\n",
       " 'With severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction.',\n",
       " 'With bad compliance or contraindication to enrollment.',\n",
       " 'Pregnant woman or lactating woman.',\n",
       " 'With contraindication to receive adjuvant chemotherapy.',\n",
       " 'Patients with renal impairment (serum creatinine more than twice the upper limit of normal).',\n",
       " 'Patients with heart failure.',\n",
       " 'Patients with sepsis or active infection.',\n",
       " 'Patients with diabetes mellitus (either primary or secondary to thalassemia).',\n",
       " 'regular consumption of medication with potential hepatotoxicity.',\n",
       " 'regular herbal medicine or antioxidant supplementation.',\n",
       " 'patients with gastrointestinal conditions preventing adsorption of oral medication.',\n",
       " 'submucosal leiomyoma,\\nendometrial hyperplasia with atypia,\\nhistory of uterine surgery',\n",
       " 'PRA > 50%\\nDSA > 1500 MFI\\nRetransplantation\\nPatients who are planning to receive mycophenolate instead of everolimus\\nPatients who have planning for follow-up in another center',\n",
       " 'History of organic brain disease\\nDSM-IV diagnosis of Alcohol or Substance Dependence within the last six months (except nicotine) or DSM-5 diagnosis of Substance Use Disorder in the last six months (except nicotine)\\nDSM-IV diagnosis of Alcohol or Substance Abuse within the last one month (except nicotine) or DSM-5 diagnosis of Substance Use Disorder in the last six months (except nicotine)\\nPregnancy or lactation\\nSevere liver dysfunction (LFT 3X upper limit of normal)\\nPrevious known hypersensitivity to tetracyclines\\nCurrent treatment with tetracycline or derivative\\nTreatment with oral contraceptives (unless a second form of birth control is used and documented)\\nTreatment with cholestyramine or colestipol\\nTreatment with Urinary alkalinizers (e.g., sodium lactate, potassium citrate)\\nTreatment with warfarin\\nTreatment with bupropion, varenicline, or nicotine replacement products in the month prior to study inclusion\\nLess than two months treatment of adjunctive medications AND less than one month on same dose: beta blockers, antidepressants, mood stabilizers, antianxiety medications.',\n",
       " 'Medical condition whose pathology or treatment would significantly increase the risk associated with the proposed protocol.',\n",
       " 'History of head injury, seizures, or stroke\\nPositive urine toxicology screen for substances of non-therapeutic use prior to craving assessments',\n",
       " 'Patients who have received prior chemotherapy for unresectable disease \\nPatients with any active or uncontrolled infection, including known HIV infection.',\n",
       " '(Patients with active hepatitis B will be placed on lamivudine.',\n",
       " 'Patients with active hepatitis C will be eligible if liver tests qualify (5.1.9) \\nPatients with psychiatric disorders that would interfere with consent or follow-up.',\n",
       " 'Pregnant or lactating women.',\n",
       " 'Men and women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.',\n",
       " 'Patients with any other severe concurrent disease, which in the judgment of the investigator, would make the patient inappropriate for entry into this study.',\n",
       " 'allergic history to dexmedetomidine\\nrefractory bradycardia < 60 bpm despite treatment\\nsevere atrioventricular block (2nd and 3rd degree)\\nprevious operation of tongue',\n",
       " 'Heart failure\\nSigns of kidney injury/failure\\nSevere allergies',\n",
       " 'Type 1 diabetes\\nuncontrolled diabetes mellitus type 2 with fasting glucose > 13.3 mmol/l confirmed on a second day\\nknown or suspected hypersensitivity to empagliflozin, glimepiride, or any excipients; and / or known or suspected hypersensitivity to sulfonylureas, sulfonamides or SGLT2 inhibitors in general\\nhistory of multiple severe hypoglycemic episodes within the last two years\\nuse of Insulin, SGLT2-inhibitor, sulfonylurea derivate or a glinide within past 3 months\\nclinical significant macular edema in both eyes and indication for intravitreal anti-VEGF treatment for both eyes at screening or baseline visit.',\n",
       " 'Eyes with a small amount of intraretinal or subretinal fluid (seen in OCT) but no need for intravitreal treatment as judged by the investigator (according to current practice patterns) may be included.',\n",
       " 'Eyes with a history of intravitreal treatment of macular edema which do not need ongoing intravitreal treatment at the time of screening may be included.',\n",
       " 'eye diseases or pathologies that prevent clear ophthalmoscopy and evaluation of study parameters, thus not allowing study participation according to the investigatorÂ´s judgment, such as (but not only) vitreous hemorrhage, mature cataract, macular pathologies other than diabetic maculopathy\\nhistory of ketoacidosis or metabolic acidosis\\nuse of loop diuretics\\nhistory of > 1 urogenital infection/year\\nany history of stroke, transient ischemic attack (TIA), instable angina pectoris or myocardial infarction within last 3 months prior to baseline visit\\ncongestive heart failure New York Heart Association (NYHA) III and IV\\nsevere valvular or left ventricular outflow obstruction disease needing intervention;\\natrial fibrillation/flutter with a mean ventricular response rate at rest >100 beats per minute\\nchronic lower urinary tract infections (but not simple asymptomatic bacteriuria)\\neGFR < 60 ml/min/1,73 m2 (MDRD-formula, confirmed on a second day)\\nchronic diarrhea, any clinical signs of volume depletion or a hematocrit > 48 % (women) and > 53 % (men)\\nelevated risk for volume depletion, e.g.',\n",
       " 'history of severe volume depletion that required medical therapy\\nchronic liver disease (including known active hepatitis) and/or screening alanine transaminase (ALT) or aspartate transaminase (AST) > 3 x upper limit of normal (ULN) (confirmed on a second day)\\nSubjects with known seropositivity to human immunodeficiency virus.',\n",
       " 'acute illness at screening or randomization according to judgement by the investigator or patient\\ndrug or alcohol abuse\\npsychosomatic or psychiatric diseases requiring hospitalization during the last 12 months\\nclinical evidence of current malignancy with exception of basal cell or squamous cell carcinoma of the skin, and cervical intraepithelial neoplasia (5 years prior to randomization)\\nany medical or surgical intervention planned for the next 13 months after randomization not allowing study participation according to the investigatorÂ´s judgment\\ncurrent participation in any other clinical trial or participation in another clinical trial within 30 days before screening',\n",
       " 'Secondary knee osteoarthritis\\nOther inflammatory Knee Osteoarthritis (e.g.',\n",
       " 'gout, rheumatoid arthritis, etc.)',\n",
       " 'Patients presenting with gastroesophageal reflux disease, peptic ulcer.',\n",
       " 'Helicobacter infected patients who have not been treated for eradication (recruitment if negative in re-examination after treatment).',\n",
       " \"Short bowel syndrome that can cause inflammatory bowel disease (ulcerative colitis, Crohn's disease) and drug absorption disorder.\",\n",
       " 'Intestinal obstruction syndrome\\nUnexplained abdominal pain\\nALT(Alanine aminotransferase) level of liver function test exceeded 5 times of reference range\\nTotal bilirubin level exceeded 2 mg / dL\\nSerum albumin level less than 2 g / dL\\nAscites\\nHepatic encephalopathy\\nHepatitis B, hepatitis C (excluding healthy carriers) or HIV positive\\nMDRD(Modification of Diet in Renal Disease) Estimated Glomerular filtration rate less than 60 mL / m2\\nPatients with hyperkalemia (over 5.5 meq / L)\\nhistory of asthma, acute rhinitis, nasal polyps, angioedema, urticaria or allergic reactions to aspirin or other non-steroidal anti-inflammatory drugs(including COX-2 inhibitors).',\n",
       " 'Malignant tumors other than basal cell or squamous cell carcinoma of the skin, CIN(Cervical Intraepitherial Neoplasia) and CIS(Carcinoma in situ) of the cervix, and intraepithelial carcinoma of other areas Within 5 years of consent date.',\n",
       " 'Medical history of hypersensitivity to the components of the investigational products.',\n",
       " '(The components of test drug 1 and 2, including the Rhein-based drug)\\nPatients with an allergic reaction to sulfonamide.',\n",
       " 'Patients with galactose intolerance, lapp lactase deficiency or glucose-galactose malabsorption.',\n",
       " 'Subjects who have not reached the prescribed period after receiving contraindicated medication or treatment before participation in this clinical trial.',\n",
       " 'Patients receiving contraindicated medication.',\n",
       " 'Alcohol and other drug abuse cases based on 6 months before screening.',\n",
       " 'Pregnant women or nursing mothers who are not willing to stop breastfeeding.',\n",
       " '(1) Menopause (non-therapy-induced amenorrhea of more than 12 months) Female\\n(2) Female infertility due to surgery (no ovaries and / or uterus)\\n(3) If you have sexual intercourse with only one male partner who has been confirmed to have no semen after fertilization.',\n",
       " '(4) Female subjects who agreed to abstinence during the clinical trial period.',\n",
       " 'If the subject is assured of an abstinence throughout the trial period.(e.g.',\n",
       " 'clergy)\\nHowever, intermittent abstinence (eg, contraception using ovulation period, symptothermal) or coitus interrupts is not a case of consent for abstinence.',\n",
       " '(5) For women of childbearing age, the following methods or methods of contraception use the effective method of contraception to be used during the period of this clinical trial:\\nOral contraceptive\\nThe contraceptive patch\\nIntra uterine device (IUD)\\ncontraceptive implant\\ncontraceptive injection\\nintrauterine hormonal apparatus\\nTubal ligation and infertility surgery\\nIf 30 days have not elapsed after the date of signing of the previous clinical trial or currently participating in other clinical trials.',\n",
       " 'Patients who are scheduled for surgery during the clinical trial period or who have difficulties in completing the protocol during this clinical trial due to other reasons.',\n",
       " 'In addition to the above, other diseases that the investigator judges to be inappropriate.',\n",
       " 'Revision cases\\nUncontrolled bleeding tendency (prothrombin conc.',\n",
       " 'Less than 70%)\\nHistory of deep venous thrombosis\\nSever liver impairment (liver failure)\\nSever renal impairment (S. creatinine more than 3)',\n",
       " 'AJCC Stage III or greater\\nUndifferentiated, Anaplastic or Medullary Thyroid Cancer\\nPlanned postoperative TSH goal other than 0.1-0.5 mU/L\\nHistory of gastrointestinal malabsorption or gastric bypass surgery\\nPregnancy\\nUse of medications that alter the absorption or metabolism of levothyroxine\\nPrior use of levothyroxine',\n",
       " 'The other types of pulmonary hypertension.',\n",
       " \"Subjects who refuse to subscribe written informed consents or can't cooperate with the trial well.\",\n",
       " 'Subjects with serious acute or chronic disease involved liver, kidney, and brain or have to use potent CYP3A4-inhibitor or nitrate to treat the underlying diseases.',\n",
       " 'Subjects who are currently treated with sildenafil for PAH or taking sildenafil or tadalafil.',\n",
       " 'Other contraindications in package insert.',\n",
       " 'Past history of hypersensitivity to aripiprazole\\nPrimary diagnosis of MDD with psychotic feature, bipolar disorder, schizophrenia, schizoaffective disorder, other psychotic disorder or anxiety disorder, a history of alcohol/ drug abuse within the past 12 months, or a diagnosis of dementia\\nClinically significant current Axis II (DSM-IV-TR) diagnosis\\nA significant risk of suicide corroborated by a score of =5 on item 10(suicidal thoughts) on the MADRS scale or by clinical judgment of the investigator\\nPregnancy or in breast-feeding\\nPresence of a serious medical illness including cardiac, hepatic, renal, respiratory, endocrinologic, neurologic, or hematologic disease or physical disorder judged to significantly affect central nervous system function\\nPatients taking antipsychotics, mood stabilizer or any psychotropic medications besides antidepressants, except benzodiazepines or beta blockers or hypnotics\\nPatients with past treatment failures of aripiprazole',\n",
       " 'Chronic HCV Infection with Genotype 2 or 3\\nAmiodarone.',\n",
       " \"Subjects previously treated with amiodarone must have stopped the amiodarone at least 60 days prior to day 1 of SOF/LDV FDC\\nCarbamazepine, phenytoin, phenobarbital, oxcarbazepine\\nRifabutin, rifampin or rifapentine\\nHIV regimens containing tenofovir or tipranavir/ritonavir\\nSt. John's wort\\nRosuvastatin\\nHave any serious or active medical or psychiatric illness which, in the opinion of the investigator, would interfere with subject treatment, assessment, or compliance\\nHistory of hepatic encephalopathy or variceal hemorrhage\\nHepatitis B surface antigen positive\\nHemoglobin (Hb) < 8 g/dL\\nPlatelets = 50,000/mm3\\nalanine aminotransferase (ALT), aspartase aminotransferase (AST), or alkaline phosphatase = 10 times upper limit of normal(ULN)\\nTotal bilirubin > 3 mg/dl\\nSevere renal impairment creatinine clearance (CrCl), i.e.\",\n",
       " '< 30 mL/min.',\n",
       " 'History of major organ transplantation with an existing functional graft.',\n",
       " 'History of clinically-significant drug allergy to nucleoside/nucleotide analogs.',\n",
       " 'Pregnant women or women planning to become pregnant\\nWomen who are breastfeeding\\nActive or recent history (= 1 year) of drug or alcohol abuse',\n",
       " 'current or recent (within one week of surgery) systemic antibiotic use, intolerance to both clindamycin and cephalexin, discovery of a persistent cutaneous malignancy at the site of the defect following the reconstructive procedure and previous reconstruction at the site of the skin/soft-tissue defect.',\n",
       " 'Unstable vital sign before surgery\\nSevere pulmonary disease requiring consistent treatment\\nIlliterate\\nPregnancy',\n",
       " 'An initial plasma sodium concentration of lower than 130 mmol/L\\nAn initial plasma sodium concentration of higher than 150 mmol/L\\nAn initial plasma potassium concentration of lower than 3.0 mmol/L\\nNeed for 10% glucose solution\\nDiabetes\\nDiabetes insipidus\\nDiabetic ketoacidosis\\nRenal disease that needs dialysis\\nProtocol-determined chemotherapy hydration\\nSevere liver disease\\nInborn errors of metabolism that need protocol-determined fluid therapy',\n",
       " 'The patients have other cancers at the same time or have the history of other cancers except controlled skin basal cell carcinoma or skin squamous cell carcinoma or carcinoma in situ of cervix uterus;\\nThe patients have active infections that were not suitable for chemotherapy;\\nThe patients have severe non-cancerous diseases.',\n",
       " 'The patients have history of neoadjuvant hormone therapy.',\n",
       " 'The patients have bilateral breast cancers or DCIS or metastatic breast cancers.',\n",
       " 'The patients are undergoing current administration of anti-cancer therapies, or are attending other clinical trials.',\n",
       " 'The patients are pregnant or lactational, or they refuse to practice contraception during the whole trial.',\n",
       " \"The patients are in some special conditions that they can't understand the written informed consent, such as they are demented or hawkish.\",\n",
       " 'The patients have allergic history or contraindication of tamoxifen.',\n",
       " 'The use of beta blockers within 2 months of randomization\\nPatients actively listed for transplantation at time of entry into the study or anticipated to undergo heart transplantation, interventional catheterization, or corrective cardiac surgery during the 7 months following entry into the study\\nSustained or symptomatic ventricular dysrhythmias uncontrolled by drug therapy or the use of an implantable defibrillator, and/or significant cardiac conduction defects, e.g., 2nd degree or 3rd degree AV block, or sick sinus syndrome, unless a functioning pacemaker is in place\\nUncorrected obstructive or severe regurgitant valve disease, nondilated cardiomyopathy, or significant systemic ventricular outflow obstruction\\nKnown renovascular hypertension or evidence of pulmonary hypertension (pulmonary vascular resistance > 6 Wood units) unresponsive to vasodilator agents such as oxygen, nitroprusside, or nitric oxide\\nHistory or current clinical evidence of moderate-to-severe fixed obstructive pulmonary disease or severe reactive airway diseases (e.g., asthma) requiring hospitalization within the past 2 years or patient currently using long-term inhaled bronchodilators\\nRenal, hepatic, gastrointestinal, or biliary disorder that could impair absorption, metabolism or excretion of orally administered medication\\nConcurrent terminal illness or other severe disease (e.g., active neoplasm) or other significant laboratory value(s) which, in the opinion of the investigator, could preclude participation or survival\\nEndocrine disorders such as primary aldosteronism, pheochromocytoma, hyper- or hypothyroidism, insulin-dependent diabetes mellitus\\nUnwillingness or inability to cooperate, or for the parents or guardians to give consent, or for the child to give assent, or any condition of sufficient severity to impair cooperation in the study\\nPregnancy or possible pregnancy at time of randomization, or female of child bearing potential who are lactating, or sexually active and not taking adequate contraceptive precautions (e.g., intrauterine device or oral contraceptives for 3 months prior to entry into the study)\\nUse of an investigational drug within 30 days of randomization, or within 5 half-lives of the investigational drug (the longer period will apply)\\nHistory of drug sensitivity or allergic reaction to alpha-blockers or beta-blockers\\nUse of any of the following medications within two weeks of randomization: MAO inhibitors, Calcium channel blockers, alpha blockers, beta blockers, disopyramide, flecainide, encainide, moricizine, propafenone, sotalol, or beta adrenergic agonists\\nHospital admission for protein losing enteropathy or plastic bronchitis within 3 months of randomization\\nActive and/or chronic protein losing enteropathy or plastic bronchitis (on inhaled medication to control the plastic bronchitis).',\n",
       " 'Hypoalbuminemia defined as serum albumin <2.0g/dL\\nRenal dysfunction defined as serum creatinine >2.0mg/dL\\nHepatic dysfunction defined as serum AST and/or ALT> 3 times upper limit of normal (approximately 120 IU/L however, will vary depending on age),\\nSignificant anemia or polycythemia defined as hemoglobin >18gm/dL or hemoglobin <7gm/dL\\nSeverely elevated serum BNP defined as BNP>300pg/ml',\n",
       " 'Left main disease\\nKnown hypersensitivity or contraindication to any of the following medications: Heparin, aspirin, clopidogrel, sirolimus, siptagliptin and statin\\nCongestive heart failure (patients with LVEF <30% or cardiogenic shock)\\nUncontrolled myocardial ischemia (repeated chest pain or dyspnea after revascularization)\\nUncontrolled ventricular arrhythmia\\nHistory of malignancy with chemotherapy\\nSerious hematologic disease (e.g.',\n",
       " 'CML, MDS)\\nCurrent infectious disease needs antibiotics therapy\\nCreatinine level >1.5 mg/dL or dependence on dialysis\\nOther severe concurrent illness (e.g.',\n",
       " 'active infection, malignancy).',\n",
       " 'Life expectancy of less than one year\\nPregnancy or women with potential childbearing\\nType I DM\\nTreatment with insulin\\nHistory of pancreatitis\\nWho cannot read the informed consent form (e.g.',\n",
       " 'illiteracy, foreigner)',\n",
       " \"adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy; 2.\",\n",
       " 'Treatment with any systemic anticancer therapy â\\x89¤ 3 weeks prior to cycle 1 day 1 3.',\n",
       " 'Uncontrolled active infection (Hepatitis B and C infection are NOT exclusion criteria) and/or known HIV infection; 4.',\n",
       " 'Renal failure requiring haemodialysis or peritoneal dialysis; 5.',\n",
       " 'Patients who are pregnant or breast-feeding; 6.',\n",
       " 'Patients with significantly diseased or obstructed gastrointestinal tract, malabsorption, uncontrolled vomiting or diarrhea resulting in inability to swallow oral medications; 7.',\n",
       " 'Presence of symptomatic CNS metastasis 8.',\n",
       " 'Unresolved toxicity from previous anti-cancer therapy or incomplete recovery from surgery, in particular oxaliplatin-induced peripheral neuropathy > grade 1.',\n",
       " '9.',\n",
       " 'Any of the following within the 12 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other thromboembolic event.',\n",
       " 'incooperative for glucose monitor\\nrefusal of insulin\\npregnancy',\n",
       " 'With the history of cognitive disorders\\nWith chronic neurological disorders\\nCannot communicate with investigators\\nCannot stand general anesthesia',\n",
       " '1.',\n",
       " 'Atrial fibrillation; \\n2.',\n",
       " 'Subject underwent cardiac pacemaker treatment; \\n3.',\n",
       " 'Subject underwent metal graft treatment; \\n4.',\n",
       " 'Claustrophobia; \\n5.',\n",
       " 'Acute myocardial infarction, cardiac ischemia indicated by 6-minute walk test, hypertrophic cardiomyopathy, constrictive pericarditis, significant valve disease or congenital heart disease, severe pulmonary hypertension; \\n6.',\n",
       " 'Ischemic heart failure without the revascularization or undergone the revascularization within last 6 months; \\n7.',\n",
       " 'Subject underwent cardiac surgery or cerebrovascular events within the previous six months; \\n8.',\n",
       " 'Subjects who plan to have cardiac transplantation; \\n9.',\n",
       " 'Severe hepatic and renal insufficiency (serum creatinine>2.0 mg /dl, AST or ALT is five times higher than the upper limit of normal range); \\n10.',\n",
       " 'Subject needs mechanical ventilation; \\n11.',\n",
       " 'Systolic blood pressure < 90mmHg, or > 160mmHg; \\n12.',\n",
       " 'Chronic heart failure complicated with acute hemodynamic disturbance or acute decompensation within last 1 month; \\n13.',\n",
       " 'Mobitz Type II or IIIÂ° atrial ventricular blockï¼\\x8csevere ventricular arrhythmia (polymorphic and frequent premature ventricular beats, frequent non-sustained ventricular tachycardia); \\n14.',\n",
       " 'Serum potassium<3.2mmol/L, or>5.5mmol/L; \\n15.',\n",
       " 'Female subject is pregnant or plan to become pregnant \\n16.',\n",
       " 'Childbearing-aged female subject who is unmarried or dose not bear child; \\n17.',\n",
       " 'Subject with life expectancy less than 6 months as assessed by investigators; \\n18.',\n",
       " 'Subject participated in any other clinical trial within the previous three months; \\n19.',\n",
       " 'Subject with previous history of tumor, or current tumor patient, or subject with pre-cancerous disease manifested by pathological examination (such as ductal carcinoma in situ or cervical epithelial dysplasia) \\n20.',\n",
       " 'Examinations (physical examination, X-ray examination, type-B ultrasonic detection or other methods) reveal that the subject has malignant mass, gland hyperplasia or adenoma with endocrine activity, or impact on heart, or endocrine function (such as pheochromocytoma, thyroid enlargement); \\n21.',\n",
       " 'The Investigator deemed for whatever reason that the subject is not likely to complete the study or comply with the study procedures (due to administration or any other reason).',\n",
       " 'Allergy, sensitivity, or absolute contraindications to any of the medications involved in the study\\npreexisting CNS depression, or taking regularly medication that cause CNS depression\\npreexisting cognitive deficits, dementia, or delirium\\nsevere respiratory comorbidities (e.g.',\n",
       " 'chronic obstructive pulmonary disease, pneumonia, respiratory failure)\\nsleep disordered breathing (diagnosed OSA, obesity hypoventilation syndrome)\\npregnancy and breast feeding\\nhistory of chronic pain or regular (at least once daily) opioid use preoperatively\\nrenal impairment - CrCl =60 mL/minute\\nnot fluent in English to be able to participate in the study process, including consent and phone interview\\nBody Mass Index >35\\ninability to take oral medication.',\n",
       " 'Patient refusal\\nAllergy to local anaesthesia\\nSevere coagulopathy\\nContralateral phrenic nerve palsy\\nLocal infection\\nModerate to severe pulmonary dysfunction (GOLD II, II, IV)',\n",
       " 'NA',\n",
       " 'Person is under 18 years of age.',\n",
       " 'Person who weighs more than 136kg.',\n",
       " 'Person who weighs less than 50kg.',\n",
       " 'Person who is pregnant.',\n",
       " 'Person has a history of chronic skin breakdown on the residual limb.',\n",
       " 'Person has conditions that would prevent participation and pose increased risk (e.g.',\n",
       " 'unstable cardiovascular conditions that preclude physical activity such as walking).',\n",
       " 'Person falls = once a week due to the reasons that could not be corrected by the new prosthesis (for ex.',\n",
       " 'problems with vestibular system).',\n",
       " 'Person is using under arm axillary crutches or walker.',\n",
       " 'Person in an emergency, life threatening situation.',\n",
       " 'Person is unwilling/unable to follow instructions.',\n",
       " 'Person who is not available to follow the entire study protocol.',\n",
       " 'Person who is participating in another study or intends to participate in another study during this study duration.',\n",
       " 'Person who cannot personally provide their consent.',\n",
       " 'Person who is not wearing prosthesis 8hours/day on average.',\n",
       " 'Person who has a score on 10m walk test less than 3km/h (~0.8m/s) (based on 10m walk test conducted during recruiting).',\n",
       " 'Person who walks on average less than 1km per day.',\n",
       " 'Person who is not able to walk on level ground in a step over step manner.',\n",
       " 'NA',\n",
       " 'NA',\n",
       " 'Psoriasis or psoriasis arthropathy\\nInflammatory bowel disease\\nUnwillingness to participate in the study with additional imaging protocols\\nExpected life-span less than <1 year\\nDiabetes (to improve the PET imaging quality)\\nProbable noncompliance\\nPregnancy\\nAge <18 years or >75 years\\nContraindication for adalimumab\\nMethotrexate used within the previous 6 months\\nA biologic medicine used within the previous 6 months',\n",
       " 'Any condition that prevents participation in the study, including pregnancy and other contraindications for Ventavis treatment (as listed in the current Ventavis Summary of Product Characteristics and patient package insert)',\n",
       " 'Hypersensitivity on Colchicine\\nThe existence of intra-cardiac thrombus on trans-esophageal echocardiography\\nPregnancy',\n",
       " 'Known coagulation defect\\nPatients on longstanding NSAID therapy\\nKnown renal impairment\\nPatients may also be excluded at the discretion of the investigator',\n",
       " \"Hypersensibility to toxin or excipients \\nMyastheny \\nDeglutition's problems \\nPast medical history of dysphagia or aspiration pneumonia \\nPregnancy (positive B-HCG test performed a maxima 72h before) or breastfeeding \\nMental , physical incapacity to fill in the questionnaires \\nGuardianship patients \\nSkin infections at the inclusion visit \\nApplication in the last 7 days at the site of injection of local treatments (apart emollients or antiseptics) or injections of botulism toxin or dynamic phototherapy or laser in the last 6 months.\",\n",
       " 'Systemic treatment with aminosides in the last 15 days \\nInclusion in another study in the last 2 months.',\n",
       " 'Patients with second primary cancer, except:adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumor curatively treated with no evidence of disease for <= 5 years.',\n",
       " 'Has known active central nervous system(CNS) metastases\\nHas an active infection requiring systemic therapy\\nPregnancy or breast feeding\\nPatients with cardiac problem\\nAny previous treatment with sunitinib',\n",
       " 'Suspect or certainty of fetal malformation,\\nPresence of conditions such as preeclampsia, multiparity, preterm labor\\nHistory of adverse reaction to a-2 adrenergic agonists\\nNicotine addiction\\nChronic use of opioid',\n",
       " 'Traumatic pulmonary contusion or laceration\\nLung reduction surgery\\nPlanned removal of more than 10 lung lesions\\nPneumonectomy\\nKnown hypersensitivity to bovine protein\\nKnown hypersensitivity to Brilliant Blue FCF (E133)\\nPresence of active infection',\n",
       " 'Congestive heart failure\\nIschemic heart disease\\nHypotension (Systolic blood pressure <100 mmHg)\\nTreatment with class I or III antiarrhythmic drugs\\nSevere hepatic or renal failure\\nPregnancy or lactation\\nHypersensitivity or contradictions to study drugs\\nAtrio-ventricular conduction disturbances\\nThyrotoxicosis\\nLife limiting disease or substance abuse which may affect participation',\n",
       " 'NA',\n",
       " 'Known hypersensitivity to statin\\nTreatment with statins during the past month prior to study.',\n",
       " 'Serum creatinine > 3 mg/dl\\nSignificant liver disease: liver enzymes 2.5 folds the upper normal limit\\nMalignancy\\nPregnancy or lactation',\n",
       " 'Had dose increase of anti-TNF agent or DMARD in the last 6 months\\nHad change of anti-TNF agent or DMARD in the last 6 months\\nTreated currently with golimumab or certolizumab\\nTreated with greater than 10 mg of prednisone (or equivalent) daily in the last 6 months\\nTreated with greater than 5 mg of prednisone (or equivalent) daily in the last 3 months\\nTreated with intramuscular or intravenous corticosteroids in the last 6 months for RA activity\\nTreated with anakinra, abatacept, or tocilizumab in the last 6 months\\nTreated with rituximab in the last 12 months\\nTreated with an investigational RA drug in the last 6 months\\nPregnant (or anticipate pregnancy during the study period) or lactating women\\nAbsence of documentation in the medical record of clinical remission for the last 6 months\\nUnwilling to discontinue anti-TNF agent\\nAbsence of documentation of negative tuberculin skin test, negative QuantiFERON-TB Gold test, or treatment for latent tuberculosis prior to starting treatment with the anti-TNF agent\\nTreatment of solid malignancy or non-melanoma skin cancer within the past 5 years, or any history of melanoma or hematologic or lymphoproliferative malignancy\\nAbsence of documentation of age-appropriate cancer screening at the time of randomization\\nAbsence of documentation of negative hepatitis B serologies, absence of completion of treatment for chronic hepatitis B, or absence of suppressive antiviral treatment\\nUnable to provide informed consent\\nAnticipate not being available or able to comply with the schedule of study visits',\n",
       " \"Current or past diagnoses of other Axis I psychiatric disorders, except for generalized anxiety disorder (GAD) symptoms occurring during a depressive episode\\nHistory of alcohol or drug dependence or abuse in the last three years\\nHistory of developmental disorder or IQ score < 70\\nPresence of acute suicidality\\nAcute grief (< 1 month)\\nCurrent or past psychosis\\nPrimary neurological disorder, including but not limited to dementia, stroke, brain tumors, epilepsy, Parkinson's disease, or demyelinating diseases\\nMRI contraindications\\nAny physical or intellectual disability adversely affecting ability to complete assessments\\nElectroconvulsive therapy in last 6 months\\nUse of antidepressant medications or other psychotropic medications in the last 4 weeks (or the last 6 weeks for fluoxetine).\",\n",
       " 'Occasional use of benzodiazepines or non-benzodiazepine sedatives (such as zolpidem, eszopiclone, or zaleplon) during this period is allowable.',\n",
       " 'A failed therapeutic trial of escitalopram in the current depressive episode (defined as at least 6 weeks of treatment at a daily dose of 10mg or higher)\\nKnown allergy or hypersensitivity to escitalopram or bupropion\\nCurrent or planned psychotherapy',\n",
       " '1.',\n",
       " 'History or presence of allergy to the study drugs or their components or drugs of their class, or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation \\n2.',\n",
       " 'Any finding of the medical examination (including blood pressure, pulse rate and electrocardiogram) deviating from normal and of clinical relevance \\n3.',\n",
       " 'History or diagnosis of any significant medical conditions: Including but not limited to gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hematological, psychiatric, neurological, oncological or hormonal disorders \\n4.',\n",
       " 'Known elevated liver enzymes in past clinical trials with any compound (experimental or marketed) \\n5.',\n",
       " 'Clinically relevant laboratory abnormalities (e.g.',\n",
       " 'Hgb<11g/dL, Hct<30g/dL, total cholesterol >240mg/dL, triglycerides >500mg/dL, fasting glucose >130mg/dL, liver function tests >2.5x upper limit of normal, baseline international normalized ratio >1.2) \\n6.',\n",
       " 'History of evidence of clinically significant hepatic, cardiac, pulmonary, endocrine, immunological, gastrointestinal, hematological, vascular or collagen disease \\n7.',\n",
       " 'History of alcohol abuse or use of any illicit drugs \\n8.',\n",
       " 'Unable to abstain from more than one beer or alcohol equivalent per day for the duration of the study \\n9.',\n",
       " 'Use of tobacco products and/or history of smoking within the past 2 months \\n10.',\n",
       " 'Pregnant or breast feeding \\n11.',\n",
       " 'Sexually active women of childbearing age who do not use an acceptable barrier method of birth control \\n12.',\n",
       " 'Hypersensitivity to caffeine, warfarin, vitamin K, omeprazole, dextromethorphan, midazolam, tipranavir, ritonavir or their excipients \\n13.',\n",
       " 'Concomitant treatment with other experimental compounds \\n14.',\n",
       " 'Concomitant administration of any prescription or over the counter medications known to alter P450 enzyme or P-gp activity \\n15.',\n",
       " 'Concomitant administration of any prescription or over the counter medications known to be highly dependent on P450 or P-gp for clearance for which elevated plasma concentrations are known to be associated with serious toxicity \\n16.',\n",
       " 'Concomitant administration of any food product known to alter P450 enzyme or P-gp activity such as grapefruit juice, Seville oranges \\n17.',\n",
       " 'Concomitant administration of any drug that could affect bleeding (e.g., aspirin, clopidogrel, ticlopidine, warfarin, heparin, low-molecular weight heparin) \\n18.',\n",
       " 'Concomitant administration of oral contraceptives (may be included with 7-day washout period) \\n19.',\n",
       " 'Concomitant administration of any herbal medications \\n20.',\n",
       " 'Inadequate venous access \\n21.',\n",
       " 'Renal or hepatic insufficiency \\n22.',\n",
       " 'Clinically unacceptable result at the screening physical examination \\n23.',\n",
       " 'Use of investigational medications within 30 days before study entry \\n24.',\n",
       " 'HIV-positive \\n25.',\n",
       " 'Body Mass Index (BMI) > 30 kg/mÂ²',\n",
       " 'NA',\n",
       " 'â\\x80¢ Patients without PN during their hospitalization',\n",
       " \"Established Osteoarthritis (Kellgren-Lawrence > 3)\\nMinimum joint space > 2 mm as measured on AP radiograph\\nHip dysplasia (center edge angle < 20Â° on AP radiograph)\\nPatients with clinically significant cardiovascular, renal, hepatic, endocrine disease, cancer or diabetes\\nPatients with ongoing infection including HIV and Hepatitis\\nPatient with history of osteomyelitis/septic arthritis\\nAnticoagulation therapy\\nPatients who are pregnant or breast feeding\\nPatients with systemic, rheumatic or inflammatory disease of the knee or chondrocalcinosis, hemochromatosis, inflammatory arthritis, arthropathy of the knee associated with juxta-articular Paget's disease of the femur or tibia, hemophilic arthropathy, infectious arthritis, Charcot's knee joint, villonodular synovitis, and synovial chondromatosis\\nPatients taking immunosuppressant medication\\nPatients with abnormal hematology or serum chemistry lab results\\nPatients receiving injection to treatment knee within 2 months of study enrollment\\nBMI greater than 35 or less than 20\",\n",
       " 'History of any malignancy or other severe diseases\\nFemale patients who are pregnant or breastfeeding before or during the three-year follow-up\\nPoor compliance or refusal to participate.',\n",
       " 'No known history of seizure activity.',\n",
       " 'Pregnant or breastfeeding.',\n",
       " 'Renal dysfunction (CrCl < 30ml/min).',\n",
       " \"Beck's Depression Inventory (BDI) =14\\nAllergy to levetiracetam.\",\n",
       " 'Diagnosis as CD first time or first year.',\n",
       " 'No history of using 5-ASA, biological or immunomodulatory therapy',\n",
       " 'Subjects who have systemic infection \\nSubjects who have human Immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) \\nSubjects who need to take the medicine which is prohibited during this study \\nSubjects who have asthma \\nSubjects who can not stop treatment with topical steroids (group 1~5), oral antibiotics, whole body photochemotherapy, immunosuppressive drug within 4 weeks before the treatment visit \\nPregnant, breast-feeding women or women who plan to become pregnant during this study (Females of childbearing potential must have a negative urine pregnancy test) \\nSubjects who currently participate in other clinical trial or participated in other clinical trial within 30 days \\nSubjects who had a serious adverse events during stem cell therapy \\nSubjects who had a hypersensitivity to antibiotics or antimycotics \\nSubjects who creatinine value is more than two times of the upper limit of the normal range at screening test \\nSubjects who aspartate transaminase/alkaline transaminase (AST/ALT) value is more than three times of the upper limit of the normal range at screening test \\nSubjects who have any other condition which the investigator judges would make patients unsuitable for study participation',\n",
       " 'patient refusal\\nage less than 40 or over 80 years\\ncombined surgical procedures\\nemergency surgery\\nLeft ventricular ejection fraction less than 50 per cent\\ncalculated creatinine clearance less than 60 mL per minute',\n",
       " 'Breast Carcinoma',\n",
       " 'Contraindications to empagliflozin, Sitagliptin\\nDPP4 inhibitors or Sodium-glucose cotransporter-2(SGLT2) inhibitors within the previous 4 weeks\\nInsulin requiring diabetes\\nPoor glucose control (HbA1C>10 %)\\nAcute coronary syndrome\\nStent placement within the previous 6 months\\nPrevious coronary artery bypass graft surgery within the previous 6 months\\nPlanned revascularization within 6 months\\nHeart failure requiring loop diuretics\\nSevere left ventricular hypertrophy (left ventricular septal wall thickness > 13mm)\\nSignificant renal disease manifested by creatinine clearance of < 30 ml/min)\\nHepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (alanine transaminase or Aspartate Aminotransferase > 3 times upper limit of normal)\\nRadiopaque material implanted in the chest wall (metal, silicone, etc.)',\n",
       " 'Contraindication to adenosine stress test\\nAny clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study.',\n",
       " \"Patient's pregnant or breast-feeding or child-bearing potential\\nExpected life expectancy < 1 year\\nUnwillingness or inability to comply with the procedures described in this protocol\",\n",
       " 'Patient diagnosed with dementia.',\n",
       " 'Patients with serious and unstable illnesses including current hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease and congestive heart failure), endocrinologic, neurologic (including stroke, transient ischemic attack, subarachnoidal bleeding, brain tumor, encephalopathy, and meningitis).',\n",
       " 'Patients with a history of allergic reactions to loxapine or amoxapine\\nPatients who have received an investigational drug within 30 days prior to the current agitation episode must be excluded.',\n",
       " 'Patients who are considered by the investigator, for any reason, to be unable to self-administer the inhalation device.',\n",
       " 'NA',\n",
       " 'The patient is participating in another clinical study using an investigational product.',\n",
       " 'The patient, in the opinion of the Investigator, is unable to adhere to the requirements of the study.',\n",
       " 'Contraindication to sitagliptin or metformin or thiazolidinedione\\nPregnant or breast feeding women\\nType 1 diabetes, gestational diabetes, or secondary forms of diabetes\\nNot appropriate for oral antidiabetic agent\\nMedication which affect glycemic control\\nDisease which affect efficacy and safety of drugs\\nAny major illness (Liver disease, Renal failure, Heart disease, Cancer, etc)',\n",
       " 'ASA> 3;\\nCoagulopathy;\\nRenal disease,\\nLiver disease,\\nHistory of recent gastro-intestinal bleeding\\nPregnancy.',\n",
       " 'Diagnosis of chronic pain currently taking opioid pain medication or with a history of drug abuse.',\n",
       " 'Patients with a self-described allergy to ASA, acetaminophen, NSAIDS and codeine.',\n",
       " 'All patients receiving a brachial plexus block for anesthesia and/or analgesia',\n",
       " 'Surgeries that include: intradetrusor Botox, vaginal mesh excision, and fistula repair\\nPregnancy\\nHistory of nephrolithiasis\\nAllergy to study medications\\nCongenital urogenital anomaly\\nNeurogenic bladder',\n",
       " 'polycystic ovaries\\nuntreated thyroid pathology\\nhypogonadotropic hypogonadism\\nuntreaed hyperprolactinemia\\nstudy drug hypersensitivity\\nprevious OHSS\\nunilateral ovariectomy\\ngenital malformation\\nBMI>40',\n",
       " 'Contraindication to bariatric surgery\\nPregnancy\\nAffiliation of health care assurance\\nPsychiatric disorders',\n",
       " '1.',\n",
       " 'Need for combined organ transplantation with an extra-renal organ and/or islet cell transplant.',\n",
       " '2.',\n",
       " 'Recipients of previous non-renal solid organ and/or islet cell transplantation.',\n",
       " '3.',\n",
       " 'Infection with HIV.',\n",
       " '4.',\n",
       " 'Inability or unwillingness of a participant and/or guardian to provide informed consent',\n",
       " 'Immunocompromised patients:\\nPatients with a known congenital or acquired immunodeficiency.',\n",
       " 'Patients who received chemotherapy less than 6 weeks ago.',\n",
       " 'Patients who received corticosteroids in the last 6 weeks.',\n",
       " 'Patients who received immunosuppressive medication in the last 6 weeks (e.g.',\n",
       " 'cyclosporin, cyclophosphamide, azathioprine).',\n",
       " 'Patients with chronic obstructive pulmonary disease who are on systemic corticosteroids.',\n",
       " 'Patients who require intensive care unit treatment.',\n",
       " 'Patients with tropical worm infection.',\n",
       " 'Patients with dexamethasone intolerance.',\n",
       " 'Pregnant and breastfeeding women.',\n",
       " 'Adults older than 45 and children younger than 18 years\\nPlatelet count higher than 30x109/l at time of screening\\nSuspicion of secondary ITP\\nPositive family history for ITP\\nPresence or history of autoimmune disease as judged by the investigator\\nHepatosplenomegaly\\nPresence or history of relevant hepatic disease as judged by the investigator\\nPresence or history of thromboembolic disease as judged by the investigator\\nPatients with splenectomy\\nWomen who are pregnant or breast feeding\\nIntention to become pregnant during the course of the study\\nLack of safe double contraception (see 7.1)\\nAny vaccination 2 weeks prior start of the study\\nDrugs with a known impact on the immune system or on platelet function must be recorded and an exclusion of the study should be discussed with the study center\\nKnown or suspected non-compliance, drug or alcohol abuse\\nInability to follow the procedures of the study, e.g.',\n",
       " 'due to language problems, psychological disorders, dementia of the study subject\\nParticipation in another study with investigational drug within the 30 days preceding and during the present study\\nPrevious enrolment into the current study\\nPrevious treatment with romiplostim or eltrombopag\\nHypersensitivity to the active substance or to any of the excipients or to E. coli derived proteins\\nEnrolment of the investigator, his/her family members, employees and other dependent persons',\n",
       " 'Emergency surgery needed\\nBowel obstruction\\nColonoscopy scheduled to be undertaken peroperatively\\nOther reason indicating mechanical preparation or contradicting it\\nAllergy to used drugs (PEG, neomycin, metronidazole)',\n",
       " 'age <18 years\\nprevious history of roux-en-y gastric bypass\\npatients undergoing other bariatric procedures\\npre-operative opioid analgesics',\n",
       " 'Known other respiratory disorders or signs for other respiratory disorders (e.g.',\n",
       " 'asthma, lung cancer, sarcoidosis, tuberculosis, lung fibrosis, cystic fibrosis, bronchoectasis).',\n",
       " 'Known history of significant inflammatory disease, other than COPD (e.g.',\n",
       " 'rheumatoid arthritis and systemic lupus erythematosus).',\n",
       " 'Known to be severely alpha-1-antitrypsin deficient (PI SZ or ZZ) \\nHaving undergone lung surgery (e.g.',\n",
       " 'lung resection including lung volume reduction surgery, lung transplant) or subjects scheduled for surgery.',\n",
       " 'Concurrent medication from Visit 1 and for the duration of the study with any of the prohibited medications: monoamine oxidase inhibitors and tricyclic antidepressants, and ritonavir (a highly potent cytochrome P450 3A4 inhibitor).',\n",
       " 'Subjects receiving chronic or prophylactic antibiotic therapy.',\n",
       " 'Serious, uncontrolled disease (including serious psychological disorders) likely to interfere with the study or impact on subject safety.',\n",
       " 'Have, in the opinion of the investigator, evidence of alcohol, drug or solvent abuse.',\n",
       " 'History of depression.',\n",
       " 'History or presence of clinically significant drug sensitivity or clinically significant allergic reaction to corticosteroids or salmeterol.',\n",
       " 'Moderate or severe COPD exacerbation (requiring corticosteroids or increased dosage of corticosteroids and/or antibiotics or hospitalization) within the 4 weeks prior to Visit 1 \\nLower respiratory tract infection within the 4 weeks prior to Visit 1 .',\n",
       " 'Pregnant or lactating female and female of childbearing potential.',\n",
       " 'Subject is a participating investigator, sub-investigator, study coordinator, or other employee of a participating investigator, or is an immediate family member of the before mentioned.',\n",
       " 'Subject is an employee of GlaxoSmithKline (GSK).',\n",
       " 'Subject participated in an investigational drug study within 30 days prior to Visit 1',\n",
       " 'NA',\n",
       " 'NA',\n",
       " 'Congestive heart failure or coronary artery disease\\nBlood pressure averaging > 159/99 mmHg\\nSerum creatinine > 1.5 mg/dL\\nDiabetes mellitus or other systemic illness\\nLeft ventricular hypertrophy by echocardiography or ECG\\nPregnancy\\nHypersensitivity to spironolactone, chlorthalidone, amlodipine, human recombinant insulin or Definity\\nAny history of substance abuse (other than tobacco)\\nHistory of gouty arthritis\\nPatients with right-to-left, bi-directional, or transient right-to-left cardiac shunts\\nHypersensitivity to perflutren, blood, blood products or albumin',\n",
       " \"can't understand patient controlled analgesia device refuse trial\",\n",
       " 'Coagulopathies (with prothrombin concentration less than 60% or INR more than 1.5)\\nIn-ability to postpone anti-coagulation medications.',\n",
       " 'Infection or injury or a lesion at the block site.',\n",
       " 'Suspected cervical vertebral column injury necessitating using a neck collar.',\n",
       " 'A compromised lung on the contralateral side of the block (Pneumothorax, hemothorax or Pneumonectomy).',\n",
       " 'Traumatic vascular injuries or operative interventions (Surgical harvesting) involving arteries of the upper limb on the operative side.',\n",
       " 'Patients with communication difficulties.',\n",
       " 'Hypersensitivity to local anesthetics and/or Dexamethasone.',\n",
       " 'Patients on perioperative intravenous (IV) steroids.',\n",
       " 'Children will be excluded if they have a history of developmental delay or inability to communicate the effects of an allergic reaction (non-verbal).',\n",
       " 'Any contraindication to allergy testing will also result in exclusion\\n(i.e.',\n",
       " 'history of a severe allergic reaction to skin tests,,\\nanaphylaxis in the past six weeks,\\npregnancy,\\nchild took any antihistamine in the past three days [including diphenhydramine (BenadrylÂ®), cetirizine (ZyrtecÂ®), loratadine (ClaritinÂ®), fexofenadine (AllegraÂ®), levocetirizine (XyzalÂ®), and desloratadine (ClarinexÂ®)] or\\nchild has a history of a condition that requires a beta blocker medicine for cardiac conditions, high blood pressure, migraine headaches, or eye drops for glaucoma (e.g.',\n",
       " 'propranolol, metoprolol, atenolol and TimopticÂ®, or BetopticÂ® eye drops).',\n",
       " 'Children who present to the PED with a rash, vomiting or current asthma symptoms including coughing, wheezing or breathing problems will also be excluded to ensure these do not mask reactions to an oral challenge.',\n",
       " 'Patients being admitted to the hospital or those who are deemed too acutely ill for participation (triage level 1 or 2 or as determined by the ED patient care team) will be excluded from the study.',\n",
       " 'During this pilot study, we will exclude non-English speaking families.',\n",
       " 'However, in subsequent studies we will include the non-English speaking population.',\n",
       " 'Children who are wards of the state, in foster care or police custody or detention will be excluded.',\n",
       " 'Children with any basal condition (trauma, infection, minor accidents, etc..) will be able to participate in the study provided they and their family are willing and do not meet the above-mentioned exclusion criteria.',\n",
       " 'any medical condition that would contraindicate use of stimulant medication\\nany prior adverse response to lisdexamfetamine dimesylate or other stimulant medication\\nuse of concurrent,non-stimulant psychoactive medication\\ndiagnosis of schizophrenia or presence of thought disorder symptoms\\nautism spectrum disorder',\n",
       " 'no consent\\nknown allergy to administered opioid\\ncontraindications to epidural analgesia\\ncoagulopathies including platelet count of less than 100,000\\nspine surgery in past',\n",
       " 'Patients under 18\\nPregnancy and Lactation\\nPatients allergic to polyglycolic / trimethylene carbonate\\nCarrier of prosthetic mesh in the ostomy\\nPatients presenting midline hernia.',\n",
       " 'Patients affected by inflammatory bowel disease',\n",
       " 'clinically significant medical or neurologic condition or neurocognitive dysfunction that would affect function and/or task performance and/or interfere with the study protocol\\nany current (or within past 2 months) medical condition requiring medication that would interact with dronabinol or interfere with the study protocol\\nrisk of harm to self or others that requires immediate intervention\\npresence of contraindications, current or past allergic or adverse reaction, or known sensitivity to cannabinoid-like substances (dronabinol/marijuana/cannabis/THC, cannabinoid oil, sesame oil, gelatin, glycerin, and titanium dioxide)\\nlack of fluency in English\\npositive drug screen or alcohol breathalyzer\\nunwilling/unable to sign informed consent document\\ncurrently pregnant (positive pregnancy test), planning pregnancy, or lactating (women)\\nunder 18 or over 50 years of age\\ntraumatic brain injury (as defined by The American Congress of Rehabilitation as a person who has had a traumatically induced physiological disruption of brain function (i.e., the head being struck, the head striking an object, and/or the brain undergoing an acceleration/deceleration movement (i.e., whiplash) without direct external trauma to the head), as manifested by at least one of the following: any loss of consciousness; any loss of memory for events immediately before or after the injury; any alteration in mental status at the time of the incident; or focal neurological deficits that may or may not be transient)\\ninability to tolerate small, enclosed spaces without anxiety (e.g.',\n",
       " 'claustrophobia), as determined by self-report and/or a preliminary session in a mock scanner\\nleft-handed;\\npresence of ferrous-containing metals within the body (e.g., aneurysm clips, shrapnel/retained particles)\\nanticipation of a required drug test in the 4 weeks following the study.',\n",
       " 'current diagnosis of a mood, anxiety, or other disorder that is more clinically salient than PTSD\\ncurrent moderate or severe alcohol/drug use disorder or in the past 8 weeks\\ncurrent or past diagnosis of bipolar and other related disorders, schizophrenia spectrum, or other psychotic disorders\\nconcomitant treatments with medication known to have drug interactions with dronabinol, such as, central nervous system depressants (barbiturates, benzodiazepines, buspirone, lithium, etc) and anticholinergic agents (atropine, scopolamine, antihistamines, etc).',\n",
       " 'Personal history of breast cancer\\nA terminal illness\\nPatients who are unable to give informed consent\\nBreast implants',\n",
       " 'Current or planned pregnancy\\nHistory of neuropathic pain, chronic pain syndrome, or preoperative use of narcotic or neuropathic pain medicine\\nRadiographic signs of osteoarthritis (> Tonis grade 1)\\nInability to attend follow up visits\\nDocumented allergy to local anesthetic',\n",
       " 'Therapy area located outside of head and neck;\\nOther skin diseases that might interfere with the efficacy evaluation;\\nTherapy area was previously received isotope or PDT or other treatment which might interfere with the efficacy evaluation;\\nAllergy to porphyrins and analogues; Photosensitivity; Porphyria; Allergic constitution;\\nScar diathesis;\\nImmunocompromised conditions;\\nElectrocardiographic abnormalities or organic heart diseases;\\nCoagulation disorders;\\nHepatic or renal functions abnormal (alanine aminotransferase or aspartate transaminase or total bilirubin > 1.5 upper limit of normal [ULN], or serum creatinine or blood urea nitrogen > 1.5 ULN);\\nPsychiatric diseases; Severe endocrinopathies;\\nPrevious therapy of PWS within the last 4 weeks;\\nParticipation in any clinical studies within the last 4 weeks;\\nBe judged not suitable to participate the study by the investigators',\n",
       " 'Active consumption of alcohol and/or drugs\\nCo-infection with human immunodeficiency virus, hepatitis C virus, or hepatitis D virus\\nHistory of autoimmune hepatitis\\nPsychiatric disease\\nEvidence of neoplastic diseases of the liver',\n",
       " 'Not available for follow-up\\nPregnant or breast-feeding\\nChronic pain syndrome defined as use of any analgesic medication on a daily or near-daily basis\\nAllergic to or intolerant of investigational medications\\nContra-indications to non-steroidal anti-inflammatory drugs: 1) history of hypersensitivity to NSAIDs or aspirin 2) active or history of peptic ulcer disease, chronic dyspepsia, or active or history of gastrointestinal bleed 3) Severe heart failure (NYHA 2 or worse) 4) hypertension (JNC7 stage 2 or worse) 5) Chronic kidney disease 3 or worse 6) Current use of anti-coagulants 7) Hepatitis 8) Alcoholism\\nContra-indications to muscle relaxants: 1) Concurrent use of centrally acting opioids; 2) Renal impairment; 3) Liver abnormality including cirrhosis or elevated enzymes 4) Use of any of the following medications: fluvoxamine, fluoroquinolones, amiodarone, mexiletine, propafenone, verapamil, cimetidine, famotidine, acyclovir, ticlopidine, oral contraceptive pills',\n",
       " 'NA',\n",
       " 'Conversion to laparotomy\\nEmergent re intervention\\nImmunosuppression\\nUmbilical hernia',\n",
       " 'Volunteers must not have been vaccinated against HPV-Gardasil-9 (both partners)\\nAny history of cervical, penile, oral or anal cancers\\nBeing pregnant or plan on immediately becoming pregnant',\n",
       " 'Contraindications for spinal anesthesia (like bleeding diathesis or regional infection at site of neuroaxial block)\\nKnown allergy to Granisetron or local anaesthetic (heavy bupivacaine, Marcaine Spinal 0.5% Heavy, 5mg/ml, AstraZeneca ampule)\\nPregnancy induced hypertension\\nCongenital or rheumatic heart diseases\\nAntepartum haemorrhage\\nFetal destress or gestational age < 36 week',\n",
       " 'UTIs = 12 within 1 year\\nPregnancy or Lactation\\nImmune disease\\nLactose intolerance\\nUrinary tract anomaly\\nSystemic infection\\nNewly started hormone therapy within the last 6 months\\nAntibiotic prophylaxis within the last 6 months\\na-D-mannose intake within the last month\\nUse of catheters\\nDiabetes mellitus\\nParticipation to other studies',\n",
       " '1.',\n",
       " 'Taking a tetracycline within 6 months or history of adverse reaction to minocycline or another tetracycline.',\n",
       " '2.',\n",
       " 'Enhanced risk from lumbar puncture, including documented or suspected cerebral mass lesion predisposing to brain herniation or bleeding diathesis.',\n",
       " '3.',\n",
       " 'Pregnancy or expectation of pregnancy during the study.',\n",
       " '4.',\n",
       " 'Active opportunistic infection or active neurological disease that might confound evaluation.',\n",
       " '5.',\n",
       " 'ADC Stage > 1.',\n",
       " '6.',\n",
       " 'Hemoglobin < 10 Gms/dL.',\n",
       " '7.',\n",
       " 'BUN or creatine above the normal limits.',\n",
       " '8.',\n",
       " 'Taking other drugs known to reduce the metabolism of minocycline and thus increase the probability of toxicity.',\n",
       " 'Subjects with hemoglobin SC or SB+ thalassemia \\nSubjects on chronic transfusion program \\nSubjects who have received RBC transfusions cannot have >15% adult hemoglobin \\nKnown positive status for HIV, active hepatitis B or hepatitis C \\nPregnant or breast feeding women \\nIndividuals with a history of malignancy are ineligible except for the following circumstances.',\n",
       " 'Individuals with a history of malignancy are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy.',\n",
       " 'Individuals with the following cancer are eligible if diagnosed and adequately treated within the past 5 years: cervical or breast cancer in situ, and basal cell or squamous cell carcinoma of the skin \\nSubjects with a history of thrombosis or other reason (other than sickle cell disease) for enhanced thrombotic risk \\nSubjects with unresolved infections \\nSevere or uncontrolled medical conditions that could compromise study participation \\nSubjects on fetal hemoglobin inducing agents \\nSubjects on any other experimental treatment within 90 days of the first dose of study drug or who have not recovered from the side effects of such therapy \\nKnown allergic reaction to a histone deacetylase inhibitor \\nSubjects who have received valproic acid for treatment of epilepsy within 30 days of enrollment \\nSubjects who have received any HDAC inhibitors other than valproic acid',\n",
       " 'Invasively mechanically ventilated >72 hours at the time of screening;\\nPatients at potential increased risk of iatrogenic probiotic infection (see Section 2.6 for detailed explanation) including specific immunocompromised populations (HIV <200 CD4 cells/ÂµL, those receiving chronic immunosuppressive medications (e.g., azathioprine, cyclosporine, cyclophosphamide, tacrolimus, methotrexate, mycofenolate, Anti-IL2), previous transplantation (including stem cell) at any time, malignancy requiring chemotherapy in the last 3 months, neutropenia [absolute neutrophil count < 500]).',\n",
       " 'However, patients receiving corticosteroids previously or presently or projected to receive corticosteroids are not excluded;\\nPatients at risk for endovascular infection (previously documented rheumatic heart disease, congenital valve disease, surgically repaired congenital heart disease, unrepaired cyanotic congenital heart disease, any intracardiac repair with prosthetic material [mechanical or bio-prosthetic cardiac valves], previous or current endocarditis, permanent endovascular devices (e.g., endovascular grafts [e.g., aortic aneurysm repair, stents involving large arteries such as aorta, femorals and carotids], inferior vena cava filters, dialysis vascular grafts), tunnelled (not short-term) hemodialysis catheters, pacemakers or defibrillators.',\n",
       " 'Patients with temporary central venous catheters, central venous dialysis catheters or peripherally inserted central catheters (PICCs) are not excluded and patients with coronary artery stents, coronary artery bypass grafts (CABG) or neurovascular coils are not excluded; patients with mitral valve prolapse or bicuspid aortic valve are not excluded providing they have no other exclusion criteria;\\nPatients with a primary diagnosis of severe acute pancreatitis, without reference to a Ranson score [Ranson 1974]).',\n",
       " 'However, patients with mild or moderate pancreatitis are not excluded;\\nPatients with percutaneous gastric or jejunal feeding tubes already in situ as per Health Canada guidance;\\nStrict contraindication or inability to receive enteral medications;\\nIntent to withdraw advanced life support as per the ICU physician;\\nPrevious enrolment in this or current enrolment in a potentially confounding tria',\n",
       " 'Weight < 800 g;\\nAirway anomalies;\\nPulmonary air leaks;\\nCraniofacial or cardiothoracic malformations',\n",
       " 'Recanalized (TIMI I-III flow) IRA at coronary angiography.',\n",
       " 'Patients in whom TIMI-3 flow was not able to be established after wire crossing, balloon angioplasty or thrombectomy.',\n",
       " 'STEMI due to bypass-graft occlusion\\nSevere heart failure or cardiogenic shock',\n",
       " 'allergy to Doxycycline or Methylprednisolone,\\npregnancy,\\ndiagnosis,\\nInflammatory arthritis or diabetes,\\nsecondary adhesive capsulitis (history of significant trauma, rotator cuff tear injury, stroke)\\nevidence of arthritis on x-ray,\\ncurrent infectious disease, and\\nany previous treatment for the for adhesive capsulitis of the affected shoulder.',\n",
       " 'Participants taking CPI combination therapies with chemotherapy are not permitted.',\n",
       " 'Pregnant, lactating, or intending to become pregnant during the study.',\n",
       " 'History of ischaemic heart disease, cardiac failure, cerebrovascular disease, liver impairment (ALT/AST>50IU/L) or stage 3-5 chronic kidney disease.',\n",
       " 'History of overdose or suicidal ideation\\nPatients weighing <55kgs.',\n",
       " 'Patients with chronic pain requiring treatment, with a known allergy to paracetamol, or concomitant use of non-steroidal anti-inflammatories , oral anticoagulants or corticosteroids.',\n",
       " 'having experienced severe allergies, trauma history and/or operation history within 3 months.',\n",
       " 'with a history of mental illness and/or family history of mental illness limb disabled.',\n",
       " 'taking medicine within one month.',\n",
       " 'suffering major events or having mood swings.',\n",
       " 'having internal and surgical disease(after having variety of physical examination such as electrocardiogram/hepatic and renal function/blood routine and urine routine)\\nchromosome aberrations in anyone of the couple.',\n",
       " 'patients who have drugs contraindications',\n",
       " 'Ongoing treatment with inotropic drugs (not norepinephrine)\\nCentral venous oxygen saturation (ScvO2) < 60% despite optimization of hematocrit and volume status\\nNeed of renal replacement therapy\\nOngoing bleeding\\nPatient or next of kin does not consent with study participation',\n",
       " 'Moderate or severe endometriosis.',\n",
       " 'Hydrosalpinx.',\n",
       " 'Uterine abnormalities or myoma.',\n",
       " 'Previous uterine surgery.',\n",
       " '1.',\n",
       " 'Personal history of stroke, brain lesions, previous neurosurgery, any personal history of seizure or fainting episode of unknown cause, or head trauma resulting in loss of consciousness, lasting over 30 minutes or with sequela lasting longer than two days.',\n",
       " 'Justification: Stroke or head trauma can lower the seizure threshold, and are therefore contra-indications for TMS.',\n",
       " 'Fainting episodes or syncope of unknown cause could indicate an undiagnosed condition associated with seizures.',\n",
       " 'Screening tool: TMS adult safety questionnaire, Medical History.',\n",
       " '2.',\n",
       " 'First-degree family history of any neurological disorder with a potentially hereditary basis, including migraines, epilepsy, or multiple sclerosis.',\n",
       " '1.',\n",
       " 'Justification: Neurological disorders can lower the seizure threshold, and are therefore contra-indications for TMS.',\n",
       " 'First-degree family history of certain neurological disorders with a hereditary component increases the risk of the subject having an undiagnosed condition that is associated with lowered seizure threshold.',\n",
       " '2.',\n",
       " 'Screening tool: TMS adult safety screening, Medical History.',\n",
       " '3.',\n",
       " 'Cardiac pacemakers, neural stimulators, implantable defibrillator, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease, with intracranial implants (e.g.',\n",
       " 'aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head that precludes MRI scanning.',\n",
       " '1.',\n",
       " 'Justification: Any metal around the head is a contraindication for both MRI and TMS, as both methods involve exposure to a relatively strong magnetic field.',\n",
       " '2.',\n",
       " 'Screening tool: TMS adult safety screening, MRI safety screening, Medical History.',\n",
       " '4.',\n",
       " 'Noise-induced hearing loss or tinnitus.',\n",
       " '1.',\n",
       " 'Justification: individuals with noise-induced hearing problems may be particularly vulnerable to the acoustic noise generated by TMS and MRI equipment.',\n",
       " '2.',\n",
       " 'Screening tools: TMS adult safety screening.',\n",
       " '5.',\n",
       " 'Current use (any use in the past 4 weeks, chronic use within 6 past six months) of any investigational drug or of any medications with psychotropic, anti or pro-convulsive action.',\n",
       " '1.',\n",
       " 'Justification: The use of certain medications or drugs can lower seizure threshold and is therefore contra-indicated for TMS.',\n",
       " '2.',\n",
       " 'Screening tools: MRI safety screening questionnaire, Medical history, Medical Assessments: Urine toxicology analyzes for presence of a broad range of prescription and nonprescription drugs.',\n",
       " '6.',\n",
       " 'Lifetime history of major depressive disorder, schizophrenia, bipolar disorder, mania, or hypomania.',\n",
       " '1.',\n",
       " 'Justification: The population of interest here is a healthy control population with no psychiatric disorders.',\n",
       " 'In subjects with depression, bipolar disorder, mania or hypomania, there is a small chance that TMS can trigger (hypo)manic symptoms.',\n",
       " '2.',\n",
       " 'Screening tools: SCID Screen Patient Questionnaire.',\n",
       " 'Potential diagnoses will be further evaluated by a counsellor.',\n",
       " '7.',\n",
       " 'Meet current DSM V criteria for moderate to severe substance use disorder (excluding nicotine), smoke daily, or urine toxicology positive for any illicit substance inconsistent with history given.',\n",
       " '1.',\n",
       " 'Justification: The population of interest here is a healthy control population with no substance use disorder.',\n",
       " 'Current use of illicit substances could impact on seizure threshold and is therefore contra-indicated for TMS.',\n",
       " '2.',\n",
       " 'Screening tools: SCID Screen Patient Questionnaire.',\n",
       " 'Potential diagnoses will be further evaluated by a counsellor, Drug Use Survey (DUS), Substance Use Disorder Evaluation, Medical Assessments: urine qualitative drug screen is performed for methadone, benzodiazepines, cocaine, amphetamine/methamphetamine, opiates, barbiturates, and tetrahydrocannabinol.',\n",
       " '8.',\n",
       " 'Have met DSM V criteria for moderate to severe substance use disorder (excluding nicotine, alcohol and cannabis) in the past, or have met DSM V criteria for moderate to severe substance use disorder for cannabis or alcohol in the past 5 years.',\n",
       " '1.',\n",
       " 'Justification: the population of interest here is a healthy control population with no present or past substance use disorder.',\n",
       " '2.',\n",
       " 'Screening tools: SCID Screen Patient Questionnaire.',\n",
       " 'Potential diagnoses will be further evaluated by a counselor.',\n",
       " 'Drug Use Survey (DUS), Substance Use Disorder Evaluation.',\n",
       " '9.',\n",
       " 'History of myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or transient ischemic attack, or any heart condition currently under medical care.',\n",
       " '1.',\n",
       " 'Justifications: the risk of TMS for individuals with a heart condition is unknown.',\n",
       " '2.',\n",
       " 'Screening tool: physical assessment (EKG), medical history.',\n",
       " '10.',\n",
       " 'Pregnant women or women with reproductive potential who are sexually active and not using an acceptable form of contraception.',\n",
       " '1.',\n",
       " 'Justification: it is unknown whether TMS poses a risk to fetuses.',\n",
       " '2.',\n",
       " 'Screening tool: Medical assessments (urine pregnancy test) at the beginning of each visit that involves TMS or MRI.',\n",
       " '11.',\n",
       " 'History of learning disability or current ADHD \\n1.',\n",
       " 'Justification: Subjects should be able to perform cognitive tasks to a high degree of accuracy, both in the MRI scanner and outside the scanner.',\n",
       " 'Subjects with ADHD/LD may engage different neural circuitry even if they can perform the tasks.',\n",
       " '2.',\n",
       " 'Screening tool: Wechsler Abbreviated Scale of Intelligence, Medical history, Adult ADHD Self-Report Scale.',\n",
       " '12.',\n",
       " 'Participation in an rTMS session less than two weeks ago.',\n",
       " '1.',\n",
       " 'Justification: in order to limit exposure to TMS, we will not enroll subjects who have received TMS less than two weeks ago.',\n",
       " '2.',\n",
       " 'Screening tool: TMS safety screening questionnaire.',\n",
       " 'The participant has Modified Hoehn & Yahr stage 5 (or stage 5 at eather on-time or off-time for the participant with wearing off phenomenon).',\n",
       " 'The participant has severe dyskinesia.',\n",
       " 'The participant has unstable systemic disease.',\n",
       " 'The participant has a Mini-Mental State Examinations (MMSE) score of <= 24. psychiatric disease.',\n",
       " 'The participant has a history of clinically significant hypertension or other reactions associated with ingestion of tyramine-rich food.',\n",
       " \"The participant has received neurosurgical intervention for Parkinson's disease (e.g., pallidotomy, thalamotomy, deep brain stimulation).\",\n",
       " 'The participant has received transcranial magnetic stimulation within 6 months.The participant has received selegiline, pethidine, tramadol, reserpine or methyldopa within 90 days.',\n",
       " 'The participant has received levodopa monotherapy, any psychoneurotic agent or antiemetic medication of dopamine agonist within 14 days.',\n",
       " 'However, the participant has been receiving quetiapine or domperidone with a stable dose regimen for >= 14 days may be included in the study.',\n",
       " 'The participant is required to take any of the excluded medications or treatments.',\n",
       " 'The participant with laboratory data meeting any of the following: \\nCreatinine >= 2 x upper limit of normal (ULN) \\nTotal bilirubin >= 2 x ULN \\nALT or AST >= 1.5 x ULN \\nALP >= 3 x ULN \\nThe participant has received any of the excluded medications or treatments during.',\n",
       " 'Patient has previously received or is receiving an organ transplant other than a liver.',\n",
       " 'Patient currently requires dialysis\\nRecipient or donor is known to be seropositive for human immunodeficiency virus (HIV)\\nPatient has received a liver transplant from a non-heart beating donor\\nPatient who is HCV negative has received an HCV positive (HCV RNA by PCR or HCV antibody) donor liver\\nPatient who is HbsAg negative has received an HbsAg positive (HBV DNA by PCR or HBV antibody) donor liver\\nPatient has received a liver transplant from a decrease donor > 70 years of age\\nPatient has a current malignancy or a history of malignancy (within the past 5 years), except hepatocellular carcinoma within UCSF Criteria and basal or non-metastatic squamous cell carcinoma of skin that has been treated successfully.',\n",
       " 'Patient is hemodynamically unstable on POD 15',\n",
       " 'recent thrombotic event',\n",
       " 'Optune compliance < 75%; they would be excluded from the final analyses.',\n",
       " 'History of craniectomy or significant skull defect (contraindication to Optune).',\n",
       " 'Active implantable medical device (i.e.',\n",
       " 'DBS, spinal cord stimulator, pacemaker, defibrillator, vagus nerve stimulator, programmable shunt).',\n",
       " 'Karnofsky Performance Status (KPS) < 60.',\n",
       " 'History or presence of any clinically significant disease or disorder \\nAny condition or disease that would render the subject unsuitable for the study, place the subject at undue risk or interfere with the ability of the subject to complete the study in the opinion of the investigator \\nHistory of clinically significant hypersensitivity or allergic drug reactions \\nAny suspicion or history of alcohol abuse and/or consumption of other drugs of abuse \\nRegular smoker (> 5 cigarettes, > 1 pipeful or > 1 cigar per day) \\nPositive for hepatitis B, hepatitis C or HIV infection \\nDietary restrictions that would prohibit the consumption of standardized meals \\nParticipation in an investigational drug or device study within 90 days prior to screening, as calculated from the follow-up from the previous study',\n",
       " 'Emergency surgery\\nMonitored Anesthesia Care (i.e., regional anesthesia alone without plans for general anesthesia)\\nSurgery involving the eye, eyebrow, forehead, or frontal scalp near the sensor placement\\nPoor health literacy\\nAllergy, or have experienced any drug reaction to ketamine\\nPregnant or lactating\\nCurrently in active alcohol withdrawal',\n",
       " 'history of major systemic illness, including uncontrolled hypertension, diabetes, chronic renal insufficiency, autoimmune diseases or malignancies\\nhistory of neurological disorders which might affect sensation such as previous stroke or peripheral neuropathy\\nhistory of substance abuse (except painkillers)\\nheavy smokers (with a daily consumption >20 cigarettes)\\npregnancy or lactation\\nany contraindication for magnetic resonance imaging (MRI)\\nand any obvious infection or inflammation over a period of at least 1 month before the study.',\n",
       " 'Chronic pain more than 3 months\\nDrug abuse\\nChronic use of analgesic drugs (more than 3 months)\\nPsychiatric illness\\nPeripheral neuropathy\\nDrug allergy\\nSevere gastroesophageal reflux disease',\n",
       " 'Currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off-label use of an investigational drug.',\n",
       " 'Current Axis I primary psychiatric diagnosis other than major depressive disorder.',\n",
       " 'Organic mental disease, including mental retardation.',\n",
       " 'History of clinically significant disease, including any cardiovascular, hepatic, renal, respiratory, hematologic, endocrinologic, or neurologic disease, or clinically significant laboratory abnormality that is not stabilized or is anticipated to require treatment during the study.',\n",
       " 'Subjects receiving an investigational agent (including different formulation and generic agents of investigational drug) in the previous 3 months prior to screening.',\n",
       " 'Women in pregnancy or lactation, or female of child bearing potential without appropriate birth control measures.',\n",
       " 'Use of antipsychotics or mood stabilizers within 5 days prior to screening.',\n",
       " 'Has received depot antipsychotic medication within one cycle prior to screening.',\n",
       " 'Known allergy or lack of response to mirtazapine.',\n",
       " 'Has received ECT or MECT within 3 months prior to screening.',\n",
       " 'History of anticholinergic drug allergy or complications (allergic reaction, skin rash, urticaria and other allergic reactions which caused by drugs).',\n",
       " 'Smokers.',\n",
       " 'Significant risk of suicidal and/or self-harm behaviors',\n",
       " \"Diagnosis of primary progressive MS\\nInability to complete an MRI (contraindications for MRI include but are not restricted to weight =140 kg, pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI, etcâ\\x80¦)\\nGadolinium intolerance\\nHistory of ischemic cerebrovascular disorders (e.g., stroke, transient ischemic attack) or ischemia of the spinal cord\\nHistory or known presence of central nervous system (CNS) or spinal cord tumor (e.g., meningioma, glioma)\\nHistory or known presence of potential metabolic causes of myelopathy (e.g., untreated vitamin B12 deficiency)\\nHistory or known presence of infectious causes of myelopathy (e.g., syphilis, Lyme disease, human T-lymphotropic virus 1 (HTLV-1), herpes zoster myelopathy)\\nHistory of genetically inherited progressive CNS degenerative disorder (e.g., hereditary paraparesis; MELAS [mitochondrial myopathy, encephalopathy, lactic acidosis, stroke] syndrome)\\nNeuromyelitis optica\\nHistory or known presence of systemic autoimmune disorders potentially causing progressive neurologic disease (e.g., lupus, anti-phospholipid antibody syndrome, Sjogren's syndrome, BehÃ§et's disease, sarcoidosis)\\nHistory of severe, clinically significant brain or spinal cord trauma (e.g., cerebral contusion, spinal cord compression)\\nVulnerable patients (Patient referred to in Articles L. 1121-5 to L. 1121-8 and L. 1122-1-2 of the French Public Health Code)\",\n",
       " 'Uncontrolled diabetes\\nUlcer infection\\nNon-diabetic ulcers Orthopedic or neuromuscular pathologic conditions',\n",
       " 'Known or suspected gram-negative infections, anaerobic infections, or fungemia\\nKnown or suspected infections that are severe, life threatening or are not included in the ABSSSI Food and Drug Administration (FDA) guidance\\nInjection drug users with a fever\\nSevere neurological disorder leading to immobility or confined to a wheelchair\\nBilateral Lower extremity involvement of the suspected infection.',\n",
       " 'Allergy to Glitazones\\nMyocardial infarction\\nHeart failure\\nAngina\\nHistory of kidney stones\\nLiver disease (abnormal liver enzymes)\\nAnemia (hemoglobin <8 g/dl)\\nCancer with current treatment\\nPrevious organ transplantation\\nImmunosuppressant therapy\\nHuman immunodeficiency virus infection\\nPregnancy or lactating\\nCurrent tobacco use\\nDilantin and oral contraceptive usage due to potential drug interaction with glitazones\\nSelf-identified history of hypoglycemia',\n",
       " 'adults 61 years old and above\\nsmokers\\npregnant women\\ntaking any prescription pain/ insulin medication\\nhas a history of taste or smell loss or other oral disorders (e.g., burning mouth syndrome)\\nhas current oral lesions, canker sores, or piercings\\nhas a history of food allergy',\n",
       " 'acute myocardial infarction, heart failure, neoplastic disease, chronic diseases that may affect the inflammatory profile both systemic and epicardial (cancer, chronic intestinal inflammation, hepatitis, AIDS); life expectancy < 6 months, previous CABG and/or other open heart surgery intervention, acute coronary syndrome',\n",
       " 'History of intolerance to LMWHs during HD\\nReceiving warfarin or other oral anticoagulant\\nPregnant patients',\n",
       " '1.',\n",
       " 'Presence of other neoplasia \\n2.',\n",
       " 'Man',\n",
       " 'Fasting plasma glucose > 7,0 mM, HbA1c > 48 mmol/mol 3 months after RYGB\\nDysregulated thyroid diseases, use of antithyroid treatment.',\n",
       " 'Late diabetic complications as retinopathy, renal insufficiency, neuropathy or previous pancreatitis.',\n",
       " 'Complications to RYGB.',\n",
       " 'Documented reactive hypoglycaemia, severe dumping (vomiting, diarrhea, severe abdominal pain after food intake)\\nCholecystectomy.',\n",
       " \"Meets criteria for Major Depressive Episode, by Diagnostic Statistical Manual of Mental Disorder - IV (TR) criteria \\nClinically significant agitation /aggression for which either 1) the frequency of agitation /aggression as assessed by the NPI is 'Very frequently', or 2) the frequency of agitation /aggression as assessed by the NPI is 'Frequently' AND the severity of the agitation as assessed by the NPI is 'Moderate', or 'Marked' \\nClinically significant delusions for which either 1) the frequency of delusions as assessed by the NPI is 'Very frequently', or 2) the frequency of delusions as assessed by the NPI is 'Frequently' AND the severity of the delusions as assessed by the NPI is 'Moderate', or 'Marked' \\nClinically significant hallucinations for which either 1) the frequency of hallucinations as assessed by the NPI is 'Very frequently', or 2) the frequency of hallucinations as assessed by the NPI is 'Frequently' AND the severity of the hallucinations as assessed by the NPI is 'Moderate', or 'Marked' \\nTreatment with psychotropic medications in the 2 weeks prior to randomization with the exception of approved treatments for dementia (ChEIs and memantine), selective serotonin reuptake inhibitor antidepressants, and trazodone (if used as an aid to facilitate sleep and not as an antidepressant); other psychotropics (with the exclusion of antipsychotics), if stable for 3 months, may be allowed only with Steering Committee approval on a case by case basis.\",\n",
       " 'Note that antipsychotics are expressly prohibited.',\n",
       " \"Treatment with methylphenidate is contraindicated in the opinion of the study physician \\nFailure of treatment with methylphenidate in the past for apathy after convincing evidence of an adequate trial as judged by study physician \\nTreatment with a medication that would prohibit the safe concurrent use of methylphenidate such as monoamine oxidase inhibitors and tricyclic antidepressants \\nNeed for acute psychiatric hospitalization or is suicidal \\nUncontrolled hypertension (medication non-compliance or past 3 months with a diastolic reading of 105 as verified by compartment pressure of the rectus sheath (CPRS)) \\nSymptomatic coronary artery disease deemed to be significant by study physician at the time of screening \\nLack of appetite that results in significant unintentional weight loss as determined by the study physician in the last three months \\nSignificant communicative impairments \\nCurrent participation in a clinical trial or in any study that may add significant burden or affect study outcomes \\nHyperthyroidism, advanced arteriosclerosis, symptomatic cardiovascular disease, serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or a family history of sudden death or death related to heart problems \\nGlaucoma, pheochromocytoma, or known or suspected hypersensitivity to methylphenidate or its excipients \\nCentral Nervous System (CNS) abnormalities (e.g., cerebral aneurysm) and/or other vascular abnormalities such as vasculitis or pre-existing stroke, motor tics or a family history or diagnosis of Tourette's syndrome, seizures (convulsions, epilepsy), or abnormal EEGs \\nAny condition that, in the opinion of the study physician, makes it medically inappropriate or risky for the patient to enroll in the trial\",\n",
       " 'Presence of another vaginal infection or STD\\nAllergy to metronidazole\\nPregnant or nursing\\nUse of oral or intravaginal antibiotics within the past 2 weeks\\nHIV or other chronic disease\\nInability to keep return appointments\\nContraindications for Lactobacillus Vaginal Suppositories(those without sexual history)',\n",
       " 'small bowel resection\\nright sided hemicolectomy\\nknown chronic diarrheal disease (celiac disease, lactose malabsorption, Inflammatory bowel diseases, incl microscopic colitis)\\npregnancy\\nwish for pregnancy within next three months\\nallergy to eggs\\nallergy to constituents in Xenbilox (capsules with chenodeoxycholic acid)\\nacute cholecystitis within two months\\nchronic cholecystitis\\ncirrhosis of the liver\\nsuspected obstructive choledocholithiasis\\nicterus',\n",
       " 'Acute pain (less than 3 months in duration)\\nPrevious serious adverse event or hypersensitivity to cannabis or cannabinoids\\nInability to understand and comply with the instructions of the study\\nPresence of significant cardiac disease (history of unstable ischemic heart disease, heart failure, severe and uncontrolled hypertension) that, in the opinion of the investigator, would put the patient at risk of a clinically significant arrhythmia or myocardial infarction\\nCurrent substance use disorder according to the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM 5)\\nLife-time history of dependence on cannabis or diagnosis of cannabis use disorder (CUD) according to the DSM 5\\nLife-time history of DSM 5 schizophrenia, bipolar disorder, or previous psychosis with or intolerance to cannabinoids\\nCurrent or history of suicidal ideation\\nPregnant, breast-feeding or female patients of child-bearing potential and male patients whose partner is of child-bearing potential, unless willing to ensure that they or their partner use effective contraception\\nHepatic impairment (aspartate aminotransferase more than three times normal) or renal function impairment (serum creatinine level >133 Âµmol/L, Estimated Glomerular Filtration Rate (eGFR) <60)\\nCognitive impairment according to MiniCog\\nThe patient is currently using or has used cannabinoid based medications within 90 days of study entry and is unwilling to abstain for the duration of the study\\nPositive urine drug screen for cannabinoids and other potential abuse substances (e.g.',\n",
       " 'alcohol, cocaine, amphetamines and methamphetamines, unprescribed opioids)\\nParticipation in another clinical trial within 30 days of enrolment in our trial',\n",
       " 'an underlying infectious disease\\nchromosomal abnormality\\nmetabolic disorder\\nspecific brain related disorder (such as tuberous sclerosis)\\nhistory of fetal cytomegalovirus infection\\nbirth asphyxia\\na history of major head injury\\na chronic use of non-steroidal anti-inflammatory drugs, (NSAID)\\nknown brain damage\\nEpilepsy\\nAbnormal Electro-cardiogram (ECG)\\nEpileptiform EEG\\nUse of psychostimulants, anti-depressants, neuroleptics or anti-convulsive agents within the past month.',\n",
       " 'Lack of cooperation in the screening phase',\n",
       " \"No informed consent for participation in the study, mental illness, which don't allow to obtain informed consent and conduct the treatment according to the protocol \\nPregnancy \\nHIV infection \\nActive cancer \\nActive hepatitis virus infection\",\n",
       " 'Unable to speak Spanish or English\\nActive smoking (within the past year)\\nAutoimmune, rheumatologic or inflammatory disease which are not psoriasis or psoriatic arthritis\\nKnown active cancer receiving treatment\\nPregnancy\\nAnemia (hemoglobin < 9 mg/dl) or thrombocytopenia (Platelet count <75), or thrombocytosis (Platelet count >600)\\nA history of severe bleeding or bleeding disorders\\nCurrent medication use which interact with either aspirin or atorvastatin\\nChronic kidney disease (CrCl < 30ml/min)\\nCongestive heart failure\\nCurrently taking aspirin or a statin.',\n",
       " 'NSAID use within the past 48 hours',\n",
       " 'Have participated in this study previously, or any other study using exenatide or GLP-1 analogs.',\n",
       " 'Have participated in an interventional, medical, surgical, or pharmaceutical study within 30 days of screening.',\n",
       " 'Have characteristics contraindicating metformin or sulfonylurea use.',\n",
       " 'Have been treated with exogenous insulin for more than 1 week within the 3 months prior to screening.',\n",
       " 'Have used drugs for weight loss within 1 month of screening.',\n",
       " \"Patients with prior fistulotomy, fistulectomy, LIFT, cutting seton or advancement flap procedure \\nFistula with multiple tracts \\nRecto-vaginal fistula \\nActive infection in the anal fistula \\nPhysical allergies or cultural objections to porcine products \\nPatient is not medically fit to undergo the LIFT procedure as judged by the treating physician \\nPrevious diagnosis of collagen disorder \\nHistory of Crohn's Disease, Irritable Bowel Syndrome, radiation therapy in the rectoanal region\",\n",
       " 'Patients with high intracranial pressure.',\n",
       " 'Patients with Multiple Sclerosis.',\n",
       " 'Patients with Guillain-BarrÃ© syndrome radiculopathy of vascular origin.',\n",
       " 'Patients with previous lumbar surgery.',\n",
       " 'Patients pregnant or lactating.',\n",
       " 'Patients with allergy or intolerance to any of the drugs used.',\n",
       " 'Patients with severe cognitive impairment.',\n",
       " 'Patients with intrathecal injectio radiculalgia.',\n",
       " 'Patients with poorly controlled major psychiatric pathology.',\n",
       " 'Patients with type I diabetes or poorly controlled type II diabetes (Hb1Ac>8.5).',\n",
       " 'Patients with glaucoma.',\n",
       " 'Patients with caudal equine syndrome.',\n",
       " 'Patients with pre-treatment with steroid injections/or local anesthetics.',\n",
       " 'Patients with central canal stenosis.',\n",
       " 'patients with chronic treatment with oral corticosteroids without stabilized pattern.',\n",
       " 'cardiac or non-cardiac illness with life expectancy of less than two years;\\nfailure to advance the IVUS catheter through the culprit lesion;\\nacute coronary syndrome\\ncongestive heart failure NYHA III-IV\\ndiabetes mellitus\\nchronic kidney disease\\nprevious PCI in the target vessel\\nheavily calcified vessels\\nallergy to metformin',\n",
       " 'Subject has documented typical atrial flutter.',\n",
       " 'Subject has any history of successful or unsuccessful treatment of AF with class I or III antiarrhythmic or sotalol with the intention to prevent an AF recurrence.',\n",
       " 'Patients pretreated with above AAD at maximum 48 hours with the intention to convert an AF episode are allowed.',\n",
       " 'Subject had any previous left atrial ablation.',\n",
       " 'Subject had any previous cardiac surgery, e.g.',\n",
       " 'prosthetic valves.',\n",
       " 'Subject has permanent pacemaker or defibrillator implant.',\n",
       " 'Subject has 2Â° type II, 3Â° degree AV-block or left/right bundle branch block pattern.',\n",
       " 'Subject has unstable angina pectoris.',\n",
       " 'Subject has history of previous myocardial infarction or percutaneous intervention during the last three months.',\n",
       " 'Subject has symptomatic carotid stenosis.',\n",
       " 'Subject has chronic obstructive pulmonary disease with detected pulmonary hypertension or any other evidence of significant lung disease.',\n",
       " 'Subject has any contraindication for oral anticoagulation.',\n",
       " 'Subject has any history of previous transient ischemic attack or stroke.',\n",
       " 'Subject has known intra-cardiac thrombus formation.',\n",
       " 'Subject has any significant congenital heart defect corrected or not (except for patent foramen ovale that is allowed).',\n",
       " 'Subject has evidence of congestive heart failure (NYHA class II, III or IV) in sinus rhythm.',\n",
       " 'Subject has hypertrophic cardiomyopathy.',\n",
       " 'Subject has abnormal long or short QT interval, signs of Brugada syndrome, known inheriting ion channel disease on the family, arrhythmogenic right ventricular dysplasia.',\n",
       " 'Subject has sarcoidosis.',\n",
       " 'Subject has pulmonary vein stent.',\n",
       " 'Subject has myxoma.',\n",
       " 'Exclusion criteria based on laboratory abnormalities\\nSubject has thrombocytosis (platelet count > 600,000 / Âµl) or thrombocytopenia (platelet count <100,000 / Âµl).',\n",
       " 'Subject has any untreated or uncontrolled hyperthyroidism or hypothyroidism.',\n",
       " 'Subject has renal dysfunction with glomerular filtration rate < 60 ml / min.',\n",
       " 'Subject has known cryoglobulinaemia.',\n",
       " 'General exclusion criteria\\nSubject has a reversible causes for AF like hyperthyroidism and alcoholism.',\n",
       " 'Subject is a pregnant woman or woman of childbearing potential not on adequate birth control: only woman with a highly effective method of contraception [oral contraception or intra-uterine device] (who must have a negative pregnancy test within 1 week of the start of the therapy) or sterile woman can be enrolled.',\n",
       " 'Subject is a breastfeeding woman.',\n",
       " 'Subject has an active systemic infection.',\n",
       " 'Subject is employed by Medtronic or by the department of any of the investigators or is a close relative of any of the investigators.',\n",
       " 'Subject is unwilling or unable to comply fully with study procedures and follow-up due to any disease condition, which can raise doubt about compliance and influencing the study outcome especially any kind of cancer, severe bleeding in history or a suspected pro-coagulant state.',\n",
       " 'Legal incapacity or evidence that a subject cannot understand the purpose and risks of the study or inability to comply fully with study procedures and follow up.',\n",
       " 'Subject has a life expectancy of = 1 year.',\n",
       " 'Subject is currently enrolled or planning to participate in a potentially confounding drug or device trial during the course of this study.',\n",
       " 'Co-enrollment in concurrent trials is only allowed when documented pre-approval is obtained from the Medtronic study manager.',\n",
       " 'Previously enrolled in this study (i.e.',\n",
       " 'patient now at repeat encounter)\\nConcomitant surgical procedure other than CABG\\nAnticoagulant treatment after the operation (e.g.',\n",
       " 'warfarin, direct thrombin inhibitors (dabigatran), FXa inhibitors (rivaroxaban, apixaban, heparin, low-molecular weight heparin, fondaparinux)\\nDischarge from the operating hospital to an ICU at another hospital\\nPregnancy or lactation\\nKnown intolerance or contraindication to ticagrelor or ASA\\nAny disorder that may interfere with drug absorption\\nAny condition other than coronary artery disease with a life expectancy <12 months\\nKnown chronic liver disease, renal disease requiring dialysis or bleeding disorder\\nAtrioventricular block II and III in patients without pacemaker\\nAny other indication for dual antiplatelet therapy, i.e.',\n",
       " 'recent stent implantation\\nDebilitating stroke within 90 days before inclusion\\nPrevious intracranial bleeding\\nTreatment with immunosuppressants (e.g.',\n",
       " 'cyclosporine and tacrolimus)\\nTreatment with strong CYP3A4-inhibitors (e.g.',\n",
       " 'ketoconazole, clarithromycin, nefazodone, ritonavir or atazanavir)\\nAny condition that in the opinion of the investigator may interfere with adherence to trial protocol',\n",
       " 'age under 18y or over 85y\\ndiabetes type 1 with complications\\nno co-operation or inadequate finnish language skills\\npersistent pain for other reason\\nsevere hepatic insufficiency or paracetamol (acetaminophen) is contraindicated for other reason\\nany type of steroid in regular use\\noxycodone contraindicated\\nmedications changing notably paracetamol (acetaminophen) and/or ropivacaine metabolism in regular use',\n",
       " 'Patients who are unwilling to participate in the study.',\n",
       " 'For the one under guardianship, the refusal of the patient will be the final decision even if the guardian is willing to participate.',\n",
       " 'Subjects who are unlikely to adhere to the study an/or poor adherence anticipated by the investigator.',\n",
       " 'Un-controlled progressive pathology.',\n",
       " 'Osteoarticular lesion which contraindicates part of the rehabilitation involved in the study.',\n",
       " 'Patients with other interventions planned prior to the end of the study period (orthosis, surgery etc.).',\n",
       " 'Surgery to the treated limb less than 6 months previously.',\n",
       " 'Pregnant woman.',\n",
       " 'Women with confirmed or suspected pregnancy\\nWomen under lactation and/or puerperium\\nHypersensibility to ingredients of intervention\\nPhysical impossibility for apply the drug\\nKnown pancreatic, renal, hepatic, heart or thyroid diseased\\nHypertension diagnosis\\nPrevious treatment for glucose\\nBody Mass Index =39.9 kg/m2\\nTriglycerides =500 mg/dL\\nTotal cholesterol =300 mg/dL\\nNight or rotating shift workers\\nBlood Pressure =140/90 mmHg',\n",
       " 'Visible skin pathology, excessive freckles, or skin blemishes in the test area.',\n",
       " 'History of skin disease or hypersensitivity and repeated contact allergies.',\n",
       " 'Sarcoma or squamous cell histology.',\n",
       " 'Metastatic disease to the breast.',\n",
       " 'Current tobacco use.',\n",
       " 'Do not sign informed consent\\nPregnant patients\\nLiver cirrhosis\\nUndifferentiated adenocarcinoma.',\n",
       " 'cT4\\nMetastatic disease (M1)\\nchronic renal failure on dialysis\\nASA IV\\nBMI <18 and> 35 kg / m2',\n",
       " 'Children (<18 years old).',\n",
       " 'Women who are known to be pregnant.',\n",
       " 'Any patient who has been previously randomized in the EvK Trial.',\n",
       " 'Patients who require endotracheal intubation without sedative medication.',\n",
       " 'For example, patients in full cardiac arrest.',\n",
       " 'Patients with a known allergy to ketamine or etomidate.',\n",
       " 'Any individual wearing a MedAlert bracelet indicating that he/she has formally opted out of the EvK Trial.',\n",
       " 'uncontrolled hypertension\\nuncontrolled diabetes\\ncreatinine > 2,5 mg/dl\\npotassium > 6 mg/dl\\nacute coronary syndrome\\nhypertrophic cardiomyopathy',\n",
       " 'Patient refusal for supraclavicular block\\nInability to give informed consent\\nAllergy to local anesthetics\\nHemidiaphragmatic dysfunction, suspected or known PNP\\nNeuromuscular disease\\nObstructive or restrictive pulmonary disease\\nMedical or anatomic contraindication to supraclavicular blockade as judged by clinician\\nPregnancy',\n",
       " 'Patients ASA III y IV\\nChronic pain history\\nDrug and alcohol abuse\\nChronic use of opioid and sedatives\\nNeuropsychiatric illness\\nNSAID and other analgesics used the 48 hours previous to the surgery\\nCMI > 30',\n",
       " 'Patients with documented allergies to propofol, dexmedetomidine, fentanyl, eggs or egg products, or soy or soy products.',\n",
       " 'A heart rate less than 50 beats/minute or grade 2 or 3 AV heart block\\nMean arterial pressure less than 55 mmHg despite appropriate fluid resuscitation and vasopressor support.',\n",
       " 'Current triglyceride level > 400 mg/dl',\n",
       " 'Intolerance or allergy to ASA, clopidogrel or ticlopidine precluding treatment for 12 months\\nConcurrent participation in other investigational study\\nFemoral sheath (artery)',\n",
       " 'Pregnancy at enrollment.',\n",
       " \"Any condition, which in the opinion of the provider, will seriously compromise the participant's ability to comply with the protocol, including adherence to PrEP medication dosing, such as active, untreated or unstable major mental illness (i.e.\",\n",
       " 'untreated psychotic disorder).',\n",
       " 'Use of prohibited medications, in particular, agents known to be nephrotoxic or drugs slow in renal excretion.',\n",
       " 'Previous participation in an HIV vaccine trial.',\n",
       " 'Participants that were documented to have received only placebo are not excluded.',\n",
       " 'Signs or symptoms suspicious for Primary HIV Infection (PHI).',\n",
       " 'Molar teeth \\nMilller Class 4 recession defects \\nPregnancy (Self-reported) \\nSmoking \\nUncontrolled local or systemic diseases that affects wound healing (diabetes, autoimmune or inflammatory disorders) \\nPast history of systemic steroid use over 2 weeks within the last 2 years \\nPoor oral hygiene on a non-compliant individual \\nIbuprofen Allergy/interlerance \\nAnticoagulant therapy (e.g.',\n",
       " 'Warfarin, Plavix, etc.',\n",
       " '), will not be automatic exclusion but patients will be required to have INR test performed and have values between 2.0 to 3.',\n",
       " 'Physician consultation will be requested to determine whether anticoagulant therapy can be discontinued for 3 days prior to surgery.',\n",
       " 'Objection to blood draw or application of blood products \\nStudents and staff from USC Ostrow school of Dentistry will not be recruited for this study',\n",
       " 'pregnant or nursing woman\\nserious concomitant illness and malignant tumor of any kind\\nhistory of hypersensitivity to test drugs\\nserious bleeding during the course of the ulcer\\nprevious gastric surgery\\nreceiving bismuth salts, PPIs, or antibiotics in the previous month.',\n",
       " 'Pregnancy, age < 18, nursing, or documented allergy to naloxone',\n",
       " 'Are pregnant or lactating.',\n",
       " 'Have participated in any other studies involving investigational products within 30 days prior to entry into this study.',\n",
       " 'Are undergoing an acute withdrawal syndrome from drugs or alcohol.',\n",
       " 'Have an Axis I diagnosis of Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or Bipolar I Disorder as diagnosed by the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), and pertinent subsequent for ruling out exclusionary diagnoses.',\n",
       " 'Have an unstable medical disorder as determined by physical examination or laboratory testing.',\n",
       " 'The primary investigator will be responsible for making this judgment based on the above.',\n",
       " 'Had an unsatisfactory response to a previous adequate trial of quetiapine as judged by a study investigator.',\n",
       " 'Patients cannot begin psychotherapy during the study period, but may continue if started prior to the study.',\n",
       " 'Patients who are currently receiving quetiapine therapy may not undergo a washout period and then restart quetiapine in the study.',\n",
       " 'Known pregnancy or breast-feeding.',\n",
       " 'Medical illness unrelated to the tumor which in the opinion of the attending physician and principal investigator will preclude administration of the agent.',\n",
       " 'This includes patients with uncontrolled infection, chronic renal insufficiency, myocardial infarction within the past 6 months, unstable angina, cardiac arrhythmias other than chronic atrial fibrillation and chronic active or persistent hepatitis, or New York Heart Association Classification III or IV heart disease.',\n",
       " 'Administration of the licensed MF59-containing vaccines, e.g.',\n",
       " 'Fluadâ\\x84¢ or Addigripâ\\x84¢ or virosome-based influenza vaccines such as Inflexal Vâ\\x84¢, InfectoVac Fluâ\\x84¢ or Invivacâ\\x84¢ during the 2006-2007 influenza season.',\n",
       " 'Administration of licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study.',\n",
       " 'Planned administration of a vaccine not foreseen by the study protocol up to 30 days after the second vaccination with H5N1 vaccine.',\n",
       " 'Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first administration of the study vaccine.',\n",
       " 'Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).',\n",
       " 'History of chronic alcohol consumption and/or drug abuse.',\n",
       " 'History of hypersensitivity to vaccines.',\n",
       " 'History of allergic disease or reactions likely to be exacerbated by any component of the vaccine (including egg and thiomersal allergy).',\n",
       " 'Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.',\n",
       " 'Acute disease at the time of enrolment.',\n",
       " 'Serious chronic disease including any medically significant chronic pulmonary, cardiovascular, renal, neurological, psychiatric or metabolic disorder, as determined by medical history and physical examination.',\n",
       " 'Administration of immunoglobulins and/or any blood products within the three months preceding the first vaccination or during the study.',\n",
       " 'Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days prior to the first vaccination, or planned use during the study period.',\n",
       " 'Any condition which, in the opinion of the investigator, prevents the subject from participation in the study.',\n",
       " \"Confirmed allergy to apatinin and or its excipients;\\nHypertension (high blood pressure) that can not be controlled by drugs;\\nA history of active hemorragge, ulcer, intestinal perforation, intestinal obstruction, or major surgery no older than 30 days;\\nNYHA III-IV heart function, or severe hepatic or renal insufficiency (Grade 4);\\nPresence of multiple factors that affect oral medications, such as difficulty swallowing, nausea, vomiting, chronic diarrhea and intestinal obstruction;\\nPregnant or lactating women, or women of child-bearing potential who have planned a pregnancy, or male and female patients who do not agree to practice adequate contraception during this study;\\nPatients who have a history of psychotropics abuse and can not quit, or who have mental disorders;\\nParticipation in other drug clinical trial within the last 4 weeks;\\nPrior therapy with VEGFR inhibitors such as sorafenib and sunitinib;\\nPresence of comorbidities that seriously affect the patient's safety or ability to complete the study, in the investigator's judgment;\\nPatients who can not tolerate apatinib treatment as judged by the investigator depending on the their medical history;\\nPatients that are considered ineligible for this study by the investigator.\",\n",
       " '1.',\n",
       " 'The patient is pregnant or breastfeeding.',\n",
       " '2.',\n",
       " 'Evidence of STEMI within 72 hours of the intended treatment on infarct related or non-infarct related artery.',\n",
       " '3.',\n",
       " 'Cardiogenic shock on presentation or during current hospitalization.',\n",
       " '4.',\n",
       " 'Left ventricular ejection fraction less than 20%.',\n",
       " '5.',\n",
       " 'Known allergies to: aspirin, clopidogrel (Plavix) and ticlopidine (Ticlid), heparin, bivalirudin, stainless steel, or contrast agent (which cannot be adequately premedicated).',\n",
       " '6.',\n",
       " 'A platelet count less than 75,000 cells/mm3 or greater than 700,000 cells/mm3 or a WBC less than 3,000 cells/mm3.',\n",
       " '7.',\n",
       " 'Acute or chronic renal dysfunction (creatinine greater than 2.5 mg/dl or less than 150Âµmol/L).',\n",
       " '8.',\n",
       " 'Subject is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints.',\n",
       " '(Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials).',\n",
       " '9.',\n",
       " 'Prior participation in this study.',\n",
       " '10.',\n",
       " 'Within 30 days prior to the index study procedure, the subject has undergone a previous coronary interventional procedure of any kind.',\n",
       " 'Note: This exclusion criterion does not apply to post-STEMI patients.',\n",
       " '11.',\n",
       " 'Stroke or transient ischemic attack within the prior 3 months.',\n",
       " '12.',\n",
       " 'Active peptic ulcer or upper gastrointestinal bleeding within the prior 3 months.',\n",
       " '13.',\n",
       " 'Subject has active sepsis.',\n",
       " '14.',\n",
       " 'Unprotected left main coronary artery disease (stenosis greater than 50%).',\n",
       " '15.',\n",
       " \"In the investigator's opinion, subject has a co-morbid condition(s) that could limit the life expectancy to less than one year, or limit the subject's ability to participate in the study or comply with follow-up requirements or impact the scientific integrity of the study.\",\n",
       " '16.',\n",
       " 'Subject has normal or insignificant coronaries (i.e.',\n",
       " 'coronary lesion(s) less than 50% stenosis).',\n",
       " '17.',\n",
       " 'Any target vessel has evidence of: \\nexcessive thrombus (e.g.',\n",
       " 'requires target vessel thrombectomy) \\ntortuousity (greater than 60 degree angle) that makes it unsuitable for proper stent delivery and deployment, \\nheavy calcification.',\n",
       " '18.',\n",
       " 'Any target lesion requires treatment with a device other than percutaneous transluminal coronary angioplasty (PTCA) prior to stent placement (e.g.',\n",
       " 'but not limited to, directional coronary atherectomy, excimer laser, rotational atherectomy, etc.).',\n",
       " '19.',\n",
       " 'Any lesion that is located in a saphenous vein graft, however, lesions located within the native vessel but accessed through the graft are eligible.',\n",
       " '20.',\n",
       " 'The target vessel is in a \"last remaining\" epicardial vessel (e.g.',\n",
       " 'greater than 2 non-target epicardial vessels and the bypass grafts to these territories [if present] are totally occluded).',\n",
       " 'NA',\n",
       " 'Contraindication to Clopidogrel \\nSmoking (current smokers and patients who quit smoking less than six months) \\nMalignancy(diagnosed or under investigation) \\nHaematological disorders (Anaemia, malignancy, bleeding disorders) \\nWomen of child-bearing potential \\nUse of corticosteroids/other antithrombotic agents(warfarin) \\nChronic liver disease (Cirrhosis, malignancy and patients with more than twice the upper limit of liver function tests) \\nUnable to consent.',\n",
       " 'Use of other investigational study drugs within 1 year prior to study entry \\nPrevious participation in this study',\n",
       " 'Pregnant or lactating women\\nPatients with severe organ dysfunction or failure\\nWith severe cardiovascular disease, or mental\\nExtraliver metastases',\n",
       " \"Women refusing HBs Ag test\\nHIV co-infection\\nHCV co-infection\\nHBV treatment ongoing at the day of inclusion\\nCreatinine clearance < 30 mL/min\\nSevere gravidic disease present at inclusion involving life threatening to the mother and/or the child\\nEvidence of pre-existing fetal anomalies incompatible with the child's life\\nImminent child's birth defined as cervix dilatation up to 7 centimeters\\nIntention to deliver in a maternity not linked to the study\\nAny concomitant medical condition that, according to the clinical site investigator would contraindicate participation in the study.\",\n",
       " 'Concurrent participation in any other clinical trial without written agreement of the two study teams',\n",
       " \"Amiodarone\\nP-glycoprotein (P-gp) inducers (e.g., rifampin, St. John's wort)\\nLiver biopsy at any time showing mHAI stage 4 or higher fibrosis OR\\nFibroScan within 12 months demonstrating liver stiffness of =9.5 kilo Pascal or\\nAST to platelet ratio index (APRI) =2.0 and Fibrosis-4 (FIB-4) =3.25\\nNOTE: If APRI and FIB-4 are discordant one of the other forms of fibrosis staging must be used.\",\n",
       " 'Known allergy/sensitivity or any hypersensitivity to components of study drugs or their formulation.',\n",
       " \"Hemochromatosis\\nAlpha-1 antitrypsin deficiency\\nWilson's disease\\nAutoimmune hepatitis\\nAlcoholic liver disease\\nDrug-related liver disease\\nSevere NC confounding conditions (stroke, head injury, or developmental learning disability).\",\n",
       " 'Regular use of anti-inflammatory drugs.',\n",
       " 'Current or recent treatment with pegylated interferon (PEG-IFN).',\n",
       " 'Other active inflammatory process (major infection, malignancy, rheumatoid arthritis/autoimmune disorder) within the prior 28 days.',\n",
       " 'Contraindications to magnetic resonance imaging (MRI).',\n",
       " 'Bleeding diathesis, thrombocytopenia, or use of anticoagulants that would contraindicate lumbar puncture.',\n",
       " 'Uncontrolled or active depression or other psychiatric disorder that in the opinion of the site investigator might preclude adherence to study requirements or impact NC functioning and assessments.',\n",
       " 'Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.',\n",
       " 'Presence of active or acute AIDS-defining opportunistic infections within 12 weeks prior to study entry.',\n",
       " 'use more than 2g a day; 5 times a week to everyday \\nSubjects who are diagnosed as suffering from psychotic illness according to DSM-IV (Axis 1)22, or with a history of CNS disease, a history of infection that might affect CNS (HIV, syphilis, cytomegalovirus, herpes), or a history of head injury with loss of consciousness,pregnant women.',\n",
       " 'the history or family history of anaphylaxis, convulsion, epilepsy, encephalopathy and psychosis\\nthe history of severe inoculation allergies\\npatients with immunodeficiency and malignant tumors during the treatment period, receiving immunosuppressive therapy (oral steroid) or HIV due to low immunity, or family members have congenital immune disease\\nNonspecific immunoglobulin was injected within one month\\ntemperature=37.1<U+2103> and infectious diseases\\nthe history of thrombocytopenia or other thrombocytopenia with a definite diagnosis\\nrespiratory disease, acute infection or chronic disease activity period\\nsevere cardiovascular disease, liver and kidney disease, and complications of diabetes\\ninfectious, suppurative and allergic dermatosis\\nother conditions that may affect the evaluation of the trail\\nany serious adverse events that have a causal relationship with the inoculation of the upper dose of the vaccine\\nthe abnormality of 4 levels (local, systemic adverse reactions and vital signs) was judged to be related to vaccination\\nother new standards of exclusion criteria for first needle\\nother conditions that may affect the evaluation of the trail',\n",
       " 'Coronary artery disease - stent\\nSevere chronic renal failure\\nCongenital or acquired thrombophilia/thrombosis event\\nKnown or suspected allergy',\n",
       " 'Current pregnancy\\nDesire/intent to become pregnant over the course of the study\\nWomen who are less than 6 weeks postpartum\\nContraindications to hormonal contraceptive use per package insert, including history of deep vein thrombosis, smoking in women older than 35 years\\nCurrent IUD\\nUnable to comprehend consent material because of language barrier or psychological difficulty',\n",
       " 'diabetes mellitus \\nsecondary hypertension \\npregnancy',\n",
       " 'Pre-existing hemoptysis of a severity > grade 3 by NCI CTCAE criteria within 4 weeks prior to study entry \\nUncontrolled hypertension \\nCHF, angina or arrhythmias \\nLVEF < 1 UNL \\nExisting a second malignancy within 5 years \\nInfected with HIV',\n",
       " 'Anticoagulation therapy\\nPrior CABG.',\n",
       " 'Active bleeding or at high risk of bleeding\\nSevere liver or renal disease.',\n",
       " 'Hypersensitivity to ticagrelor\\nHistory of intracranial hemorrhage',\n",
       " '1.',\n",
       " 'Prior treatment with gemcitabine, carboplatin (except in the adjuvant setting), or Iniparib.',\n",
       " '2.',\n",
       " 'Past or current history of neoplasm other than the entry diagnosis, with the exception of treated non-melanoma skin cancer or carcinoma in-situ of any primary site, or invasive cancers treated definitively, with treatment ending >5 years previously and no evidence of recurrences.',\n",
       " '3.',\n",
       " 'A history of cardiac disease, as defined by: \\nMalignant hypertension \\nUnstable angina \\nCongestive heart failure \\nMyocardial infarction within the previous 6 months \\nSymptomatic, unstable or uncontrolled, cardiac arrhythmias.',\n",
       " 'Patients who have stable, rate-controlled atrial fibrillation are eligible for study enrollment.',\n",
       " '4.',\n",
       " 'Active brain metastases.',\n",
       " 'Patients with treated brain metastases are eligible, if (1) radiation therapy was completed at least 2 weeks prior to study entry; (2) follow-up scan shows no disease progression; and (3) patient does not require steroids.',\n",
       " '5.',\n",
       " 'Women who are pregnant or lactating.',\n",
       " '6.',\n",
       " 'Any serious, active infection (> Grade 2) at the time of treatment.',\n",
       " '7.',\n",
       " 'A serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.',\n",
       " '8.',\n",
       " 'A major surgical procedure, or significant traumatic injury â\\x89¤28 days of beginning treatment, or anticipation of the need for major surgery during the course of the study.',\n",
       " '9.',\n",
       " 'Uncontrolled or intercurrent illness including, that in the opinion of the investigator may increase the risks associated with study participation or administration of the investigational products, or that may interfere with the interpretation of the results.',\n",
       " '10.',\n",
       " 'History of any medical or psychiatric condition or laboratory abnormality that, in the opinion of the investigator, may increase the risks associated with the study participation or administration of the investigational products, or that may interfere with the interpretation of the results.',\n",
       " '11.',\n",
       " 'Known or suspected allergy/hypersensitivity to any agent given in the course of this trial.',\n",
       " \"The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.\",\n",
       " 'Known or suspected sensitivity to Dexamethasone Acetate (DXA) \\nMechanical tricuspid heart valve \\nSubject is enrolled in any other concurrent study without prior written approval from Boston Scientific (BSC), with the exception of local mandatory governmental registries and observational studies/registries that are not in conflict and do not affect the following: \\nSchedule of procedures for the RELIANCE 4-Front Study (i.e.',\n",
       " 'should not cause additional or missed visits); \\nRELIANCE 4-Front Study outcome (i.e.',\n",
       " 'involve medications that could affect the heart rate of the subject); \\nConduct of the RELIANCE 4-Front Study per Good Clinical Practice (GCP)/ International Organization for Standardization (ISO) 14155:2011/ 21 CFR 812/ local regulations \\nCurrently on the active heart transplant list \\nDocumented life expectancy of less than 12 months \\nWomen of childbearing potential who are or might be pregnant at the time of study enrollment (method of assessment upon physician discretion) \\nCurrently requiring chronic dialysis',\n",
       " 'Hemochromatosis, iron overload, defined as TSAT > 45%\\nKnown hypersensitivity to FerinjectÂ®.',\n",
       " 'Known active infection, CRP>20 mg/L, clinically significant bleeding, active malignancy.',\n",
       " 'Chronic liver disease and/or screening alanine transaminase (ALT) or aspartate transaminase (AST) above three times the upper limit of the normal range.',\n",
       " 'Immunosuppressive therapy or renal dialysis (current or planned within the next 6 months).',\n",
       " 'History of erythropoietin, i. v. or oral iron therapy, and blood transfusion in previous 12 weeks and/or such therapy planned within the next 6 months.',\n",
       " 'Unstable angina pectoris as judged by the investigator, clinically significant uncorrected valvular disease or left ventricular outflow obstruction, obstructive cardiomyopathy, poorly controlled fast atrial fibrillation or flutter, poorly controlled symptomatic brady- or tachyarrhythmias.',\n",
       " 'Acute myocardial infarction or acute coronary syndrome, transient ischemic attack or stroke within the last 3 months.',\n",
       " 'Coronary-artery bypass graft, percutaneous intervention (e.g.',\n",
       " 'cardiac, cerebrovascular, aortic; diagnostic catheters are allowed) or major surgery, including thoracic and cardiac surgery, within the last 3 months.',\n",
       " 'Participation in a CHF training program.',\n",
       " 'Known HIV/AIDS.',\n",
       " \"Inability to fully comprehend and/or perform study procedures in the investigator's opinion.\",\n",
       " 'Vitamin B12 and/or serum folate deficiency according to the laboratory (re-screening is possible after substitution therapy).',\n",
       " 'Pregnancy or lactation.',\n",
       " 'Participation in another clinical trial within previous 30 days and/or anticipated participation in another trial during this study.',\n",
       " 'Anticoagulation',\n",
       " 'Patients Level III or greater on the American Society of Anesthesiologists (ASA) physical status classification system (as determined by the anesthesiologist)\\nPatients with chronic conditions that would limit our ability to develop the study according to objectives, such as neurodevelopmental conditions preventing patients from understanding the Oucher tool\\nHepatic or renal disease\\ncardiac disease\\nactive infection\\ndiabetes mellitus\\nsickle cell disease\\nknown coagulation disorders\\npre- operative treatment with anti-emetics, steroids, or analgesics\\nAcetaminophen allergy or already receiving acetaminophen within 24 h of surgery\\nComplicating health factors precluding the use of opioids or acetaminophen\\nany other factors which would interfere with pain assessment and management\\nPatients weighing more than 30 kg that would exceed maximum dexamethasone dose\\nPatients who live without a home telephone\\npatient living without parental supervision.',\n",
       " 'endometrial hyperplasia with atypia,\\nestrogen-progestin therapy in the 2 months before enrollment,\\nautoimmune diseases,\\nchronic, metabolic, systemic and endocrine disorders, including hyperandrogenism, hyperprolactinemia, diabetes mellitus and thyroid disease,\\nhypogonadotropic hypogonadism,\\nmajors clinical conditions',\n",
       " '1.',\n",
       " 'Patients with lumbar common diseases(e.g., Lumbar disc, Lumbar spinal stenosis, Lumbar slippage, etc)\\n2.',\n",
       " 'Researchers think that Patients with disease may be interference results(e.g., Spinal deformity, spine fracture, ankylosing spondylitis, spinal tuberculosis and spinal infection, spinal tumor, pelvic inflammatory disease and other disease of department of gynaecology, etc)\\n3.',\n",
       " 'Patients with other nervous system diseases(e.g., cerebral tumor, neurinoma, trigeminal neuralgia,etc)\\n4.',\n",
       " 'Patients with Magnetic resonance imaging contraindication ,including claustrophobic syndrome patients\\n5.',\n",
       " 'Patients with recent (less than 3 years) use chemical drugs or have obvious psychological problems\\n6.',\n",
       " 'In the past 2 months involved in other drugs or devices clinical trials',\n",
       " 'History of curettage or other intrauterine surgery \\nHistory of post-abortion complication or infection',\n",
       " 'Ductal carcinoma in situ (DCIS; stage 0 cancer), \\nAdvanced or distant metastatic stage, \\nReceiving any neoadjuvant therapy, \\nHistory of receiving any antibiotics within prior 3 months, \\nHistory of immunodeficiency, \\nHaving a remote infection, \\nHistory of reaction to study antibiotics, \\nDenial of signing the consent form.',\n",
       " 'Contraindication to antiplatelet therapy\\nNeed to continue clopidogrel due to stroke, peripheral disease, significant carotid disease or recent acute coronary syndrome\\nMajor bleeding history or bleeding diathesis\\nPregnancy',\n",
       " 'Presence of VTE upon admission\\nPregnant or nursing\\nInability to give informed consent by patient or healthcare proxy\\nContraindication to enoxaparin\\nContraindication to aspirin\\nEpidural or subdural hematoma\\nPresence, or removal within the last 12 hours, of an epidural or spinal catheter, or recent (within the last 12 hours) epidural or spinal anesthesia/procedures',\n",
       " 'Preexisting ocular diseases or conditions other than age related cataracts, have contraindications for cataract surgery;\\nPreexisting systemic diseases or conditions that may confound the results of the study;\\nPrevious ocular surgery history or ocular trauma that may confound the results of the study;\\nRequire combined surgery that may confound the results of the study;\\nPrevious participation in other clinical trial within 30 days of this study start;\\nSystemic or ocular medications that may confound the outcome of the intervention\\nPregnant, lactating, or planning to become pregnant during the course of the trial;',\n",
       " 'NA',\n",
       " 'age <18 years;\\nPregnancy\\ninability to give informed written consent;\\nprevious thoracic surgery or thrombolytic therapy for pleural infection;\\nmedical thoracoscopy cannot be performed within 48 hours;\\ninability to tolerate procedure due to hemodynamic instability or severe hypoxemia;\\ninability to correct coagulopathy;\\npresence of a homogeneously echogenic effusion on pleural US27 -',\n",
       " \"Concomitant antiplatelet or anticoagulant use \\nCalculated creatinine clearance < 30 mL/min by Cockcroft-Gault formula \\nAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 times upper limit of normal (ULN) \\nTotal bilirubin > 2 x ULN \\nThrombocytopenia < 50 x 10 gigalitres (Gl) \\nHigh bleeding risk or spontaneously prolonged prothrombin time or activated partial thromboplastin time > 1.5 x ULN \\nBody weight <50 or >120 kg \\nConcomitant use of CYP3A4 or p-glycoprotein inducers or inhibitors \\nUse of Ginkgo biloba or St. John's Wort within 14 days before first dose of study drug \\nDexamethasone use within last 3 months \\nWomen of Childbearing potential without proper contraceptive measures, pregnancy or breast feeding \\nLife expectancy less than 3 months \\nInability to swallow or issues with malabsorption \\nAny other medical, social, logistical, geographical or psychological factors, which in the opinion of the investigator, would prohibit follow-up, compliance and study completion\",\n",
       " 'Current wheeze\\nUnderlying chronic illness other than asthma (e.g.',\n",
       " 'bronchiectasis, cyanotic congenital heart disease or cardiac failure, neuromuscular disorders, immunodeficiency) that could potentially influence the current illness\\nSevere malnutrition (weight-for-height Z-score <-3)\\nComplicated (effusion, empyema or abscess) pneumonia, including tuberculosis\\nExtra-pulmonary infection requiring antibiotic therapy (e.g.',\n",
       " 'meningitis)\\nBeta-lactam allergy\\nPreviously enrolled\\nLack a mobile phone and/or unable to return for follow-up clinic visits during the next 24 months',\n",
       " 'Diabetes mellitus or plasma glucose >11,1 at admission.',\n",
       " 'Receiving steroids at the time of transplantation or likely to need steroids after transplantation.',\n",
       " 'Multiorgan transplants and/or previously transplanted with any other organ than kidney.',\n",
       " 'Panel reacting antibodies(PRA) >25% in most recent test or considered to be of high risk for rejection which requires an enhanced immunosuppression.',\n",
       " 'Renal transplants from HLA-identical sibling.',\n",
       " 'Hypersensitivity to, or disability to take immunosuppressive drugs.',\n",
       " 'Blood group(ABO)-incompatible transplants.',\n",
       " 'Unlikely to comply with the study requirements.',\n",
       " 'Transplant from donor positive for HIV, HBsAg, Hepatitis C.\\nFemale of childbearing potential planing/being pregnant or unwilling to use contraception.',\n",
       " 'Intranasal steroid use within the last three months\\nCurrent systemic steroid use\\nPrior septal surgery\\nIndividuals who are pregnant or actively breastfeeding',\n",
       " '1.',\n",
       " 'Currently enrolled in another research trial for investigative nutritional or other therapies thought to have an impact on immune system functioning.',\n",
       " '2.',\n",
       " 'Unable to consent to the study.',\n",
       " '3.',\n",
       " 'Women who are pregnant or are attempting conception, especially in the presence of a history of recurrent spontaneous abortion.',\n",
       " '4.',\n",
       " 'Other medical complications that might preclude one from participating in the study, i.e., recent heart attack or stroke or chronic kidney disease.',\n",
       " '5.',\n",
       " 'Currently taking immunomodulatory medication, i.e.',\n",
       " 'interferon.',\n",
       " '6.',\n",
       " 'Currently taking other medications thought to have an impact on immune system functioning, i.e., chemotherapeutic agents.',\n",
       " '7.',\n",
       " 'Known allergy to rice, rice bran, or related food products.',\n",
       " '8.',\n",
       " 'Known allergy to mushrooms or related food products.',\n",
       " '9.',\n",
       " 'History of malignancies related to the NK cell line, including: NK cell leukemias and T-cell large granular lymphocyte leukemias, NK-cell lymphoproliferative disease of granular lymphocytes, and NK cell lymphomas, e.g., nasal and nasal-like NK/T-cell lymphomas.',\n",
       " '10.',\n",
       " 'Current smoker.',\n",
       " 'the child has temperature > 39.0â\\x97¦C or a severe acute illness as defined by the examining nurse\\nthe child has as a mid upper arm circumference < 110 mm and is older than 6 months (most feasible local indicator of AIDS and chronic immunosuppressive disease)\\nthe child has experienced a severe allergic reaction after previous vaccination, drug or food.',\n",
       " 'the child is enrolled in an ongoing study of Bacillus Calmette Guerin vaccine and is < 2 months old\\nFor the RECAMP-MV trial: the child is enrolled in RECAMP-OPV',\n",
       " '(1)Women who are pregnant and/or lactating; or women who intend to conceive within a year;\\n(2)History of allergies to enalapril, folic acid or other components of the compound drug;\\n(3)History of adverse reactions or intolerance to enalapril or other ACE inhibitors, or drugs or supplements containing folic acid;\\n(4)Diagnosis or suspicion of secondary hypertension;\\n(5)Known serious medical conditions, including: Cardiovascular: patients with clinically diagnosed cardiac dysfunction (NYHA class III and above), hypertrophic obstructive cardiomyopathy, clinically significant valvular heart disease, acute coronary syndrome within the last 3 months, or percutaneous coronary intervention (PCI), or coronary artery bypass graft (CABG); or abnormal pre-enrollment ECG test results with clinically significant arrhythmias (atrial flutter, atrial fibrillation, grade II-III atrioventricular block, etc.',\n",
       " '); Digestive: a previous diagnosis of various types of viral hepatitis that are still in the active phase; abnormal pre-enrollment liver function test results (ALT, AST, GGT, TBIL, or DBIL 3 times higher than normal, ALB = 30g/L); gastrectomy and/or gastrojejunostomy; gastrointestinal dysfunction; Urinary: pre-enrollment serum creatinine greater than 200umol/L; clinical diagnosis of renal artery stenosis, isolated kidney, kidney transplantation and/or other diseases; Endocrine: type 1 diabetes or uncontrolled type 2 diabetes (fasting blood glucose above 11.1 mmol/L at pre-enrollment); previous diagnosis of hyperthyroidism and failure to correct; Respiratory: pulmonary heart disease; chronic obstructive pulmonary disease; Neuropsychiatric: recent transient ischemic attack or stroke (within the last 3 months); peripheral or severe autonomic dysfunction; mental or nervous system dysfunction, inability to express desire; known drug or alcohol dependence; Malignancy, malnutrition, hematopoietic disorders and other serious diseases.',\n",
       " \"(6)Significant signs of abnormalities as seen in laboratory tests or physical characteristics, which, at the discretion of the investigators, indicates that the patient is experiencing a serious illness or, may affect the observation and evaluation of the drug's efficacy or adverse events, or renders the patient unsuitable for participating in this study;\\n(7)Patients currently taking folate, B12, or B6, or any compounds containing them, who express an inability or a refusal to stop usage;\\n(8)Regular usage of folic acid supplements or compounds containing folic acid in the past 3 months;\\n(9)Participation in a clinical trial for a drug that has not yet been officially approved for marketing within one month prior to the first visit.\",\n",
       " 'Diabetes mellitus type 1\\nrenal insufficiency III-V Â°\\nCirrhosis hepatis (Child B or higher)\\nChronic alcohol abuse\\nrheumatic disease (RA, SpA, SLE)\\nMalignancies (<5 years)\\nEating Disorder (anorexia nervosa, bulimia)\\nbone-specific pretreatment (DMAB, TPTD, strontium ranelate, SERMs) Bisphosphonate treatment is allowed',\n",
       " 'Patients with a calculated PRA higher than 0% per solid phase and / or anti-HLA class I and / or class II antibodies detectable by single antigen test (LuminexÂ®).',\n",
       " 'Positive result of Cross Match.',\n",
       " 'Patients who receive a graft from a cadaver donor.',\n",
       " 'Identical HLA patients\\nPatients who have undergone a previous solid organ transplant (including kidney transplant) or who are going to receive another solid organ transplant concomitantly.',\n",
       " 'Glomerular primary focal and segmental sclerosis\\nAtypical hemolytic uremic syndrome (aHUS) / thrombotic thrombocytopenic purpura syndrome.',\n",
       " 'Patients with chronic infection with Hepatitis B virus (HBV) and / or active infection with Hepatitis C virus (positive PCR result) at the time of transplant.',\n",
       " 'Patients with infection with the known Human Immunodeficiency Virus (HIV).',\n",
       " 'Patients with active systemic infection that requires the continued administration of antibiotics.',\n",
       " 'Patients with any neoplasm except localized skin cancer and who is receiving adequate treatment.',\n",
       " 'Patients with severe anemia (hemoglobin <6g / dl), leukopenia (WBC <2500 / mm3) and / or thrombocytopenia (platelets <80,000 / mm3).',\n",
       " 'Patients who are hemodynamically unstable even if they have hemoglobin levels> 6g / dL.',\n",
       " 'Patients with intestinal pathology or severe diarrhea that may decrease absorption according to medical criteria.',\n",
       " 'Patients with known hypersensitivity to any of the drugs used in this study.',\n",
       " 'Patients who have received any investigational drug in the 30 days prior to their inclusion in this study.',\n",
       " 'Potentially fertile women who do not agree to use reliable contraceptive measures during the trial, who are pregnant, breastfeeding or who present a positive pregnancy test at the time of their inclusion in the study.',\n",
       " 'Patients who are legally detained in an official institution.',\n",
       " 'Prior treatment with enzalutamide or abiraterone acetate for > 14 days prior to enrollment and completion of baseline tests.',\n",
       " 'Receipt of chemotherapy for prostate or other cancer within the past 12 months with residual cognitive deficits, or receipt of chemotherapy for mCRPC.',\n",
       " 'Patients/physicians planning treatment with chemotherapy during the 12 month period of the investigation are also ineligible.',\n",
       " \"History of cognitive impairment or dysfunction, including a history of dementia, Alzheimer's disease, stroke with residual cognitive deficits, cognitive dysfunction related to alcohol or substance abuse, or cognitive dysfunction related to prior treatment for any cancer.\",\n",
       " 'Patients with a seizure history, history of recurrent falls, or known brain metastases are excluded from this clinical trial because of their poor prognosis and because of their heightened risk of seizure or progressive cognitive and/or neurologic dysfunction that would confound the evaluation.',\n",
       " 'Uncontrolled intercurrent illness including, but not limited to, uncontrolled diabetes, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III and IV heart failure), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations/substance abuse that would limit compliance with study requirements.',\n",
       " 'Patients with a \"currently active\" second malignancy other than non-melanoma skin cancers are not eligible.',\n",
       " 'Patients are not considered to have a \"currently active\" malignancy if they have completed all therapy and are now considered without evidence of disease for 1 year.',\n",
       " 'Patients with cognitive dysfunction related to treatment of another malignancy, including a history of \"chemo-brain\", are ineligible.',\n",
       " 'Patients taking psychotropic medications or illicit drugs that may alter cognition, concentration, or behavior.',\n",
       " 'Appropriate treatment by a licensed provider with medications for depression or anxiety, including but not limited to SSRIs, SNRIs, and standard dose benzodiazepines at a stable dose, is permitted',\n",
       " 'Uncontrolled medical problems including pulmonary, cardiovascular or orthopedic disease\\nAny debilitating disease prior to the SCI that caused exercise intolerance\\nPremorbid, ongoing major depression or psychosis, altered cognitive status\\nHistory of head injury or stroke\\nMetal plate in skull\\nHistory of seizures\\nReceiving drugs acting primarily on the central nervous system, which lower the seizure threshold (see appendix 2)\\nPregnant females\\nOngoing cord compression or a syrinx in the spinal cord or who suffer from a spinal cord disease such as spinal stenosis, spina bifida, MS, or herniated disk\\nIndividuals with scalp shrapnel, cochlear implants, or aneurysm clips.',\n",
       " 'Patients who had history of systemic antibiotic usage over the previous 4 months \\nPatients who were pregnant \\nPatients who had received non-surgical periodontal treatment within the past 6 months \\nPatients who had received surgical periodontal treatment within the past 12 months \\nPatients who were smokers \\nPatients with a history of stroke or an acute cardiovascular event over the previous 12 months.',\n",
       " 'Exclusion criteria includes ICUs with an average length of stay of less than 2 days;\\nHCA hospitals that are not able to transfer or merge data into the centralized data warehouse for the baseline and intervention periods of the study are also excluded.',\n",
       " '1.',\n",
       " \"Unable to ambulate at least 150 feet prior to stroke, or experienced intermittent claudication while walking; \\n2. history of congestive heart failure, unstable cardiac arrhythmias, hypertrophic cardiomyopathy, severe aortic stenosis, angina or dyspnea at rest or during ADL's; \\n3.\",\n",
       " 'History of oxygen dependence; \\n4.',\n",
       " 'Preexisting neurological disorders, dementia or previous stroke; \\n5.',\n",
       " 'History of major head trauma; \\n6.',\n",
       " 'Legal blindness or severe visual impairment; \\n7. history of psychosis or other Axis I disorder that is primary; \\n8.',\n",
       " 'Life expectancy <1 yr.; \\n9.',\n",
       " 'Severe arthritis or other problems that limit passive range of motion; \\n10.',\n",
       " 'History of DVT or pulmonary embolism within 6 months; \\n11.',\n",
       " 'Uncontrolled diabetes with recent weight loss, diabetic coma, or frequent insulin reactions; \\n12.',\n",
       " 'Severe hypertension with systolic >200 mmHg and diastolic >110 mmHg at rest; \\n13. attempt of suicide in the last 2 years or at suicidal risk assessed by SCID interview; \\n14.',\n",
       " 'Previous or current enrollment in a clinical trial to enhance motor recovery; 15) currently exercising â\\x89¥ 2 times per week (â\\x89¥20 minutes); \\n16) Presence of non-MR compatible implants, pregnancy or severe claustrophobia.',\n",
       " 'Patients that do not have a valid Ontario Health Insurance Plan (OHIP) number at time of first transfusion\\nPatients that require emergent release of a RBC transfusion and in whom emergency randomization could not be completed\\nPatients with complex antibody profile in which it is impossible to match RBC units',\n",
       " 'History of acute coronary syndrome in the past 30 days.',\n",
       " 'History of congesting heart failure with left ventricular ejection fraction <30% or exacerbation in the past 30 days.',\n",
       " 'Current dialysis treatment.',\n",
       " 'Known furosemide hypersensitivity.',\n",
       " 'Contraindications to placement of a Foley catheter in the bladder.',\n",
       " 'Patient has been permanently discontinued from nilotinib treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason\\nPatient has participated in a Novartis sponsored combination trial where nilotinib was dispensed in combination with another study medication and patient is still receiving combination therapy\\nPatients who are currently receiving treatment with any medications that have the potential to prolong the QT interval or inducing Torsade de Pointes and the treatment cannot be either safely discontinued at least one week prior to nilotinib treatment or switched to a different medication prior to start of nilotinib treatment and for the duration of the study\\nPregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hcG laboratory test.',\n",
       " 'Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during the study and for 30 days after the final dose of nilotinib.',\n",
       " 'Subject unwilling to cease use of any treatment for erectile dysfunction during the study, including oral medication, vacuum devices, constrictive devices, injections, urethral suppositories, gels, any over-the-counter or nonprescription medications, and products purchased via the internet\\nSubject receiving dopamine agonists, nitrates, alpha-receptor blocking agents, or antihypertensive medication (see other exclusionary medications listed below)\\nSubject with a history of syncope within the last 6 months prior to screening\\nSubject with symptomatic postural hypotension (severe dizziness or fainting\\nSubject with hypotension and a resting systolic blood pressure of < 90 mmHG or hypertension with a resting systolic blood pressure > 170 mmHG or a resting diastolic blood pressure > 110 mmHG\\nSubject with any underlying cardiovascular condition, including unstable angina pectoris, which preclude sexual activity\\nSubject with a history of myocardial infarction, stroke or life-threatening arrhythmia within 6 months prior to screening\\nSubject with uncontrolled atrial fibrillation/flutter at screening (defined as ventricular response rate = 100 bpm)\\nSubject with a bleeding disorder\\nSubject with a history of prostatectomy because of prostate cancer, including nerve sparing techniques.',\n",
       " \"Subjects with a history of surgical procedures for the treatment of benign prostate hypertrophy are permitted, with the exception of cryosurgery, cryotherapy or cryoablation\\nSubject with hereditary degenerative retinal disorders such as retinitis pigmentosa\\nSubject with a history of loss of vision because of non-arteritic anterior ischemic optic neuropathy (NAION), history of temporary or permanent loss of vision, including unilateral loss of vision\\nSubject with a history of congenital QT prolongation\\nSubject with a penile anatomical abnormality (e.g., penile fibrosis, fractures, or Peyronie's disease) which, in the investigator's opinion, could significantly impair sexual performance.\",\n",
       " \"This will be based on subject's reported medical history (penile exam not required)\\nSubject with primary hypoactive sexual desire.\",\n",
       " \"Subject with a spinal cord injury\\nSubject with a severe chronic or acute liver disease, history of moderate (Child-Pugh B), or severe (Child-Pugh C) hepatic impairment\\nSubject with clinically significant chronic hematological disease which could lead to priapism such as sickle cell anemia, multiple myeloma, and leukemia\\nSubject with active peptic ulceration\\nSubject with a history of malignancy within the past 5 years (other than squamous or basal cell skin cancer)\\nSubject with a history of a positive test for Hepatitis B surface antigen (HbsAg) or Hepatitis C\\nSubject with a known hypersensitivity to any component of the investigational medications, monoamine oxidase inhibitors, phosphodiesterase type 5 inhibitors or phenylethylamines\\nSubjects with a history of drug or alcohol abuse within the past 6 months\\nSubjects currently consuming =5 units of alcohol per day\\nSubject who is illiterate or unable to understand the Informed Consent Form, questionnaires or subject diary\\nSubject who, in the opinion of the investigator, will be noncompliant with the visit schedule or study procedures\\nSubject with any unstable medical, psychiatric, or substance abuse disorder that in the opinion of the investigator is likely to affect the subject's ability to complete the study or preclude the subject's participation in the study\\nDiagnosis of any other neurologic disease\\nUncontrolled Diabetes (Hemoglobin A1C > 7.5)\",\n",
       " 'latex allergy\\nnon-reassuring fetal status\\nHIV\\nactive herpes outbreak\\nPrior uterine scar\\nContraindication to prostaglandins according to current Parkland protocol\\nContraindication to vaginal delivery',\n",
       " 'previous brain surgery;\\ncognitive impairment (< 120 points on the Mattis Dementia Rating Scale)\\nmoderate-to-severe depression (> 25 points on the Beck Depression Inventory)\\nmarked brain atrophy as detected by magnetic resonance imaging\\nother medical or psychiatric coexisting disorders that could increase the surgical risk or interfere with completion of the trial',\n",
       " 'Ulcers due to non-diabetic etiology.',\n",
       " 'Uncontrolled diabetes defined as HbA1c above 70 mmol/mol and insufficient nutritional status.',\n",
       " 'Ulcers older than 1 year.',\n",
       " 'Any of gangrene, osteomyelitis, cellulitis, or Charcot osteoarthropathy.',\n",
       " '<37 weeks gestation, H/o Cesarean Section, Multiple Gestation, Pre-eclampsia, Narcotics within 3 hours prior to labor epidural placement, Chronic Pain (as defined by chronic opiate consumption), Women who are participating in another study that will impact protocol',\n",
       " 'Renal impairment\\nEvidence or history of clinically significant allergic reactions to varenicline\\nA cardiovascular event in the past month\\nHistory of alcohol or drug dependence in the past year\\nMajor depressive disorder in the last year requiring treatment\\nHistory of panic disorder, psychosis, bipolar disorder, or eating disorders\\nUse of tobacco products other than cigarettes in past 30 days\\nUse of pharmacotherapy in the month prior to enrollment, including prior use of varenicline\\nPregnant, contemplating getting pregnant, or breastfeeding\\nPlans to move from Kansas City during the treatment and follow-up phase\\nAnother household member enrolled in the study\\nEvidence of current severe major depressive disorder or suicidal ideation',\n",
       " 'Subjects with cognitive, psychiatric, or other problems that preclude informed consent.',\n",
       " 'Patients with history of glucose intolerance or diabetes.',\n",
       " 'Patient on chemotherapy \\nPeople with any open or bleeding wounds at any sensor plate contact surface location \\nPeople with any type of implantable device \\nPeople with missing hand(s) and/or leg(s) \\nPregnant women or women who are uncertain about a possible pregnancy \\nPatients sensitive to chemicals used to induce sweating \\nPatients with heat intolerance \\nPatients with bleeding disorders \\nPatients on current anticoagulant therapy \\nPatients with keloids on the intended biopsy site \\nPeople with hypersensitivity to local amide-type anesthetics',\n",
       " 'Inability to provide an informed consent\\nEvidence of oral distant metastasis or other malignancies\\nThe patient has received prior surgery for primary tumor or lymph node ( except for biopsy )\\nPrior radiotherapy for primary tumor\\nThe patient has previously received anti-tumor biological targeted therapy\\nThe patient has received chemotherapy or immunotherapy for primary tumors\\nPrior malignancy within the previous 5 years (except for cured skin basal cell carcinoma or cervical carcinoma in situ)\\nWith 3-4 grad Allergy to any drug in the treatment\\nPeripheral neuropathy> 1 grade\\nAny unstable systematic disease (including active infection, uncontrolled high blood pressure, unstable angina, onset of angina within the last 3 months, congestive heart failure, myocardial infarction within the previous 12 months, severe arrhythmia needing drug treatment, liver, kidney or metabolic disease)\\nHIV positive\\nChronic diseases requiring immune agents or hormone therapy\\nPregnant or lactating women\\nDrug/alcohol abuse, psychological or spiritual illness that may interfere compliance to the study\\nPatients with epilepsy requiring medications (such as steroids or antiepileptic drugs)\\nThe patient has participated in other experimental therapy studies within 30 days\\nResearchers believe that the situation is unsuitable for participation in the group',\n",
       " 'a history of non-standard treatment(chemotherapy or surgery)\\nsecondary osteosarcoma or well-differentiated parosteal osteosarcoma\\nevident dysfunction of cardia,liver and kidney, or pregnant women or women during lactation',\n",
       " 'Died before TAVI\\nNot willing to participate',\n",
       " 'asthma and COPD',\n",
       " 'General danger signs or symptoms of severe malaria\\nAnaemia, defined as Hb <9g/dl\\nG6PD deficiency (as determined by FST)\\nPregnant women as determined by Urine Ã\\x9f-HCG pregnancy test\\nKnown hypersensitivity to any of the drugs given',\n",
       " 'Women who are pregnant or breastfeeding (pregnancy defined as the state of a female after conception until the termination of gestation, confirmed by a positive human chorionic gonadotropin laboratory test (> 5mIU/mL)\\nWomen of child bearing potential must be practicing effective contraception implemented during the trial and for at least 28 days following the last dose of study medication\\nTromboembolic event (CVA or transient ischemic attack, AMI) less than 3 months prior to the intravitreal injection of bevacizumab\\nHistory of hypersensitivity for bevacizumab.',\n",
       " \"History of prostate, bladder, or rectal cancer \\nHistory of transurethral resection of the prostate (TURP), open prostate surgery, or radiofrequency or microwave therapies \\nHistory of open bladder, rectosigmoid colon, or other pelvic surgery \\nPatient is unwilling to discontinue alpha blockers 1 month after study treatment \\nPatient is unwilling to discontinue 5-alph reductase inhibitors 1 month after study treatment \\nNeurogenic bladder or other neurologic disorder impacting bladder function such as Parkinson's disease, multiple sclerosis, cerebral vascular accident or diabetes \\nAny other confounding bladder or urethral pathology, including urethral stricture, bladder neck contracture, or bladder atonia \\nActive prostatitis or urinary tract infection \\nCystolithiasis within the past 3 months \\nSerum creatinine > 1.7mg/dL \\nInability to discontinue oral anticoagulant 2-5 days prior to study treatment \\nCoagulation disturbances not normalized by medical treatment \\nIodinated contrast allergy that, in the opinion of the Investigator, cannot be adequately premedicated \\nGelatin allergy \\nKnown severe peripheral vascular disease or major iliac arterial occlusive disease \\nInterest in future fertility \\nClinically significant cardiac arrhythmia or other cardiac disease (including congestive heart failure), uncontrolled diabetes mellitus, clinically significant respiratory disease, or known immunosuppression \\nOther condition that the Investigator believes puts the patient at risk for a complication during the procedure\",\n",
       " 'Inadequate bone marrow reserve \\nhistory of poorly controlled hypertension',\n",
       " 'Moderate or severe endometriosis.',\n",
       " 'Hydrosalpinx.',\n",
       " 'Uterine abnormalities.',\n",
       " 'Myoma.',\n",
       " 'Previous uterine surgery.',\n",
       " 'HIV infection at screening\\nparticipation in previous or concurrent HIV vaccine trials\\nlactating, pregnant or planning pregnancy\\nrenal function impairment (serum creatinine >1.5 mg/dl), Fanconi syndrome\\nabnormal liver function tests (AST/ALT > 43 U/L), liver disease, viral hepatitis, hepatitis B virus (HBV) infection\\nserum phosphorus <2.2mg/dl, osteoporosis\\nknown sensitivity to components of the TruvadaÂ® formulation\\nany immunosuppressive treatment, such as systemic corticosteroids\\nassumption of medication that interacts with TruvadaÂ®\\nhigh likelihood of poor adherence to PREP and clinic attendance\\nany condition that in the opinion of the attending physician could endanger the health of the participant or render her unsuitable to participate in the trial',\n",
       " 'Subjects with hypersensitivity reaction to Statin and Ezetimibe\\nSubjects with severe kidney disease\\nSubjects with HIV positive result at the screening\\nPregnant or breast-feeding subjects\\nSubjects with taking any medication affecting level of LDL (Fenofibrate, Omega 3 fatty aicd etc.)',\n",
       " 'Insulin-treated Subjects\\nOther exclusions applied',\n",
       " 'younger than 18 years old\\nHBsAg positive or HBcAb negative or hepatitis B virus DNA positive at baseline\\npregnant or lactating women',\n",
       " \"Legally incompetent or mentally impaired (e.g., minors, Alzheimer's subjects, dementia, etc.)\",\n",
       " 'Younger than 18 years of age\\nAny patient considered a vulnerable subject\\nHave bleeding or clotting disorder\\nPreoperative anticoagulation therapy\\nAbnormal coagulation profile\\nRenal disorder or insufficiency\\nSickle cell disease',\n",
       " 'Intracranial infection.',\n",
       " 'Severe respiratory and circulatory system diseases.',\n",
       " 'Hematologic malignancies.',\n",
       " 'Positive serological tests such as AIDS, hepatitis B virus, hepatitis C virus and syphilis ï¼\\x88antigen or antibodyï¼\\x89.',\n",
       " 'Tumors.',\n",
       " 'Genetic and metabolic diseases.',\n",
       " 'Known or suspected allergy to trial product(s) or related products \\nSubjects who are unlikely to comply with protocol requirements, e.g.',\n",
       " 'uncooperative attitude, inability to return for the final visit \\nSubjects who previously enrolled in this study \\nFemales of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods \\nThe receipt of any investigational product within 3 months prior to this trial',\n",
       " '1.',\n",
       " 'The subject is a pregnant or lactating female.',\n",
       " '2.',\n",
       " 'The subject has pre-existing sustained supine hypertension greater than 180mmHg systolic and 110mmHg diastolic BP or had these measurements at the Screening Visit.',\n",
       " 'Sustained is defined as persistently greater at 2 separate measurements at least 5 minutes apart with the subject supine and at rest for the 5 minutes.',\n",
       " '3.',\n",
       " 'Subjects taking concomitant medications of interest are excluded unless those medications are reviewed and discussed with the Medical Monitor or Study Physician and documented prior to enrolling the subject.',\n",
       " 'If agreement is reached between the Investigator and Sponsor for the subject to continue in the study, all allowed medications should be maintained at a constant dose throughout the study.',\n",
       " '4.',\n",
       " 'The Principal Investigator deems any clinical laboratory test (at the Screening Visit) abnormality to be clinically significant \\n5.',\n",
       " 'The subject has participated in other studies of investigational drugs or devices within 30 days prior to enrollment in this study (other than Study SPD426-406).',\n",
       " '6.',\n",
       " 'Current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully comply with the requirements of the study or complete the study, or any condition that presents undue risk from the investigational product or study procedures.',\n",
       " '7.',\n",
       " 'The subject has a concurrent chronic or acute illness, disability, or other condition (including significant unexpected laboratory or electrocardiogram [ECG] findings) that might confound the results of the tests and/or measurements administered in this study, or that might have increased the risk to the subject.',\n",
       " '8.',\n",
       " 'Known or suspected intolerance or hypersensitivity to the investigational product(s), closely-related compounds, or any of the stated ingredients.',\n",
       " '9.',\n",
       " 'Prior enrollment failure or randomization in this study.',\n",
       " '10.',\n",
       " 'History of alcohol abuse or other substance abuse within the last year.',\n",
       " 'Taking other drugs which can influence the lipid profile (eg.',\n",
       " 'Niacin, Fibrates;\\nSerum creatinine level > 2.0 mg/dL\\nSerum aspartate transaminase > 3 times upper limit of normal\\nSerum alanine transaminase > 3 times upper limit of normal\\nHaving anaphylactic reaction for Rosuvastatin;\\nHaving the other contraindications for Rosuvastatin;\\nHaving plan to be pregnant;\\nHaving life expectancy less than 1 year',\n",
       " 'Lack of understanding of the study\\ncontra-indication to nicotine replacement therapy\\nhealth status incompatible with detention in police cells\\nserious mental disorder\\nusual place of residence outside Seine-Saint-Denis',\n",
       " 'unstable condition, COPD exacerbation\\nmild (GOLD 1) or very severe COPD (GOLD 4)\\nrequirement for oxygen therapy at low altitude residence\\nhypoventilation\\npulmonary hypertension\\nmore than mild or unstable cardiovascular disease\\nuse of drugs that affect respiratory center drive\\ninternal, neurologic or psychiatric disease that interfere with protocol compliance including current heavy smoking (>20 cigarettes per day), inability to perform 6 min walk test.',\n",
       " 'previous intolerance to moderate altitude (<2600m).',\n",
       " 'exposure to altitudes >1500m for >2 days within the last 4 weeks before the study.',\n",
       " 'pregnant or nursing patients',\n",
       " 'Patient with a chronic pain condition, major unexpected surgical complication, unexpected prolonged intubation, patient refusal, local anesthetic allergy, any contraindication to regional anesthesia, greater than 2 attempts by resident and greater than 1 attempt by staff anesthesiologist for TAP block.',\n",
       " 'History of recurrent UTI (defined as three culture proven UTIs within last 12 months)\\nSystemic neuromuscular disease known to affect the lower urinary tract\\nUndergoing concomitant prolapse surgery\\nPrevious incontinence surgery\\nTreatment with anticholinergic medication in the last 2 months\\nPrevious bladder injection with onabotulinumtoxinA\\nPrisoner Status\\nPregnancy',\n",
       " 'Hemodynamically unstable in need of acute treatment \\nMost recent hCG > 5000 mIU/mL \\nPatient obtaining care in relation to a recently completed pregnancy (delivery, spontaneous or elective abortion) \\nDiagnosis of gestational trophoblastic disease \\nSubject unwilling or unable to comply with study procedures \\nKnown hypersensitivity to MTX \\nPresence of clinical contraindications for treatment with MTX \\nPrior medical or surgical management of this gestation \\nSubject unwilling to accept a blood transfusion',\n",
       " 'Unable or unwilling to provide informed consent.',\n",
       " 'Active ischemia (acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on ECG) or another reversible cause of VT (e.g.',\n",
       " 'drug-induced arrhythmia), had recent acute coronary syndrome within 30 days, coronary revascularization (<90 days bypass surgery, <30 days percutaneous coronary intervention), or have CCS functional class IV angina.',\n",
       " 'Note that biomarker level elevation alone after ventricular arrhythmias does not denote acute coronary syndrome or active ischemia.',\n",
       " 'Are ineligible to take the antiarrhythmic drug to which they would be assigned due to allergy, intolerance or contraindication\\nAre known to have protruding left ventricular thrombus or mechanical aortic and mitral valves\\nHave had a prior catheter ablation procedure for VT\\nAre in renal failure (Creatinine clearance <15 mL/min), have NYHA Functional class IV heart failure, or a systemic illness likely to limit survival to <1 year\\nHave had recent ST elevation myocardial infarction or non-ST elevation MI (< 30 days); note that biomarker elevation alone after ventricular arrhythmias does not denote MI.',\n",
       " 'Are pregnant.',\n",
       " 'Having experienced severe allergies, trauma history and/or operation history within 3 months; \\nWith a history of mental illness and/or family history of mental illness; \\nLimb disabled; \\nTaking medicine within one month; \\nSuffering major events or having mood swings.',\n",
       " 'Pregnancy\\nKnown hypersensitivity to study drug (ferric carboxymaltose or equivalent) or its excipients\\nKnown or suspected haemoglobinopathy/thalassaemia\\nBone marrow disease\\nHaemochromatosis\\nRenal dialysis\\nErythropoietin or IV iron in the previous 4 weeks',\n",
       " 'NA',\n",
       " 'NA',\n",
       " 'NA',\n",
       " 'Use of investigational drugs either within 5 half-lives of enrollment, or within 30 days, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer.',\n",
       " 'Major surgery in the last 3 months prior to baseline or planned major surgery or cardiac intervention during the study.',\n",
       " \"Cancer or other significant co-morbidities implying that the patient's condition is unstable.\",\n",
       " 'Comorbidities that can be associated with elevated natriuretic peptide (NP) levels: renal insufficiency, (eGFR < 25 ml/min/1.73 mÂ² calculated according to MDRD formula), recent (less than 3 months) cerebral trauma or recent (less than 3 months) cerebrovascular incident, novel diagnosis or acute exacerbation of COPD within the last 3 months.',\n",
       " 'Patients who are primarily managed and regularly followed-up by a cardiologist for their HF\\nHighly frail patients whose estimated lifespan due to comorbidities by the judgement of the investigator is less than 6 months.',\n",
       " 'Patients are not expected to be alive for longer than 3 months.',\n",
       " 'Mini-mental State Examination (MMSE) [18] score = 23.\\nhistory of dementia, psychiatric illness or any diseases of central nervous system.',\n",
       " 'current use of sedatives or antidepressant.',\n",
       " 'alcoholism and drug dependence.',\n",
       " 'patients previously included in this study (for patients who have second intra-abdominal surgery during the study period).',\n",
       " 'difficult to follow up or patients with poor compliance.',\n",
       " 'uncontrolled hypertension (> 180/100 mmHg)',\n",
       " 'DSM-IV-TR substance-related disorders (except nicotine)\\nsignificant medical or neurological conditions\\nmental retardation or organic brain damage',\n",
       " 'Immunosuppresant host\\nChronic cardiovascular/pulmonary disease\\nHospital acquired infection',\n",
       " 'Anaphylactic reaction to a previous dose of influenza vaccine or to any of its components\\nKnown Immunoglobulin E (IgE)-mediated hypersensitivity to eggs manifested as hives, swelling of the mouth and throat, difficulty in breathing, hypotension, or shock\\nGuillain- BarrÃ© syndrome within eight weeks of a previous influenza vaccine\\nUse of aspirin or salicylate- containing products within 30 days before enrollment\\nHousehold members of children in Group A',\n",
       " 'American Association of Anesthesiology class 1-3\\nAmerican Heart Association class >3\\nBMI >37\\nInsulin treated diabetes\\nPregnancy or breast feeding\\nSensistivity/allergy against anesthetic agents\\nInadequate understanding about the study\\nDepressed kidney function and/or AKI\\nDepressed liver function\\nGenetic malignant hyperthermia',\n",
       " 'Has other dermatological conditions that may interfere with clinical assessments\\nAllergy or sensitivity to corticosteroids or any drug hypersensitivity or intolerance that would compromise patient safety or study results\\nHistory of an adverse reaction to Cortrosynâ\\x84¢ or similar test reagents\\nChronic infectious disease, system or organ disorder or other medical condition that would place patient at undue risk by study participation',\n",
       " 'NA',\n",
       " 'Congestive heart failure, history of ventricular tachycardia, ventricular fibrillation or multifocal ventricular extrasystoles or QTc prolongation.',\n",
       " 'Patients with atrial fibrillation taking any anticoagulant therapy or patients with a history of cardioembolic ischemic stroke or hemorrhagic stroke.',\n",
       " 'Patients with a history (= 12 months) of acute coronary syndrome receiving dual antiplatelet therapy, or patients receiving monotherapy with aspirin.',\n",
       " 'Patients with hepatic impairment (child-Pugh staging, calibration = 5) or renal impairment (creatinine clearance = 30ml / min), recent peptic ulcer, a history of hypersensitivity to cilostazol, cancer patients undergoing treatment.',\n",
       " ...]"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "exc_data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "3773"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(exc_data)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### write them to one big txt file for creating annotations"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### inclusion_data "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "with open(\"inclusion_data.txt\", \"w\", encoding=\"unicode_escape\") as f:\n",
    "    for each_sentence in inc_data:\n",
    "    #     f.write(each_sentence)\n",
    "        f.writelines(each_sentence)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### exclusion_data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [],
   "source": [
    "with open(\"exclusion_data.txt\", \"w\", encoding=\"unicode_escape\") as f:\n",
    "    for each_sentence in exc_data:\n",
    "    #     f.write(each_sentence)\n",
    "        f.writelines(each_sentence)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Step 2: Create annotation data using Markup tool for NER model training"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "# custom ner training"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "                 "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Installing Spacy"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "import spacy\n",
    "import collections\n",
    "from collections import Counter"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Check the spaCy Version"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[1m\r\n",
      "============================== Info about spaCy ==============================\u001b[0m\r\n",
      "\r\n",
      "spaCy version    3.2.1                         \r\n",
      "Location         /home/sobha/anaconda3/lib/python3.7/site-packages/spacy\r\n",
      "Platform         Linux-5.11.0-43-generic-x86_64-with-debian-bullseye-sid\r\n",
      "Python version   3.7.6                         \r\n",
      "Pipelines        en_core_web_sm (3.2.0)        \r\n",
      "\r\n"
     ]
    }
   ],
   "source": [
    "!python -m spacy info"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Followed the below tutorial link\n",
    "### Steps to build the custom NER model for detecting the job role in job postings in spaCy 3.0:"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### https://turbolab.in/build-a-custom-ner-model-using-spacy-3-0/\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "\n",
    "### Load a spaCy model and check if it has ner pipeline"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "# !python -m spacy download en_core_web_sm\n",
    "\n",
    "import spacy "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['tok2vec', 'tagger', 'parser', 'attribute_ruler', 'lemmatizer', 'ner']"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "nlp = spacy.load('en_core_web_sm')\n",
    "nlp.pipe_names"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Daniil Medvedev\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #aa9cfc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Novak Djokovic\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">PERSON</span>\n",
       "</mark>\n",
       " have built an intriguing rivalry since the \n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Australian\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       " Open decider, which the \n",
       "<mark class=\"entity\" style=\"background: #c887fb; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Serb\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">NORP</span>\n",
       "</mark>\n",
       " won comprehensively.</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "sentence = 'Daniil Medvedev and Novak Djokovic have built an intriguing rivalry since the Australian Open decider, which the Serb won comprehensively.'\n",
    "doc = nlp(sentence)\n",
    "\n",
    "from spacy import displacy\n",
    "displacy.render(doc, style='ent', jupyter=True)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[(Daniil, 'B', 'PERSON'),\n",
       " (Medvedev, 'I', 'PERSON'),\n",
       " (Novak, 'B', 'PERSON'),\n",
       " (Djokovic, 'I', 'PERSON'),\n",
       " (Australian, 'B', 'NORP'),\n",
       " (Serb, 'B', 'NORP')]"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "[(X, X.ent_iob_, X.ent_type_) for X in doc if X.ent_type_]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Used SpaCy NER annotation tool by agateteam- http://agateteam.org/spacynerannotate/ to annotate and got the text below which i asssigned to \"trainData\" ( also for future rerference saved the annotated data to file named spacyannotation.json)\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "###              Numeric   Nominal   Ordinal  Sentence/Sentiment                      - Entities"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "trainData= [(\"Aged 22 and older, undergoing 1 or 2 level spinal decompression\",{\"entities\":[(0,18,\"Numeric\"),(19,63,\"Ordinal\")]}),\n",
    "(\"Age 50 or over Diagnosed Giant Cell Arthritis Headache, jaw pain, vision loss Shoulder and/or hip pain\",{\"entities\":[(0,15,\"Numeric\"),(25,46,\"Nominal\"),(46,102,\"Ordinal\")]}),\n",
    "(\"Aged between 50-80.Have been diagnosed with Polymyalgia Rheumatica (PMR).Have experienced improvement in PMR symptoms with Prednisone.\",{\"entities\":[(0,18,\"Numeric\"),(44,72,\"Nominal\"),(73,134,\"Ordinal\")]}),\n",
    "(\"Aged 18 years or older Diagnosis of Ankylosing Spondylitis or Axial Spondyloarthritis\",{\"entities\":[(0,23,\"Numeric\"),(36,85,\"Nominal\")]}),\n",
    "(\"Aged over 18 years Confirmed diagnosis of bronchiectasis within 5 years Pulmonary exacerbation requiring antibiotics in the past 12 months\",{\"entities\":[(0,18,\"Numeric\"),(42,56,\"Nominal\"),(72,138,\"Ordinal\")]}),\n",
    "(\"Aged between 40 and 85 years Diagnosed with COPD A history of cardiovascular disease, including heart failure, ischaemic heart disease, tachyarrhythmias, and hypertension\",{\"entities\":[(0,29,\"Numeric\"),(44,48,\"Nominal\"),(49,170,\"Ordinal\")]}),\n",
    "(\"Aged 18-85, diagnosed non-cystic fibrosis bronchiectasis, two or more exacerbations in the past 12 months.\",{\"entities\":[(0,10,\"Numeric\"),(22,56,\"Nominal\"),(58,106,\"Ordinal\")]}),\n",
    "(\"Aged 18 or older, diagnosis of IgAN, on a stable dose of an ACE inhibitor or ARB / unable to tolerate this therapy.\",{\"entities\":[(0,16,\"Numeric\"),(31,35,\"Nominal\"),(37,115,\"Ordinal\")]}),\n",
    "(\"Aged 18 years or older, hypertensive, no more than 3 current blood-pressure lowering medications.\",{\"entities\":[(0,23,\"Numeric\"),(24,36,\"Nominal\"),(38,97,\"Ordinal\")]}),\n",
    "(\" 18 years of age, undergoing a surgical procedure resulting in a closed approximately linear incision\",{\"entities\":[(1,16,\"Numeric\"),(17,100,\"Ordinal\")]}),\n",
    "(\"Are 18-50 years of age. Have a current/recent skin infection.No ongoing illness or history of serious chronic/progressive disease.\",{\"entities\":[(0,22,\"Numeric\"),(61,130,\"Ordinal\"),(24,60,\"Nominal\")]}),\n",
    "(\"Healthy woman aged between 18 and 49 years of age Pregnant with no known increased risk for complications Singleton pregnancy\",{\"entities\":[(14,49,\"Numeric\"),(50,125,\"Ordinal\")]}),\n",
    "(\"Aged between 5 - 14 years Newly diagnosed with Acute rheumatic fever\",{\"entities\":[(0,25,\"Numeric\"),(47,68,\"Nominal\")]}),\n",
    "(\"Viral respiratory disease Acute presentation to Middlemore Emergency Department or Intensive care unit\",{\"entities\":[(26,102,\"Ordinal\"),(0,26,\"Nominal\")]}),\n",
    "(\"Age>=18 Diagnosis of Essential Thrombocythemia Failure of standard therapy, e.g. Hydroxyurea\",{\"entities\":[(0,7,\"Numeric\"),(31,46,\"Nominal\"),(47,92,\"Ordinal\")]}),\n",
    "(\"Age >= 18 Diagnosed with Relapsed or Refractory Multiple Myeloma.\",{\"entities\":[(0,10,\"Numeric\"),(25,65,\"Nominal\")]}),\n",
    "(\"Age >= 18 Diagnosed with Myelodysplastic Syndrome (MDS)Anemia\",{\"entities\":[(0,9,\"Numeric\"),(25,61,\"Nominal\")]}),\n",
    "(\"age >= 18 Newly diagnosed multiple myeloma Ineligible for autologous stem cell transplant No prior treatment for multiple myeloma except localised radiotherapy or a short course of steroids\",{\"entities\":[(0,9,\"Numeric\"),(26,43,\"Nominal\"),(43,189,\"Ordinal\")]}),\n",
    "(\"Age>=18 Diagnosed with Relapsed or Refractory Multiple Myeloma No long-term use of Prednisone\",{\"entities\":[(0,7,\"Numeric\"),(23,63,\"Nominal\")]}),\n",
    "(\"Aged 18 to 65 Chronic Hepatitis B infection On stable NUC treatment (e.g Entecavir orTenofovir)\",{\"entities\":[(0,13,\"Numeric\"),(13,43,\"Nominal\"),(44,95,\"Ordinal\")]}),\n",
    "(\"Age less than 65 years, have diagnosed ulcerative colitis and experiencing increase in daily stool frequency and/or rectal bleeding, no allergy to antibiotic vancomycin, willing to undergo two colonoscopy procedures as part of the study (3 months apart)\",{\"entities\":[(0,22,\"Numeric\"),(39,57,\"Nominal\"),(170,253,\"Ordinal\")]}),\n",
    "(\"Aged between 18-70 years old Diagnosis of Non-alcoholic Fatty Liver Disease Have a BMI between 25 to 50 kg/m2\",{\"entities\":[(0,29,\"Numeric\"),(42,75,\"Nominal\"),(83,109,\"Numeric\")]}),\n",
    "(\"Male or postmenopausal female, aged 18-80 years old, diagnosed Nonalcoholic Steatohepatitis, no other chronic liver disease\",{\"entities\":[(31,91,\"Nominal\")]}),\n",
    "(\"Type 1 Myocardial infarction Have at least two coronary artery territories of disease > 50% Be on treatment for Diabetes\",{\"entities\":[(0,28,\"Nominal\"),(92,120,\"Ordinal\"),(29,91,\"Ordinal\")]}),\n",
    "(\"Aged 20 or older, myocardial ischemia, able to undergo PTCA, stenting and CABG,recent travel history, able to speak English\",{\"entities\":[(0,16,\"Numeric\"),(18,37,\"Nominal\"),(39,78,\"Ordinal\"),(79,123,\"Sentence/Sentiment\")]})\n",
    "]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {},
   "outputs": [],
   "source": [
    "trainData=[\n",
    "(\"Aged 22 and older, undergoing 1 or 2 level spinal decompression\",{\"entities\":[(0,18,\"Numeric\"),(19,63,\"Ordinal\")]}),\n",
    "(\"Age 50 or over Diagnosed Giant Cell Arthritis Headache, jaw pain, vision loss Shoulder and/or hip pain\",{\"entities\":[(0,15,\"Numeric\"),(25,46,\"Nominal\"),(46,102,\"Ordinal\")]}),\n",
    "(\"Aged between 50-80.Have been diagnosed with Polymyalgia Rheumatica (PMR).Have experienced improvement in PMR symptoms with Prednisone.\",{\"entities\":[(0,18,\"Numeric\"),(44,72,\"Nominal\"),(73,134,\"Ordinal\")]}),\n",
    "(\"Aged 18 years or older Diagnosis of Ankylosing Spondylitis or Axial Spondyloarthritis\",{\"entities\":[(0,23,\"Numeric\"),(36,85,\"Nominal\")]}),\n",
    "(\"Aged over 18 years Confirmed diagnosis of bronchiectasis within 5 years Pulmonary exacerbation requiring antibiotics in the past 12 months\",{\"entities\":[(0,18,\"Numeric\"),(42,56,\"Nominal\"),(72,138,\"Ordinal\")]}),\n",
    "(\"Aged between 40 and 85 years Diagnosed with COPD A history of cardiovascular disease, including heart failure, ischaemic heart disease, tachyarrhythmias, and hypertension\",{\"entities\":[(0,29,\"Numeric\"),(44,48,\"Nominal\"),(49,170,\"Ordinal\")]}),\n",
    "(\"Aged 18-85, diagnosed non-cystic fibrosis bronchiectasis, two or more exacerbations in the past 12 months.\",{\"entities\":[(0,10,\"Numeric\"),(22,56,\"Nominal\"),(58,106,\"Ordinal\")]}),\n",
    "(\"Aged 18 or older, diagnosis of IgAN, on a stable dose of an ACE inhibitor or ARB / unable to tolerate this therapy.\",{\"entities\":[(0,16,\"Numeric\"),(31,35,\"Nominal\"),(37,115,\"Ordinal\")]}),\n",
    "(\"Aged 18 years or older, hypertensive, no more than 3 current blood-pressure lowering medications.\",{\"entities\":[(0,23,\"Numeric\"),(24,36,\"Nominal\"),(38,97,\"Ordinal\")]}),\n",
    "(\" 18 years of age, undergoing a surgical procedure resulting in a closed approximately linear incision\",{\"entities\":[(1,16,\"Numeric\"),(17,100,\"Ordinal\")]}),\n",
    "(\"Are 18-50 years of age. Have a current/recent skin infection.No ongoing illness or history of serious chronic/progressive disease.\",{\"entities\":[(0,22,\"Numeric\"),(61,130,\"Ordinal\"),(24,60,\"Nominal\")]}),\n",
    "(\"Healthy woman aged between 18 and 49 years of age Pregnant with no known increased risk for complications Singleton pregnancy\",{\"entities\":[(14,49,\"Numeric\"),(50,125,\"Ordinal\")]}),\n",
    "(\"Aged between 5 - 14 years Newly diagnosed with Acute rheumatic fever\",{\"entities\":[(0,25,\"Numeric\"),(47,68,\"Nominal\")]}),\n",
    "(\"Viral respiratory disease Acute presentation to Middlemore Emergency Department or Intensive care unit\",{\"entities\":[(26,102,\"Ordinal\"),(0,26,\"Nominal\")]}),\n",
    "(\"Age>=18 Diagnosis of Essential Thrombocythemia Failure of standard therapy, e.g. Hydroxyurea\",{\"entities\":[(0,7,\"Numeric\"),(31,46,\"Nominal\"),(47,92,\"Ordinal\")]}),\n",
    "(\"Age >= 18 Diagnosed with Relapsed or Refractory Multiple Myeloma.\",{\"entities\":[(0,10,\"Numeric\"),(25,65,\"Nominal\")]}),\n",
    "(\"Age >= 18 Diagnosed with Myelodysplastic Syndrome (MDS)Anemia\",{\"entities\":[(0,9,\"Numeric\"),(25,61,\"Nominal\")]}),\n",
    "(\"age >= 18 Newly diagnosed multiple myeloma Ineligible for autologous stem cell transplant No prior treatment for multiple myeloma except localised radiotherapy or a short course of steroids\",{\"entities\":[(0,9,\"Numeric\"),(26,43,\"Nominal\"),(43,189,\"Ordinal\")]}),\n",
    "(\"Age>=18 Diagnosed with Relapsed or Refractory Multiple Myeloma No long-term use of Prednisone\",{\"entities\":[(0,7,\"Numeric\"),(23,63,\"Nominal\")]}),\n",
    "(\"Aged 18 to 65 Chronic Hepatitis B infection On stable NUC treatment (e.g Entecavir orTenofovir)\",{\"entities\":[(0,13,\"Numeric\"),(13,43,\"Nominal\"),(44,95,\"Ordinal\")]}),\n",
    "(\"Age less than 65 years, have diagnosed ulcerative colitis and experiencing increase in daily stool frequency and/or rectal bleeding, no allergy to antibiotic vancomycin, willing to undergo two colonoscopy procedures as part of the study (3 months apart)\",{\"entities\":[(0,22,\"Numeric\"),(39,57,\"Nominal\"),(170,253,\"Ordinal\")]}),\n",
    "(\"Aged between 18-70 years old Diagnosis of Non-alcoholic Fatty Liver Disease Have a BMI between 25 to 50 kg/m2\",{\"entities\":[(0,29,\"Numeric\"),(42,75,\"Nominal\"),(83,109,\"Numeric\")]}),\n",
    "(\"Male or postmenopausal female, aged 18-80 years old, diagnosed Nonalcoholic Steatohepatitis, no other chronic liver disease\",{\"entities\":[(31,91,\"Nominal\")]}),\n",
    "(\"Type 1 Myocardial infarction Have at least two coronary artery territories of disease > 50% Be on treatment for Diabetes\",{\"entities\":[(0,28,\"Nominal\"),(92,120,\"Ordinal\"),(29,91,\"Ordinal\")]}),\n",
    "(\"Aged 20 or older, myocardial ischemia, able to undergo PTCA, stenting and CABG,recent travel history, able to speak English\",{\"entities\":[(0,16,\"Numeric\"),(18,37,\"Nominal\"),(39,78,\"Ordinal\"),(79,123,\"Sentence/Sentiment\")]}),\n",
    "(\"Patients with biopsy-proven metastatic carcinoid tumors or other neuroendocrine tumors (Islet cell, Gastrinomas and VIPomas) with at least one measurable lesion (other than bone) that has either not been previously irradiated or if previously irradiated has demonstrated progression since the radiation therapy \",{\"entities\":[(14,20,\"Nominal\"),(28,55,\"Nominal\"),(65,87,\"Nominal\"),(87,124,\"Nominal\"),(133,161,\"Ordinal\"),(179,310,\"Sentence/Sentiment\")]}),\n",
    "(\"Female patients must have a negative serum pregnancy test at screening. (Not applicable to patients with bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal.) \",{\"entities\":[(37,52,\"Nominal\"),(73,99,\"Sentence/Sentiment\"),(105,127,\"Nominal\"),(135,147,\"Nominal\"),(177,191,\"Nominal\")]}),\n",
    "(\"Karnofsky Performance Status > 60 \",{\"entities\":[(0,33,\"Ordinal\")]}),\n",
    "(\"Must have a life expectancy of greater than three (3) months \",{\"entities\":[(11,60,\"Numeric\")]}),\n",
    "(\"Patients on Sandostatin Lar (long acting somatostatin analogue) must be on a stable dose for 30 days prior to study entry and short acting somatostatin analogues must be judged to be on a clinically stable dose by the investigator prior to study entry \",{\"entities\":[(12,27,\"Nominal\"),(29,62,\"Nominal\"),(63,122,\"Sentence/Sentiment\"),(139,151,\"Nominal\"),(162,251,\"Sentence/Sentiment\")]}),\n",
    "(\"The patient has no major impairment of renal or hepatic function, as defined by the following laboratory parameters: total bilirubin <1.5 X ULN; AST, ALT<2.5X ULN (<5 X ULN if liver metastases are present) \",{\"entities\":[(39,44,\"Nominal\"),(48,64,\"Nominal\"),(117,172,\"Numeric\")]}),\n",
    "(\"Patients with biopsy-proven metastatic carcinoid tumors or other neuroendocrine tumors (Islet cell, Gastrinomas and VIPomas) with at least one measurable lesion (other than bone) that has either not been previously irradiated or if previously irradiated has demonstrated progression since the radiation therapy \",{\"entities\":[(14,20,\"Nominal\"),(28,55,\"Nominal\"),(65,87,\"Nominal\"),(87,124,\"Nominal\"),(133,161,\"Ordinal\"),(179,310,\"Sentence/Sentiment\")]}),\n",
    "(\"ECOG performance status of 0,1, or 2. \",{\"entities\":[(0,37,\"Ordinal\")]}),\n",
    "(\"Must have had a treatment-free interval of greater than 6 months following response to platinum. \",{\"entities\":[(0,96,\"Sentence/Sentiment\")]}),\n",
    "(\"At least 4 weeks since last surgery or radiation therapy. \",{\"entities\":[(0,57,\"Sentence/Sentiment\")]}),\n",
    "(\"Have had one prior platinum-based chemotherapy regimen for the treatment of primary disease. \",{\"entities\":[(19,54,\"Nominal\"),(54,92,\"Sentence/Sentiment\")]}),\n",
    "(\"Have had one prior platinum-based chemotherapy regimen for the treatment of primary disease. \",{\"entities\":[]}),\n",
    "(\"Patients with reproductive capability must agree to practice adequate contraception methods. \",{\"entities\":[(0,92,\"Sentence/Sentiment\")]}),\n",
    "(\"Patient must give written informed consent before participating in any study-specific procedure, randomization, or receiving investigational product. \",{\"entities\":[(0,149,\"Sentence/Sentiment\")]}),\n",
    "(\"Females of childbearing potential: negative serum or urine pregnancy test \",{\"entities\":[(0,49,\"Numeric\"),(72,153,\"Numeric\"),(181,244,\"Numeric\")]}),\n",
    "(\"Serum creatinine less than or equal to 2.0 mg/dL (Note: Patients with a serum creatinine greater than or equal to 1.4 and less than or equal to 2.0 mg/dL must demonstrate a 24-hour urinary creatinine clearance greater than or equal to 50 mL/min) \",{\"entities\":[(0,49,\"Numeric\")]}),\n",
    "(\"Serum bilirubin less than or equal to 1.5 x institutional upper limit of normal (ULN) \",{\"entities\":[(0,85,\"Numeric\")]}),\n",
    "(\"Platelet count greater than or equal to 100 x 10^9/L \",{\"entities\":[(0,52,\"Numeric\")]}),\n",
    "(\"Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L without growth factor use in the 2 weeks before study randomization \",{\"entities\":[(0,70,\"Numeric\"),(103,110,\"Numeric\")]}),\n",
    "(\"Hemoglobin (hgb) greater than or equal to 10 g/dL without transfusional support or growth factor use in the 4 weeks before study randomization \",{\"entities\":[(0,50,\"Numeric\"),(108,115,\"Numeric\")]}),\n",
    "(\"Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2 \",{\"entities\":[(0,69,\"Ordinal\")]}),\n",
    "(\"18 years of age or older \",{\"entities\":[(0,24,\"Numeric\")]}),\n",
    "(\"Measurable disease \",{\"entities\":[(0,18,\"Sentence/Sentiment\")]}),\n",
    "(\"Estimated weight loss less than or equal to 10% in the 3 months before study randomization \",{\"entities\":[(0,47,\"Ordinal\"),(55,64,\"Numeric\")]}),\n",
    "(\"Life expectancy greater than or equal to 6 months \",{\"entities\":[(0,49,\"Numeric\")]}),\n",
    "(\"Initial radiotherapy field of treatment to encompass greater than or equal to 30% of the esophagus \",{\"entities\":[(8,98,\"Ordinal\")]}),\n",
    "(\"Unresectable (locally advanced) stage IIIa or IIIb disease \",{\"entities\":[(32,58,\"Nominal\")]}),\n",
    "(\"Patients with a histologically or cytologically proven diagnosis of NSCLC \",{\"entities\":[(0,67,\"Sentence/Sentiment\"),(68,73,\"Nominal\")]}),\n",
    "(\"Meet DSM-IV criteria for BPD as assessed by the Structured Clinical Interview for DSM-IV Personality Disorders (SCID-II). \",{\"entities\":[(5,20,\"Nominal\"),(25,28,\"Nominal\"),(82,121,\"Nominal\")]}),\n",
    "(\"Be able to speak, read and write English and follow simple instructions for completing self-rated scales \",{\"entities\":[(0,104,\"Sentence/Sentiment\")]}),\n",
    "(\"Be between age 18 and 55 years \",{\"entities\":[(3,30,\"Numeric\")]}),\n",
    "(\"Provide written informed consent before beginning any study related activities \",{\"entities\":[(0,78,\"Sentence/Sentiment\")]}),\n",
    "(\"Stable (8 wks or longer) concurrent medications including benzodiazepines, sedative hypnotics, antipsychotics, and antidepressants.\",{\"entities\":[(0,131,\"Sentence/Sentiment\")]}),\n",
    "(\"Completion of a 14-week open label trial of one the following SRI's: fluoxetine 80 mg/day, paroxetine 60 mg/day, fluvoxamine 300 mg/day, clomipramine 250 mg/day, sertraline 200 mg/day, citalopram 60 mg/day, escitalopram 30 mg/day and demonstrating a non or partial responses to SRI treatment (CGI-I of 3 or 4, Y-BOCS reduction of < 35%) \",{\"entities\":[(69,89,\"Numeric\"),(91,111,\"Numeric\"),(113,135,\"Numeric\"),(137,160,\"Numeric\"),(162,183,\"Numeric\"),(185,205,\"Numeric\"),(207,229,\"Numeric\")]}),\n",
    "(\"Outpatient with primary DSM- IV OCD \",{\"entities\":[(24,35,\"Nominal\")]}),\n",
    "(\"Patients must have a predicted life expectancy of at least 12 weeks. \",{\"entities\":[(30,68,\"Numeric\")]}),\n",
    "(\"Patients must have a Zubrod performance status of 0-2. \",{\"entities\":[(0,53,\"Ordinal\")]}),\n",
    "(\"Patients must have measurable disease. If prior radiation therapy was administered, measurable disease must be outside the radiation field. \",{\"entities\":[(0,37,\"Ordinal\"),(39,82,\"Ordinal\"),(84,138,\"Ordinal\")]}),\n",
    "(\"Patients must agree to have a 20 cc blood sample drawn in addition to routine labs with each cycle of chemotherapy. \",{\"entities\":[(23,115,\"Ordinal\")]}),\n",
    "(\"Tissue from tumor must be available. This may be paraffin embedded tissue from previous biopsy/resection or if it is not available, a repeat biopsy must be performed. The requirement for biopsy may be waived if alpha-fetoprotein is greater than 500 ng/mL and in the investigators opinion not explained by a concurrent hepatic inflammatory process. \",{\"entities\":[(12,18,\"Nominal\"),(211,255,\"Numeric\"),(255,347,\"Sentence/Sentiment\")]}),\n",
    "(\"Unresectable, histologically confirmed hepatocellular carcinoma with evident disease limited to liver. \",{\"entities\":[(0,102,\"Ordinal\")]}),\n",
    "(\"Patients must have adequate hepatic function as documented by a serum bilirubin less than or equal to 2x the institutional upper limit of normal, regardless of whether patients have liver involvement secondary to tumor. Patients may not have ascites or the ascites must be responsive to diuretics. \",{\"entities\":[(14,144,\"Ordinal\"),(177,218,\"Ordinal\")]}),\n",
    "(\"Patients must have adequate renal function as documented by a calculated creatinine clearance 60. \",{\"entities\":[(15,98,\"Ordinal\")]}),\n",
    "(\"Patients must have a pre-treatment granulocyte count (i.e., segmented neutrophils + bands) of greater than or equal to 1,500/mm3, a hemoglobin level of greater than or equal to 9 gm/dl, and platelet count greater than or equal to 50,000/mm3. The granulocyte requirement may be waived if in the investigator's opinion the lower count reflects hypersplenism with adequate bone marrow reserves. \",{\"entities\":[(35,128,\"Numeric\"),(132,184,\"Numeric\"),(190,240,\"Numeric\")]}),\n",
    "(\"Patients must have a predicted life expectancy of at least 12 weeks. \",{\"entities\":[(30,68,\"Numeric\")]}),\n",
    "(\"Patients must have a Zubrod performance status of 0-2. \",{\"entities\":[(0,53,\"Ordinal\")]}),\n",
    "(\"Patients must have measurable disease. If prior radiation therapy was administered, measurable disease must be outside the radiation field. \",{\"entities\":[(0,37,\"Ordinal\"),(39,82,\"Ordinal\"),(84,138,\"Ordinal\")]}),\n",
    "(\"Patients must agree to have a 20 cc blood sample drawn in addition to routine labs with each cycle of chemotherapy. \",{\"entities\":[(23,115,\"Ordinal\")]}),\n",
    "(\"Tissue from tumor must be available. This may be paraffin embedded tissue from previous biopsy/resection or if it is not available, a repeat biopsy must be performed. The requirement for biopsy may be waived if alpha-fetoprotein is greater than 500 ng/mL and in the investigators opinion not explained by a concurrent hepatic inflammatory process. \",{\"entities\":[(12,18,\"Nominal\"),(211,255,\"Numeric\"),(255,347,\"Sentence/Sentiment\")]}),\n",
    "(\"Unresectable, histologically confirmed hepatocellular carcinoma with evident disease limited to liver. \",{\"entities\":[(0,102,\"Ordinal\")]}),\n",
    "(\"8. Left ventricular ejection fraction should be at least 30%. \",{\"entities\":[(3,61,\"Ordinal\")]}),\n",
    "(\"7. Significant stenosis has been defined as a stenosis of more than 50% in luminal diameter (in at least one view, on visual interpretation or preferably by QCA); \",{\"entities\":[(15,23,\"Nominal\"),(24,161,\"Ordinal\")]}),\n",
    "(\"6. Total occluded vessels. One total occluded major epicardial vessel or side branch can be included and targeted as long as one other major vessel has a significant stenosis amenable for SA, provided the age of occlusion is less than one month e.g. recent instability, infarction with ECG changes in the area subtended by the occluded vessel. Patients with total occluded vessels of unknown duration or existing longer than one month and a reference over 1.50 mm should not be included, not even as a third or fourth vessel to be dilated; \",{\"entities\":[(0,24,\"Nominal\"),(26,42,\"Nominal\"),(47,67,\"Nominal\"),(94,257,\"Ordinal\"),(259,313,\"Ordinal\")]}),\n",
    "(\"5. Multivessel disease with at least one significant stenosis in LAD and with treatment of the lesion in another major epicardial coronary artery. A two-vessel disease or a three-vessel disease may be viewed as a combination of a side branch and a main epicardial vessel provided they supply different territories; left anterior descending, left circumflex and right coronary artery); \",{\"entities\":[(3,69,\"Ordinal\"),(73,145,\"Ordinal\"),(147,313,\"Ordinal\")]}),\n",
    "(\"4. de novo native vessels; \",{\"entities\":[(0,22,\"Ordinal\")]}),\n",
    "(\"3. At least 2 lesions (located in different vessels and in different territories) potentially amenable to stent implantation; \",{\"entities\":[(81,124,\"Ordinal\"),(3,80,\"Ordinal\")]}),\n",
    "(\"2. Patients who are eligible for coronary revascularization (angioplasty or CABG); \",{\"entities\":[(0,78,\"Ordinal\")]}),\n",
    "(\"Patients with stable (Canadian Cardiovascular Society 1, 2, 3 or 4) or unstable (Braunwald class IB, IC, IIB, IIC, IIIB, IIIC) angina pectoris and ischemia, or patients with atypical chest pain or even those who are asymptomatic provided they have documented myocardial ischaemia (e.g. treadmill exercise test, radionuclide scintigraphy, stress echocardiography, Holter tape); \",{\"entities\":[(0,67,\"Ordinal\"),(71,126,\"Ordinal\"),(126,155,\"Ordinal\"),(160,194,\"Ordinal\"),(259,279,\"Nominal\")]}),\n",
    "(\"Single or twin pregnancies \",{\"entities\":[(0,26,\"Nominal\")]}),\n",
    "(\"Pregnant women with abdomen discumfort and ultrasound diagnosis of polyhydramnios (AFI>25cm) \",{\"entities\":[(0,8,\"Nominal\"),(15,92,\"Ordinal\")]}),\n",
    "(\"No prior treatment with Ventavis or other active treatments for primary pulmonary hypertension within 6 weeks of date of study inclusion (unless otherwise advised by Bayer Schering Pharma) \",{\"entities\":[(24,32,\"Nominal\"),(36,188,\"Ordinal\")]}),\n",
    "(\"Patient with primary pulmonary hypertension (i.e. Idiopathic Pulmonary Arterial Hypertension or Familial Pulmonary Arterial Hypertension) and classified as NYHA functional class III (NYHA = New York Heart Association) \",{\"entities\":[(20,43,\"Nominal\"),(50,92,\"Nominal\"),(95,136,\"Nominal\"),(156,217,\"Ordinal\")]}),\n",
    "(\"The treating physician has chosen Ventavis as a suitable long-term treatment for the patient \",{\"entities\":[(34,42,\"Nominal\"),(43,92,\"Nominal\")]}),\n",
    "(\"Patients suspected to have vitamin B12 deficiency defined as a plasma vitamin B12 below the reference interval (<200 pmol/L). \",{\"entities\":[(27,49,\"Nominal\"),(50,124,\"Nominal\")]}),\n",
    "(\"Non-smoking \",{\"entities\":[(0,11,\"Ordinal\")]}),\n",
    "(\"Users of at least 2 cups of caffeinated coffee per day who are willing to be randomized to any of the interventions. \",{\"entities\":[(0,116,\"Sentence/Sentiment\")]}),\n",
    "(\"Body mass index 25-35 kg/m2 \",{\"entities\":[(0,27,\"Numeric\")]}),\n",
    "(\"Aged at least 18 years with an ability and willingness to give written informed consent. \",{\"entities\":[(0,22,\"Numeric\"),(23,87,\"Ordinal\")]}),\n",
    "(\"If female, willing to use contraception throughout the study \",{\"entities\":[(11,60,\"Ordinal\")]}),\n",
    "(\"Sufficient number of umbilical cord blood units available for transplantation \",{\"entities\":[(16,26,\"Nominal\"),(30,40,\"Nominal\"),(40,154,\"Ordinal\"),(155,232,\"Ordinal\")]}),\n",
    "(\"Women between 40 to 70 years of age. \",{\"entities\":[(6,35,\"Numeric\")]}),\n",
    "(\"Healthy postmenopausal women with 50 or more moderate to severe hot flushes. \",{\"entities\":[(0,75,\"Ordinal\")]}),\n",
    "(\"Histologically proven recurrent or persistent endometrial cancer that is not amenable to curative treatment with surgery and/or radiation therapy AND has failed 2 previous treatment regimens \",{\"entities\":[(22,64,\"Nominal\"),(66,190,\"Ordinal\")]}),\n",
    "(\"Measurable metastatic disease \",{\"entities\":[(11,29,\"Nominal\")]}),\n",
    "(\"Subjects must have failed at least two previous chemotherapy regimens. Paclitaxel must have been a component of one or both regimens and cisplatin or carboplatin must have been a component of one or both regimens. \",{\"entities\":[(0,69,\"Ordinal\"),(71,213,\"Ordinal\")]}),\n",
    "(\"Primary tumor must have been diagnosed histologically as either epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (not borderline or low malignant potential epithelial carcinoma). \",{\"entities\":[(0,14,\"Nominal\"),(64,89,\"Nominal\"),(91,112,\"Nominal\"),(117,142,\"Nominal\"),(186,206,\"Nominal\")]}),\n",
    "(\"Measurable metastatic disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) \",{\"entities\":[(11,29,\"Nominal\"),(44,97,\"Ordinal\")]}),\n",
    "(\"Progression on prior therapy with a hormonal agent if estrogen receptor or progesterone receptor positive, and/or with trastuzumab if HER2-neu positive. If patient has progressed through hormone or trastuzumab therapy only, must have received one chemotherapy regimen. \",{\"entities\":[(0,105,\"Ordinal\"),(119,130,\"Nominal\"),(134,151,\"Ordinal\"),(153,267,\"Ordinal\")]}),\n",
    "(\"Progression on or failure to respond to at least one previous chemotherapy regimen for metastatic disease \",{\"entities\":[(0,105,\"Ordinal\")]}),\n",
    "(\"Measurable metastatic disease (>1cm) in at least one site other than bone-only \",{\"entities\":[(0,78,\"Ordinal\")]}),\n",
    "(\"Metastatic cervical cancer (CX) \",{\"entities\":[(0,31,\"Nominal\")]}),\n",
    "(\"Metastatic endometrial cancer (EM) \",{\"entities\":[(0,34,\"Nominal\")]}),\n",
    "(\"Metastatic ovarian cancer (OV) \",{\"entities\":[(0,30,\"Nominal\")]}),\n",
    "(\"Metastatic breast cancer (BR)\",{\"entities\":[(0,29,\"Nominal\")]}),\n",
    "(\"Diagnosis of one of the following malignancies: \",{\"entities\":[(34,46,\"Nominal\")]}),\n",
    "(\"Normal organ function within 14 days of study entry\",{\"entities\":[(0,51,\"Ordinal\")]}),\n",
    "(\"If female and of childbearing potential, are willing to use adequate contraception (hormonal, barrier method, abstinence) prior to study entry and for the duration of study participation. \",{\"entities\":[(17,39,\"Nominal\"),(41,83,\"Ordinal\"),(84,92,\"Ordinal\"),(94,108,\"Ordinal\"),(110,120,\"Ordinal\"),(122,187,\"Sentence/Sentiment\")]}),\n",
    "(\"Ovarian, endometrial or cervical - Gynecologic Oncology Group (GOG) performance score 2\",{\"entities\":[(0,87,\"Ordinal\")]}),\n",
    "(\"Breast - Karnofsky score > 50; \",{\"entities\":[(0,29,\"Ordinal\")]}),\n",
    "(\"Body Mass Index (BMI) >21 kg/m^2 and <35 kg/m^2. \",{\"entities\":[(0,48,\"Numeric\")]}),\n",
    "(\"HbA1c between 7.1% and 11.0%, inclusive. \",{\"entities\":[(0,39,\"Ordinal\")]}),\n",
    "(\"Treated with a stable dose of one of the following for at least 3 months prior to screening: * >=1000 mg/day immediate-release metformin; or metformin >=1000 mg/day and sulfonylurea; or sulfonylurea/metformin combination therapy. \",{\"entities\":[(94,136,\"Numeric\"),(141,164,\"Numeric\"),(169,181,\"Nominal\"),(186,198,\"Nominal\"),(199,228,\"Nominal\"),(0,91,\"Ordinal\")]}),\n",
    "(\" Aged 20 or older,\",{\"entities\":[(1,17,\"Numeric\")]}),\n",
    "(\" AGE>18 years\",{\"entities\":[(1,13,\"Numeric\")]}),\n",
    "(\" Age>18 years age ,\",{\"entities\":[(1,18,\"Numeric\")]}),\n",
    "(\" age>18 years age ,\",{\"entities\":[(1,18,\"Numeric\")]}),\n",
    "(\" Aged above 18 years and under 65 years\",{\"entities\":[(1,39,\"Numeric\")]}),\n",
    "(\" Aged over 18 years and under 65 years\",{\"entities\":[]}),\n",
    "(\" Aged above 18 years and below 65 years\",{\"entities\":[(1,39,\"Numeric\")]}),\n",
    "(\" aged above 18 years and below 65 years\",{\"entities\":[(1,39,\"Numeric\")]}),\n",
    "(\" aged above 18 and under 65\",{\"entities\":[(1,27,\"Numeric\")]}),\n",
    "(\" aged above 18 and below 65\",{\"entities\":[(1,27,\"Numeric\")]}),\n",
    "(\" aged above 18\",{\"entities\":[(1,14,\"Numeric\")]}),\n",
    "(\" AGE above 10\",{\"entities\":[(1,13,\"Numeric\")]}),\n",
    "(\" age above 10\",{\"entities\":[(1,13,\"Numeric\")]}),\n",
    "(\" AGE below 10\",{\"entities\":[(1,13,\"Numeric\")]}),\n",
    "(\" age below 10\",{\"entities\":[(1,13,\"Numeric\")]}),\n",
    "(\" aged below 20\",{\"entities\":[(1,14,\"Numeric\")]}),\n",
    "(\" aged 60 and under\",{\"entities\":[(1,18,\"Numeric\")]}),\n",
    "(\" aged 20 or younger\",{\"entities\":[(1,19,\"Numeric\")]}),\n",
    "(\"aged 20\",{\"entities\":[(0,7,\"Numeric\")]}),\n",
    "(\" Age<65\",{\"entities\":[(0,6,\"Numeric\")]}),\n",
    "(\" age less than 65 years old\",{\"entities\":[(1,27,\"Numeric\")]}),\n",
    "(\" age less than 65 yrs\",{\"entities\":[(1,21,\"Numeric\")]}),\n",
    "(\" Age less than 65 years,\",{\"entities\":[(1,24,\"Numeric\")]}),\n",
    "(\" age 18 to 80 years old\",{\"entities\":[(1,23,\"Numeric\")]}),\n",
    "(\" Aged 18-80 years\",{\"entities\":[(1,17,\"Numeric\")]}),\n",
    "(\" aged 18-80 years old,\",{\"entities\":[(1,21,\"Numeric\")]}),\n",
    "(\" age under 66 yrs\",{\"entities\":[(1,17,\"Numeric\")]}),\n",
    "(\" AGE under 66\",{\"entities\":[(1,13,\"Numeric\")]}),\n",
    "(\" Age under 66\",{\"entities\":[(1,13,\"Numeric\")]}),\n",
    "(\" age under 66\",{\"entities\":[(1,13,\"Numeric\")]}),\n",
    "(\" age under 66 years\",{\"entities\":[(1,19,\"Numeric\")]}),\n",
    "(\" aged over 18 yrs\",{\"entities\":[(1,17,\"Numeric\")]}),\n",
    "(\" aged over 18 years\",{\"entities\":[(1,19,\"Numeric\")]}),\n",
    "(\" aged over 18\",{\"entities\":[(1,13,\"Numeric\")]}),\n",
    "(\" Aged over 18\",{\"entities\":[(1,13,\"Numeric\")]}),\n",
    "(\" age over 18\",{\"entities\":[(1,12,\"Numeric\")]}),\n",
    "(\" Age over 18\",{\"entities\":[(1,12,\"Numeric\")]}),\n",
    "(\" age <=65 yrs\",{\"entities\":[(1,13,\"Numeric\")]}),\n",
    "(\" age<=65yrs\",{\"entities\":[(1,11,\"Numeric\")]}),\n",
    "(\" age<18yrs\",{\"entities\":[(1,10,\"Numeric\")]}),\n",
    "(\" age>=18yrs\",{\"entities\":[(1,11,\"Numeric\")]}),\n",
    "(\" age>=18 yrs\",{\"entities\":[(1,12,\"Numeric\")]}),\n",
    "(\" age >18 yrs\",{\"entities\":[(1,12,\"Numeric\")]}),\n",
    "(\" age greater than 18 years and less than 65 years\",{\"entities\":[(1,49,\"Numeric\")]}),\n",
    "(\" age greater than 18 and less than 65 years\",{\"entities\":[(1,43,\"Numeric\")]}),\n",
    "(\" age less than 65 years\",{\"entities\":[(1,23,\"Numeric\")]}),\n",
    "(\" age lesser than 45 years\",{\"entities\":[(1,25,\"Numeric\")]}),\n",
    "(\" age greater than 18 years\",{\"entities\":[(1,26,\"Numeric\")]}),\n",
    "(\" age greater than 18\",{\"entities\":[(1,20,\"Numeric\")]}),\n",
    "(\" aged greater than 18\",{\"entities\":[(1,21,\"Numeric\")]}),\n",
    "(\" Age greater than 18\",{\"entities\":[(1,20,\"Numeric\")]}),\n",
    "(\" Aged above 18 years and under 65 years\",{\"entities\":[(1,39,\"Numeric\")]}),\n",
    "(\"Aged over 18 years and under 65 years\",{\"entities\":[(0,37,\"Numeric\")]}),\n",
    "(\" aged between 18 and 65 years\",{\"entities\":[(1,29,\"Numeric\")]}),\n",
    "(\" aged between 18 and 65\",{\"entities\":[(1,23,\"Numeric\")]}),\n",
    "(\" Aged between 18 to 65\",{\"entities\":[(1,22,\"Numeric\")]}),\n",
    "(\" aged 18 to 65\",{\"entities\":[(1,14,\"Numeric\")]}),\n",
    "(\" Aged 18 to 65,\",{\"entities\":[(1,14,\"Numeric\")]}),\n",
    "(\" AGE<=65\",{\"entities\":[(1,8,\"Numeric\")]}),\n",
    "(\" age<=65\",{\"entities\":[(1,8,\"Numeric\")]}),\n",
    "(\" age<65\",{\"entities\":[(1,7,\"Numeric\")]}),\n",
    "(\" Age<=65\",{\"entities\":[(1,8,\"Numeric\")]}),\n",
    "(\" Age<65\",{\"entities\":[(1,7,\"Numeric\")]}),\n",
    "(\" aged between 5-65\",{\"entities\":[(1,18,\"Numeric\")]}),\n",
    "(\" age between 5-65\",{\"entities\":[(1,17,\"Numeric\")]}),\n",
    "(\" aged between 5-64 years\",{\"entities\":[(1,24,\"Numeric\")]}),\n",
    "(\" Aged between 5-64 years,\",{\"entities\":[(1,24,\"Numeric\")]}),\n",
    "(\" age > 18 < 65 years\",{\"entities\":[(1,20,\"Numeric\")]}),\n",
    "(\" age>18<65years\",{\"entities\":[(1,15,\"Numeric\")]}),\n",
    "(\" age>18<65\",{\"entities\":[(1,10,\"Numeric\")]}),\n",
    "(\" age < = 65 years\",{\"entities\":[(1,17,\"Numeric\")]}),\n",
    "(\" age < = 18 years\",{\"entities\":[(1,17,\"Numeric\")]}),\n",
    "(\" age > = 18 years old\",{\"entities\":[(1,21,\"Numeric\")]}),\n",
    "(\" age > = 18 years\",{\"entities\":[(1,17,\"Numeric\")]}),\n",
    "(\" age > = 18\",{\"entities\":[(1,11,\"Numeric\")]}),\n",
    "(\" AGE>=18\",{\"entities\":[(1,8,\"Numeric\")]}),\n",
    "(\" age >= 18\",{\"entities\":[(1,10,\"Numeric\")]}),\n",
    "(\" age>=18\",{\"entities\":[(1,8,\"Numeric\")]}),\n",
    "(\" Age 18,\",{\"entities\":[(2,8,\"Numeric\")]}),\n",
    "(\" age from 18-65 years\",{\"entities\":[(1,21,\"Numeric\")]}),\n",
    "(\" age from 18-65\",{\"entities\":[(1,15,\"Numeric\")]}),\n",
    "(\" aged from 18 to 65\",{\"entities\":[(1,19,\"Numeric\")]}),\n",
    "(\"AGED from 18 to 65\",{\"entities\":[(0,18,\"Numeric\")]}),\n",
    "(\" Aged 18 years or older, \",{\"entities\":[(1,23,\"Numeric\")]}),\n",
    "(\" Aged between 5 - 14 years,\",{\"entities\":[(1,26,\"Numeric\")]}),\n",
    "(\" aged from 18 to 65 years\",{\"entities\":[(1,25,\"Numeric\")]}),\n",
    "(\" ages from 18 to 65 years\",{\"entities\":[(1,25,\"Numeric\")]}),\n",
    "(\" ages from 18 to 65\",{\"entities\":[(1,19,\"Numeric\")]}),\n",
    "(\" ages 18-65\",{\"entities\":[(1,11,\"Numeric\")]}),\n",
    "(\" age 50-65\",{\"entities\":[(1,10,\"Numeric\")]}),\n",
    "(\"age 10-15\",{\"entities\":[(0,9,\"Numeric\")]}),\n",
    "(\" ages 18 or younger\",{\"entities\":[(1,19,\"Numeric\")]}),\n",
    "(\" Aged 18 years or younger, \",{\"entities\":[(1,25,\"Numeric\")]}),\n",
    "(\"between ages 18-85 years of age\",{\"entities\":[(0,31,\"Numeric\")]}),\n",
    "(\"Male and females between ages 18-85 years of age\",{\"entities\":[(17,47,\"Numeric\")]}),   \n",
    "(\"type 2 diabetic, age 18 and over, informed consent, \",{\"entities\":[(0,15,\"Nominal\"),(17,32,\"Numeric\"),(34,50,\"Sentence/Sentiment\")]})  \n",
    "]\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Convert the annotated data into the spaCy bin object"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 213/213 [00:00<00:00, 1070.19it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Skipping entity\n",
      "Skipping entity\n",
      "Skipping entity\n",
      "Skipping entity\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "import spacy\n",
    "from spacy.tokens import DocBin\n",
    "from tqdm import tqdm\n",
    "nlp = spacy.blank('en') # load a new spacy model\n",
    "db = DocBin() # create a DocBin object\n",
    "for text, annot in tqdm(trainData): # data in previous format\n",
    "    doc = nlp.make_doc(text) # create doc object from text\n",
    "    ents = []\n",
    "    for start, end, label in annot['entities']: # add character indexes\n",
    "        span = doc.char_span(start, end, label=label, alignment_mode='contract')\n",
    "        if span is None:\n",
    "            print('Skipping entity')\n",
    "        else:\n",
    "            ents.append(span)\n",
    "    try:\n",
    "        doc.ents = ents # label the text with the ents\n",
    "        db.add(doc)\n",
    "    except:\n",
    "        print(text, annot)\n",
    "db.to_disk('./train.spacy') # save the docbin object"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Generate the config file to train via Command line"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[38;5;2m✔ Auto-filled config with all values\u001b[0m\r\n",
      "\u001b[38;5;2m✔ Saved config\u001b[0m\r\n",
      "/home/sobha/Orion-CustomNER/config.cfg\r\n",
      "You can now add your data and train your pipeline:\r\n",
      "python -m spacy train config.cfg --paths.train ./train.spacy --paths.dev ./dev.spacy\r\n"
     ]
    }
   ],
   "source": [
    "!python -m spacy init fill-config /home/sobha/Orion-CustomNER/base_config.cfg /home/sobha/Orion-CustomNER/config.cfg"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Training the model using the command line"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [],
   "source": [
    "#in base_config.cfg file edited paths as below\n",
    "#train = ./train.spacy\n",
    "#dev = ./dev.spacy"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### To save the  model output in the specified folder as an argument at the command line."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\u001b[38;5;4mℹ Saving to output directory: /home/sobha/Orion-CustomNER/output\u001b[0m\n",
      "\u001b[38;5;4mℹ Using CPU\u001b[0m\n",
      "\u001b[1m\n",
      "=========================== Initializing pipeline ===========================\u001b[0m\n",
      "[2022-01-04 17:48:53,593] [INFO] Set up nlp object from config\n",
      "[2022-01-04 17:48:53,608] [INFO] Pipeline: ['tok2vec', 'ner']\n",
      "[2022-01-04 17:48:53,615] [INFO] Created vocabulary\n",
      "[2022-01-04 17:48:53,616] [INFO] Finished initializing nlp object\n",
      "[2022-01-04 17:48:54,107] [INFO] Initialized pipeline components: ['tok2vec', 'ner']\n",
      "\u001b[38;5;2m✔ Initialized pipeline\u001b[0m\n",
      "\u001b[1m\n",
      "============================= Training pipeline =============================\u001b[0m\n",
      "\u001b[38;5;4mℹ Pipeline: ['tok2vec', 'ner']\u001b[0m\n",
      "\u001b[38;5;4mℹ Initial learn rate: 0.001\u001b[0m\n",
      "E    #       LOSS TOK2VEC  LOSS NER  ENTS_F  ENTS_P  ENTS_R  SCORE \n",
      "---  ------  ------------  --------  ------  ------  ------  ------\n",
      "  0       0          0.00     45.56    0.00    0.00    0.00    0.00\n",
      "  6     200       1429.26   4104.22   36.04   43.48   30.77    0.36\n",
      " 13     400       2694.80   3207.53   80.31   82.26   78.46    0.80\n",
      " 23     600       2821.73   1914.56   91.34   93.55   89.23    0.91\n",
      " 35     800       1625.94    718.01   92.91   95.16   90.77    0.93\n",
      " 49    1000       3977.77    563.99   92.91   95.16   90.77    0.93\n",
      " 67    1200        841.90    279.42   92.91   95.16   90.77    0.93\n",
      " 89    1400        560.29    230.99   92.91   95.16   90.77    0.93\n",
      "116    1600        426.37    200.78   92.91   95.16   90.77    0.93\n",
      "149    1800       1508.02    245.75   92.91   95.16   90.77    0.93\n",
      "188    2000        165.61    206.18   92.91   95.16   90.77    0.93\n",
      "237    2200        151.24    244.17   92.91   95.16   90.77    0.93\n",
      "297    2400        265.04    267.06   92.91   95.16   90.77    0.93\n",
      "\u001b[38;5;2m✔ Saved pipeline to output directory\u001b[0m\n",
      "/home/sobha/Orion-CustomNER/output/model-last\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "os.environ[\"KMP_DUPLICATE_LIB_OK\"]=\"TRUE\"\n",
    "!python -m spacy train /home/sobha/Orion-CustomNER/config.cfg --paths.train /home/sobha/Orion-CustomNER/train.spacy --paths.dev /home/sobha/Orion-CustomNER/dev.spacy --output /home/sobha/Orion-CustomNER/output"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [],
   "source": [
    "# !spacy train /home/sobha/Orion-CustomNER/config.cfg --output /home/sobha/Orion-CustomNER/output --paths.train /home/sobha/Orion-CustomNER/train.spacy --paths.dev /home/sobha/Orion-CustomNER/train.spacy"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Load & Test the model"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Load the model."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "metadata": {},
   "outputs": [],
   "source": [
    "import spacy\n",
    "\n",
    "nlp = spacy.load('/home/sobha/Orion-CustomNER/output/model-last') #load the model-last"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Take the unseen data to test the model prediction."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Aged 20 or older\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Numeric</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    myocardial ischemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Nominal</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    able to undergo PTCA, stenting and CABG\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Ordinal</span>\n",
       "</mark>\n",
       "</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "sentence = 'Aged 20 or older, myocardial ischemia, able to undergo PTCA, stenting and CABG'\n",
    "\n",
    "doc = nlp(sentence)\n",
    "\n",
    "from spacy import displacy\n",
    "displacy.render(doc, style='ent', jupyter=True)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "nlp2 = spacy.load('/home/sobha/Orion-CustomNER/output/model-best') #load the model-best"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Aged 20 or older\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Numeric</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    myocardial ischemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Nominal</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    able to undergo PTCA, stenting and CABG\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Ordinal</span>\n",
       "</mark>\n",
       "</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "sentence = 'Aged 20 or older, myocardial ischemia, able to undergo PTCA, stenting and CABG'\n",
    "\n",
    "doc = nlp(sentence)\n",
    "\n",
    "from spacy import displacy\n",
    "displacy.render(doc, style='ent', jupyter=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Type 1 Myocardial infarction\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Nominal</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Have at least two coronary artery territories of disease &gt; 50%\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Ordinal</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Be on treatment for Diabetes\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Ordinal</span>\n",
       "</mark>\n",
       "</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "sentence2='Type 1 Myocardial infarction Have at least two coronary artery territories of disease > 50% Be on treatment for Diabetes'\n",
    "doc2 = nlp(sentence2)\n",
    "\n",
    "from spacy import displacy\n",
    "displacy.render(doc2, style='ent', jupyter=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Age &gt;= 18\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Numeric</span>\n",
       "</mark>\n",
       " Newly diagnosed \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    multiple myeloma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Nominal</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #e4e7d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Ineligible for autologous stem cell transplant\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Ordinal</span>\n",
       "</mark>\n",
       " </div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "sentence ='Age >= 18 Newly diagnosed multiple myeloma Ineligible for autologous stem cell transplant '\n",
    "doc = nlp(sentence)\n",
    "\n",
    "from spacy import displacy\n",
    "displacy.render(doc, style='ent', jupyter=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Age&gt;=18\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Numeric</span>\n",
       "</mark>\n",
       "</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "sentence ='Age>=18'\n",
    "doc = nlp(sentence)\n",
    "\n",
    "from spacy import displacy\n",
    "displacy.render(doc, style='ent', jupyter=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    age less than 18\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Numeric</span>\n",
       "</mark>\n",
       "</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "sentence ='age less than 18'\n",
    "doc = nlp(sentence)\n",
    "\n",
    "from spacy import displacy\n",
    "displacy.render(doc, style='ent', jupyter=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    age greater than 18\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Numeric</span>\n",
       "</mark>\n",
       "</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "sentence ='age greater than 18'\n",
    "doc = nlp(sentence)\n",
    "\n",
    "from spacy import displacy\n",
    "displacy.render(doc, style='ent', jupyter=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Life expectancy greater than or equal to 6 months\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Numeric</span>\n",
       "</mark>\n",
       "</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "sentence ='Life expectancy greater than or equal to 6 months' \n",
    "doc = nlp(sentence)\n",
    "\n",
    "from spacy import displacy\n",
    "displacy.render(doc, style='ent', jupyter=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Metastatic breast cancer (BR)\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Nominal</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Metastatic ovarian cancer (OV)\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Nominal</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Metastatic endometrial cancer (EM)\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Nominal</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Metastatic cervical cancer (CX)Breast - Karnofsky score &gt; 50\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Nominal</span>\n",
       "</mark>\n",
       "</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "sentence ='Metastatic breast cancer (BR) Metastatic ovarian cancer (OV) Metastatic endometrial cancer (EM) Metastatic cervical cancer (CX)Breast - Karnofsky score > 50'\n",
    "doc = nlp(sentence)\n",
    "\n",
    "from spacy import displacy\n",
    "displacy.render(doc, style='ent', jupyter=True)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    type 2 diabetic\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Nominal</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    age 18 and over\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Numeric</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    informed consent\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Sentence/Sentiment</span>\n",
       "</mark>\n",
       ",</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "sentence='type 2 diabetic, age 18 and over, informed consent,'\n",
    "doc = nlp(sentence)\n",
    "from spacy import displacy\n",
    "displacy.render(doc, style='ent', jupyter=True)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "\n",
    "\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
